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INTRODUCTION 
Aging is not a cause of anemia; but is seen as a predisposing factor 
to anemia. Anemia is a common hematological problem  in the geriatric 
age group and its incidence increases with increasing age1. Studies have 
demonstrated that anemia in old age have unique causes, adverse effects 
and functional outcome2. The prevalence of anemia in the general 
population  has been shown  to range from 8 to 44%3. The third National 
Health and Nutrition Examination Survey (NHANES-III) of WHO study 
revealed prevalence of anemia as 11% of men and 10.2% of women aged 
65 years and older4. The etiology is multi-factorial, the most common 
causes being Anemia of Chronic disease, Nutritional deficiencies 
followed by Unexplained anemia4. Myelo-dysplastic Syndrome (MDS) is 
more common in older adults and accounts for a significant number of 
unexplained anemias in elderly4. The median age at which MDS is 
diagnosed is between 60-75 years.  To understand the cause and effect of 
anemia on the old person, it is essential to look into the bone marrow for 
specific changes, for example the diagnosis, classification and 
prognostication of MDS is, based on the peripheral blood film and Bone 
Marrow morphology of the patient5. Hence Bone Marrow Morphology 
remains the cornerstone and most often the gold standard of disease 
diagnosis and is an important tool that complements cytogenetic finings 
for prognostic discrimination6. Our present study was designed as a 
prospective descriptive study of the Bone Marrow morphology in 
Geriatric patients with Anemia. 
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AIMS AND OBJECTIVES 
 
We aim  
1. To evaluate the clinical presenting features and the basic, 
hematological parameters in Geriatric patients with Anemia. 
2. To evaluate the morphological alterations of Bone marrow 
aspirates in these Geriatric patients with Anemia. 
3. To correlate these morphological alterations of Bone marrow 
aspirates with the clinical and basic hematological parameters in 
these patients. 
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REVIEW OF LITERATURE 
I. The Elder 
Geriatrics or geriatric medicine focuses on health care of elderly 
people.  The term geriatrics comes from the Greek word geron meaning 
"old man" and iatros meaning "healer". The age sixty five is considered 
the mean geriatric age and according to Zauber & Zauber(1987),  the 
older individuals can  generally be classified  into three age categories– 
the young old, age sixty five to seventy four years, the old- old, age 
seventy four to eighty four and the very old, age eighty five and older7. 
The number and proportion of elderly persons is increasing worldwide 
and this contributes to the global growing population. Currently there are 
nearly five hundred million (7%) adults sixty five years and older 
throughout the world and by 2030, the older population will double to 
one billion (12%) 8. Of the total world population of 6,464,750, nearly 
5,253,484 live in the lesser developed regions, and about two thirds of all 
geriatric people are living in these developing regions. By the year 2025, 
this number  is projected to rise further9. This shifting demographic trend 
demands the health care system to get equipped accordingly to serve the 
present and the future need of the community. Although advanced age is 
considered a risk factor for many diseases it does not equate age, disease 
and disabilities. The decline in physiological reserve in organs makes the 
elderly more prone  for diseases and have more complications from mild 
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problems. Over the past decade, Anemia has grown as an important risk 
factor and is associated with an array of undesirable outcomes in elder 
adults, including hospitalization, disability and mortality. Anemia is an 
insidious disease and is associated with a wide range of negative health 
conditions in the elderly. The continuum of conditions range from a 
simple decrease in physical performance and muscular activity, to severe 
complications that lead to hospitalization and mortality (Denny SD et al., 
2006; Penninx BW et al.,2003 and 2006)10,11 Anemia can have 
significantly more severe complications in the older individuals than in 
the young and are bound to impede the quality of life. The prevalence of 
anemia range from eight to forty four percent with  a significant increase  
in men who are 85 years or older. The third National Health and Nutrition 
Examination Survey (NHANES-III) of WHO study estimated the 
prevalence of anemia as eleven percent in men and 10.2% in women aged 
sixty five years and older. Guralnik JM et al. (2004) estimated that the 
prevalence of anemia is 10.6% in people who were 65 years and older. 
This study,  based on the data from Phases 1 and 2 of the NHANES III 
survey, showed that in individuals over the age of 85, the prevalence of 
anemia rose to 26.1% for males and 20.1% for females. It also revealed 
that anemia has an impact on mortality in geriatric patients with other co-
existing disease states, which is of greater significance. Although anemia 
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is common in the elderly, a low hemoglobin level cannot simply be 
dismissed as a normal part of aging.  
II. Normal hematopoiesis 
The process of Hematopoiesis begins in the yolk sac at third week 
of intra uterine life. From third month onwards, Hematopoiesis starts in 
Liver which continues up to sixth month. Bone marrow starts taking over 
the function from fourth month onwards and from then on it is almost the 
only source of blood cells at and after birth12. 
Bone marrow is made up of (a) cellular elements of hemopoietic 
stem cells, proliferating and differentiating progenitors and 
morphologically recognizable precursors and (b) stroma. There is a 
critical interaction between stromal cells and the hemopoietic progenitor 
cells12. Islands of Erythroblasts are seen in central parts of the marrow in 
close proximity to sinusoids. Myeloblasts are frequently found adjacent to 
the trabecular surfaces. Megakaryocytes are normally present in the 
central parts of the bone marrow amongst the erythroid and myeloid 
precursors. Monocytic precursors are usually not recognizable in the 
marrow sections. Lymphocytes are seen interstitially and also around 
arterial vessels, in the central parts of the marrow. 
The process of hematopoiesis begins with the production of blood 
cells from hematopoietic stem cells (HSC) which have extensive potential 
of proliferation to produce more stem cells (self-renewal) and 
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differentiate in to progenitor cells. Progenitor cells (lineage committed 
cells) are committed to one lineage, i.e., myeloid or lymphoid. Their 
proliferative potential is limited as compared to HSCs. Late progenitor 
cells (committed progenitor cells) possess receptors for various cytokines. 
Late progenitor cells differentiate into morphologically recognizable 
maturing cells like proerythroblasts, early normoblasts etc. As these cells 
mature, proliferative potential decreases and finally mature white cells, 
red cells and platelets are produced. 
Stem cells in the marrow are surrounded by non-hemopoietic cells 
and proliferating and differentiating precursors. Non- hemopoietic cells 
like stromal cells, macrophages, fibroblasts, endothelial cells, fat cells etc 
form the microenvironment of marrow which controls the self renewal 
and differentiation of HSCs.  
Hemopoietic growth factors (cytokines) are hormone like inducers 
of proliferation and differentiation of HSCs. These cytokines act on 
progenitor cells through surface receptors and their action is lineage 
specific12. 
III. Hematopoiesis in the Elder 
The Aging process is associated with a decline in function of 
multiple organ systems, such as cardiovascular system, renal system, 
pulmonary, musculo-skeletal system   and notably the hematopoietic 
process. As age advances, most cells lose their ability to divide, however, 
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the Bone Marrow and gastro intestinal mucosal cells retain their mitotic 
activity. In infancy, the Marrow is estimated to occupy 80% to 100% of 
the medullary spaces of long bones and a few flat bones, which gradually 
shrinks with advancing age decreasing to 50% by 30 years of age, and 
these further declines to 30% by 65 years of age13.  
Erythrocytes:  
Anemia is frequently found in elderly individuals. The stimulating 
effects of androgens on erythropoiesis results in a higher hemoglobin 
levels in men when compared to women. Unlike in young and middle 
aged persons, both elderly men and women have an equal chance of 
developing anemia because of a decrease in androgen levels in elderly 
males (Allan RN & Alexander MK; 1965) 14. 
Leukocytes:  
The total leukocyte count or WBC differential count remains 
almost normal in healthy elderly persons with no underlying pathologic 
conditions,    when compared with middle aged individuals. 14.  
Lymphocytes:   
Age allied defects in lympho cytogenesis such as immune 
senescence and other factors, affects cellular and hum oral immunity. The 
thymus disappears by early middle age, and from then on the adults 
depend on the T cell responses in other secondary tissues.  The number of 
naïve T cells decreases as age advances, thus increasing the dependency 
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on memory T cells.  In the elderly, an impaired responsiveness of Tcells 
to mitogens and antigens is present as a result of a decreased expression 
of co-stimulator CD28. The function of B lymphocyte depends on 
interaction with T cells. When T cell inadequacies occur, there may be a 
decreased ability to generate an antibody response14.   
Platelets:  
The platelet count is not altered significantly with age. However, 
the function of platelets may be altered due to decreased platelet 
membrane protein kinase C activity and increased levels of ß-
thromboglobulin14.  
IV. Anemia in the Elder 
Anemia, is not a diagnosis in itself, but is an objective sign of a 
deeper disease. Anemia is defined as a condition in which the 
concentration of hemoglobin in peripheral blood is below the level that is 
normal for the level for that age and sex of the individual15. Functionally, 
it is defined as an insufficient RBC mass to adequately deliver oxygen to 
the peripheral tissues16. The normal limit of hemoglobin concentration 
varies among different organizations, countries and laboratories. In 
addition, many other factors can influence a healthy person’s hemoglobin 
level, including smoking status, altitude of residence, ethnic background, 
and physiologic fluctuations of plasma volume17. Because clinical 
laboratories do not adjust for these factors, interpretation of hemoglobin 
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test results is the responsibility of the clinicians. The World Health 
Organization(WHO) criteria of anemia is based on a hemoglobin 
concentration lower than 120g/L(12.0G/dl) in women and 
130g/L(13.0g/dl) in men18. The interpretation of hematologic data in the 
context of old age is particularly a matter of concern nowadays. This 
could partly be attributed due to the remarkable heterogeneity of the 
processes related to senescence and partly due to the intricacies in sorting 
out the effects of age per se from the effects of the occult disease 
processes that go together with aging. This results in an ambiguous 
situation wherein it is unclear whether the low hemoglobin levels 
observed is primarily due to age or an underlying disease. Many elderly 
people maintain normal blood counts in spite of low hemoglobin levels. 
Many variables are postulated that contribute to anemia in the elderly 
such as (1) decline in physical activity, (2) altered cardiovascular 
function, (3) decreased bone marrow function and (4) chronic 
inflammatory disorders19. This process of an undercurrent anemia 
possesses a higher mortality risk of anemic elderly than in non anemic 
elderly.  
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Table 1:  Grading of the severity of anemia20 
Grade of Severity  Hemoglobin Level 
Within Normal Limits >12gms/dl 
Mild 10 - 11.9gms/dl 
Moderate 7.1 - 9.9gms/dl 
Severe < 7.0gms/dl 
 
V. Classification of anemia21 
              I. Physiologic Classification  
             II. MorphologicClassification 
I) Physiologic Classification  
A) Blood loss 
B) Increased rate of destruction (hemolytic anemias) 
1) INTRINSIC (intracorpuscular) abnormalities of red cells 
A) Hereditary 
    I. Red cell membrane disorders:- 
 Disorders of membrane cytoskeleton  
 Disorders of lipid synthesis 
 ii. Red cell enzyme deficiencies 
 Glycolytic enzymes 
 Enzymes of hexosemonophosphate shunt. 
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iii. Disorders of hemoglobin synthesis 
b) Acquired 
 Membrane defect 
2) EXTRINSIC (Extra corpuscular) abnormalities 
a) Antibody mediated 
b) Mechanical trauma to red cells 
c) Infections: malaria, hookworm 
d) Chemical injury: lead poisoning 
e) Sequestration in mononuclear phagocyte system: hypersplenism 
C) Impaired red cell production 
(i) Disturbance of proliferation and differentiation of stem cells: 
(ii) Disturbance of proliferation and maturation of erythroblasts 
 
MORPHOLOGICAL CLASSIFICATION 
I. Normocytic Anemias 
II. Microcytic Anemias 
III. Macrocytic Anemias 
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VI. Etiology of Anemia in Elder 
       The principal causes of anemia in geriatric persons were evaluated 
in the Third National Health and Nutritional Examination Survey 
(NHANES III) and are as follows4: 
1. One third were  related to  Blood Loss / Nutrition deficiency - Iron 
deficiency and iron with folate and/or B12 deficiency ,  Folate 
and/or B12 deficiencies. 
2. One third due to Chronic Renal disease, Anemia of Chronic disease 
or both.  
3. Remaining one third was Unexplained Anemia.  
In another study, the Stanford study, Unexplained anemia 
accounted for 35%, hematologic malignancy accounted for up to 22%, 
Iron deficiency anemia 12%, Anemia of Inflammation 6%,  Renal 
insufficiency  4% and  others  10%27. In addition Drug induced anemia 
secondary to various medications such as Nonsteroidal Anti-
inflammatory drugs, anti-platelet medications, steroids, etc are well 
known to occur in elderly. One of the challenges in identifying the 
etiology of anemia in elderly patients is the diversity of potentially 
contributing factors (eg, alcohol use and medications). Thus, anemia in 
older persons is multifactorial, and evaluation of low hemoglobin may be 
more challenging than in adolescents or young adults. 
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VII. Pathophysiology of Anemia in Elder 
1. Anemia of Inflammation:   
Anemia of chronic disease, or  Anemia of chronic Inflammation, is 
the most common form of anemia in the elderly. The anemia that is 
observed in patients with chronic infections, inflammatory disorders, or 
malignant diseases that persist for more than one to two months is called 
Anemia of Chronic Disease (AOCD)22. Elis A et al (1996)23 have shown 
that most common anemia in elderly is Normocytic Normochromic type. 
The most  common conditions associated with AOCD are rheumatologic 
disorders, particularly, Rheumatoid Arthritis, Tuberculosis, Pelvic 
Inflammatory Disease(PID), AIDS/HIV, Systemic Inflammatory 
Response Syndrome(SIRS), Chronic Osteomyelitis, Inflammatory Bowel 
Disease(IBD),  Hodgkin’s and Non-Hodgkin’s lymohomas and Cancers 
of various organs. Classically, it is characterized by the occurrence of 
hypoferrenemia in the presence of normal or abundant reticulo-
endothelial iron stores. On a biochemical basis, it is characterized by a 
low serum iron level, low to normal transferrin level and low iron binding 
capacity with an elevated serum ferritin.  
The etiology is multifactorial. Three principal mechanisms are 
involved in the pathogenesis of AOCD24. These are (1) a shortened 
erythrocyte survival, due to a potential extra corpuscular defect (2) 
impaired marrow response due to inhibitory effect of cytokines on 
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erythropoiesis, and (3) disturbance in iron metabolism, in which iron in 
the bone marrow macrophages is not available for erythropoiesis. 
Cytokines that are frequently implicated in the pathogenesis of AOCD are 
IL-1, IL-6, TNF, and the Interferons, The serum or plasma concentrations 
of these cytokines are increased in patients with disorders associated with 
AOCD. Recent studies reveal that the key factor in the pathogenesis of 
AOCD is the   antimicrobial peptide Hepcidin25. It is produced by the 
hepatocytes and is a principal regulator of iron metabolism.  It has been 
shown to hamper    iron absorption from the intestine and to arrest release 
of iron from  enterocytes, hepatocytes and macrophages. Elevated levels 
of hepcidin have been demonstrated in patients with AI. Various complex 
mechanisms involving a number of inflammatory-mediated cellular 
pathways have been implicated in the regulation of hepcidin synthesis. 
Hepcidin is an acute phase reactant and its synthesis is potently induced 
by IL-6.  The  In CHIANTI study26 or "Invecchiare in Chianti" study 
carried out recently analyzed the association of hepcidin levels in urine, 
proinflammatory markers, and anemia. In this study it was observed that 
although there was an association of  C-reactive protein and IL-6  with 
anemia and reduced iron levels, no association was found with higher 
urinary hepcidin levels. Hence from this study it was postulated that an 
increase in hepcidin synthesis occurs only in presence of blatant 
inflammation. Also in AI, elevated lactoferrin levels, interferes with 
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normal iron cycling and contributes to increased iron stores.  Laboratory  
Features: Characteristically, serum iron concentration is decreased, total 
iron-binding capacity (or serum transferrin concentration) is reduced, and 
transferrin saturation is subnormal though not to the same degree as in 
iron deficiency.  Patients with Anemia of Chronic inflammation have 
mild to moderate anemia, and a variable hypochromia. The degree of 
anemia   tends to correlate in severity with the underlying disease, and 
rarely may it progress to a much higher degree. In AOCD, the RBCs are 
usually normochromic and normocytic, but in about one third of patients 
with AI, they may be microcytic.  Hypochromia  is more common and 
precedes  microcytosis, unlike in iron deficiency, where hypochromia 
typically follows microcytosis. This feature often helps in distinguishing 
Iron deficiency anemia from AOCD.  A mild anisocytosis and 
poikilocytosis may be detected, but these changes tend to be less 
prominent than in iron-deficient persons. There is no increase in 
reticulocyte count. Bone marrow is normocellular or mildly hypercellular 
with a normoblastic hematopoiesis. The reticulo endothelial iron content 
is increased. Normal sideroblasts contain one to four tiny blue inclusion 
bodies in Prussian blue iron staining. In AI, the number of Sideroblasts is 
reduced to 5 to 20% of the total quantity of  Normoblasts (normal, 30 to 
50%). In Bone marrow aspirates stained for iron, in iron deficiency 
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anemia, both the macrophage iron and the number of sideroblasts are 
reduced. 
AOCD has to be differentiated from Anemia of Renal disease, 
chronic blood loss, drug induced hemolysis or Marrow suppression, 
Thalassemias, Endocrine disorders such as testicular failure, 
hypothyroidism and hyperthyroidism. These conditions need to be ruled 
out before assigning a patient with the diagnosis of AOCD. Treatment of 
the underlying disease usually resolves the anemia. Other treatment 
modalities include erythropoietin therapy and blood transfusion. 
2. Anemia in Patients with Cancer:  
Much of the anemia commonly observed in patients with Cancer 
can be attributed to the mechanisms involved in ACD; however, certain 
processes unique to Malignancy may also contribute. The potential 
mechanisms are -  Erythroid precursors may be displaced from marrow 
by metastatic tumor, tumor-induced fibrosis, or tumor-associated marrow 
necrosis. The treatment of Cancer can also produce or exacerbate anemia 
by a variety of mechanisms, including impaired erythropoietin production 
and cytotoxic effects of therapy on erythroid progenitors2.  
3. Anemia of Renal Disease:   
Anemia of Chronic Renal Insufficiency is due to loss of interstitial 
cells of kidney with reduction in production of erythropoietin (EPO) in 
response to hypoxia. The severity of anemia increases as the renal 
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function is compromised. In addition anemia is further accentuated 
because of (a) suppression of erythropoiesis by toxic metabolic products 
of renal failure30. (b) reduce red cell survival (c) bleeding due to impaired 
platelet function. Progressive uremia results in plasma expansion and 
hemodilution. There is functional iron deficiency due to depletion of iron 
pool since the increased iron stores are not available for utilization by the 
bone marrow for erythropoiesis. Additional factors associated with 
chronic renal failure will also contribute to the development of anemia, 
and these should be regarded as complications and not   fundamental 
components of the Anemia of Renal insufficiency itself. For instance, in 
the presence of infection or inflammation associated with renal disease, 
Anemia of chronic disease is likely to be observed. Iron deficiency 
anemia may develop because of hematuria, blood loss from the 
gastrointestinal tract or from retention of blood in the hemodialysis 
apparatus tubing. The Megaloblastic anemia due to folate deficiency may 
also occur in patients on dialysis but is rare. Certain types of renal 
disorders, including the Hemolytic-Uremic syndrome or Thrombotic 
Thrombocytopenic purpura, are associated with Microangiopathic 
Hemolytic Anemia. Finally, aluminum intoxication can cause Microcytic 
anemia in dialysis patients. The blood film usually shows normocytic 
normochromic anemia along with few burr cells and poikilocytes. 
Reticulocyte is low for the degree of anemia. The bone marrow is usually 
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normocellular with nearly normal erythroid elements. In chronic renal 
failure, iron stores are increased unless the patient has got associated iron 
deficiency. Bone marrow biopsy, besides showing increased iron stores, 
demonstrates a picture of Renal Osteodystrophy especially in cases of 
advanced chronic renal failure. The bony trabeculae demonstrate 
increased osteoblastic and osteoclastic activity with lacunar resorption of 
bone resulting in saw tooth irregularity of the trabecular surface. There is 
associated paratrabecular fibrosis. Patients respond to erythropoietin 
therapy27. 
4. Anemia of Liver Disease:  
The term Anemia of Liver disease refers to a mild to moderate 
anemia associated with liver disease in the absence of any complicating 
factors such as Blood loss, Marrow suppression by exogenous agents, or 
Nutritional deficiency. This syndrome apparently results from a 
combination of intravascular dilution due to volume overload, shortened 
red cell survival, and impaired ability of the marrow to respond optimally 
to the anemia. In addition, some patients develop a severe hemolytic 
anemia associated with morphologically abnormal erythrocytes (spur 
cells). Alcohol abusers can develop a characteristic Sideroblastic anemia, 
often accompanied by impaired folate metabolism or overt folate 
deficiency or may have direct suppression of hematopoiesis by alcohol. 
Individuals with cirrhosis of any etiology are at increased risk for 
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hemorrhage. Blood loss occurs in 24 to 70% of patients with alcoholic 
cirrhosis. In liver diseases, a Normocytic or Macrocytic anemia 
develops27.  
5. Anemia of Endocrine Disorders:  
Many Endocrine disorders may initially manifest with anemia. The 
common disorders that produce anemia are Hypothyroidism, 
Hypopituitarism, and Adrenal insufficiency.  The anemia is mild to 
moderate and is usually not associated with symptomatology (other than 
that associated with the underlying endocrinopathy). However the 
severity of anemia may be masked by a decreased plasma volume that 
occurs in some disorders. The anemia is  “Adaptive”. and may reflect a 
physiologically appropriate hemoglobin concentration because the 
hormone deficiency often results in reduced oxygen requirements. In 
most of the endocrine diseases the anemia is Normocytic  and 
Normochromic but may be Macrocytic27. 
6. Anemia of Collagen Vascular Diseases:  
Anemia of Chronic disease appears in Collagen Vascular diseases 
such as Dermatomyositis, Polyarteritis nodosa, Rheumatoid arthritis, 
Systemic Lupus Erythematosus, and Temporal arteritis (including 
polymyalgia rheumatica). The latter is essentially a disease of geriatric 
patients27 
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7. Iron Deficiency Anemia:  
Iron deficiency anemia produces a Microcytic Hypochromic 
anemia. It is the most common form of anemia prevalent in India28. It is 
the most wide spread form of nutritional anemia throughout the world29. 
Common causes of IDA include lack of dietary iron, chronic blood loss 
and malabsorption states. In geriatric individuals, chronic bleeding from 
the Gastro intestinal tract and Genitor urinary tract are major causes apart 
from nutritional deficiency. The gastro intestinal causes of blood loss 
include Peptic ulcer, Oesophageal or Gastric Varices, Hemorrhoids, 
NSAID intake, vascular anomalies such as Angiodysplasia and 
Malignancies. Other less common causes are chronic respiratory tract 
infections, renal, bladder and prostatic lesions etc. The pathogenesis of 
iron deficiency anemia involves (i) impaired hemoglobin synthesis (ii) 
impaired cellular proliferation (iii) diminished iron containing proteins.         
Laboratory Findings:  
Diagnosis is based on peripheral blood findings, bone marrow 
morphology and iron stores and assessment of Iron status. Low levels of 
serum Iron, serum Ferritin and an increased serum Iron binding capacity 
is noted. An increase in plasma transferrin receptor is a sensitive indicator 
of tissue iron deficiency. The Mean Corpuscular Volume and Mean 
Corpuscular Hemoglobin values are reduced in most patients, and the 
Mean Corpuscular Hemoglobin Concentration is reduced in long-
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standing or severe disease. The Red cell Distribution Width (RDW) is 
increased in iron deficiency, and this often is useful in distinguishing iron 
deficiency from Thalassemia trait conditions in which the RDW is 
normal.  The chief finding on blood smear is hypochromia, observed as 
an increase in the size of the region of central pallor. The more severe the 
anemia, the more severe the hypochromia and the greater the percentage 
of erythrocytes affected. When hypochromia is extreme, most of the red 
blood cells appear as mere rings. Tiny microcytes and a moderate number 
of poikilocytes, particularly tailed and elongated elliptical forms (pencil 
cells), are also found. The total white blood cell count is usually normal, 
but mild reduction in polymorphs may occur in long-standing cases of 
iron deficiency. Recent large-volume hemorrhage may cause a slight 
neutrophilic leukocytosis, and occasional myelocyte may be found in 
peripheral blood. In iron deficiency due to parasitic infestation, 
eosinophilia may be present. Another feature that commonly 
accompanies iron deficiency is an elevated platelet count. The 
thrombocytes are often increased to approximately twice the normal 
level, but the number return to normal after iron treatment. The cause of 
the thrombocytosis of iron deficiency is unclear.30 
Bone Marrow Finding:  
There is absent or severely reduced Macrophage iron in the marrow 
and also in spleen, and liver of iron-deficient subjects. Fewer than 10% of 
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the marrow normoblasts are Sideroblasts. In addition, the iron-deficient 
bone marrow is characterized by mild to moderate Erythroid hyperplasia. 
There may be striking nuclear distortions, resembling those found in 
Dyserythropoietic anemias. Karyorrhexis and nuclear budding are 
particularly common, but multinuclearity, nuclear fragmentation, and 
even intranuclear bridging may be observed31. The individual 
normoblasts appear small and may have scanty cytoplasm, often with 
irregular, ragged borders. When therapy is given, Erythroid hyperplasia 
initially increases, but as erythropoiesis is restored to normal, the 
cellularity of the marrow likewise becomes normal. 
The differential diagnosis includes Thalassemias, AOCD and 
Sideroblastic anemia. The Anemia of Chronic disease may be microcytic, 
but it is more commonly normocytic. Iron stores are normal and clinical 
features of chronic disorders are usually present.  Sideroblastic anemia 
may be microcytic, normocytic, or even macrocytic. Bone marrow 
demonstrates increased iron stores with ring sideroblasts. 
8. Vitamin B12 / Folate Deficiency:  
Vitamin B12 / Folate deficiency produce a Macrocytic anemia. 
Megaloblastic anemias are characterized by retarded DNA synthesis 
while RNA synthesis is normal resulting in an imbalanced cell growth.    
The Mean Corpuscular Volume increases slightly with age but it 
generally does not lead to significant Macrocytosis. Though serum levels 
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of Vitamin B12 are subnormal (10-15%), anemia due to B12 deficiency is 
not so common in elderly (1-2%)32. Common causes of cobalamin 
deficiency are inadequate diet, malabsorption, increased requirements as 
in disseminated cancer and intrinsic factor deficiency. Pernicious anemia 
is
 a chronic disease resulting from deficiency of intrinsic factor leading to 
impaired absorption. It is more common over the age of 60 years33. The 
etiopathogenesis involves damage to gastric parietal cells caused by 
cellular and humoral immune reactions leading to impaired secretion of 
hydrochloric acid, pepsin and intrinsic factor.  
9. Folate Deficiency:  
Like Cobalamin deficiency, Folate deficiency characteristically 
causes Macrocytic anemia. Simultaneous iron deficiency may mask 
macrocytic anemia resulting in a normocytic anemia especially in elderly 
persons34. The causes of folate deficiency are unbalanced diet; impaired 
absorption associated with Tropical sprue, small bowel resection and 
increased requirements as in Hemolytic anemias, Myeloproliferative 
disorders and hemodialysis.  The distinction of cobalamin and folic acid 
deficiency is necessary as anemia resulting from cobalamin deficiency 
improves with folate therapy, but folic acid therapy does not revert the 
neurologic damage caused by cobalamin deficiency.  
 Other causes of megaloblastic anemia are defective folate/ vitamin B12 
metabolism, Hereditary Orotic aciduria and Lesch- Nyhan syndrome. 
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Laboratory Diagnosis:  
Hematologic findings are similar in both B12/Folate deficiency. 
The classic blood count findings are anemia, a high MCV and Mean 
Corpuscular Hemoglobin (MCH), and, in more advanced cases, 
thrombocytopenia and neutropenia. The reticulocyte count is low due to 
ineffective erythropoiesis. Also there is an increase in lactate 
dehydrogenase levels, unconjugated bilirubin, and low serum haptoglobin 
levels due to a poorly understood component of intravascular hemolysis 
in these patients. The characteristic features in peripheral smear are 
hypersegmented neutrophils and macro ovalocytes. Hypersegmentation 
of neutrophil nuclei is a constant feature and is defined as   finding one or 
more neutrophils with six or more nuclear lobes or showing that at least 4 
to 5% of neutrophils have five lobes.  Hypersegmentation often precedes 
anemia, but it is not found in subclinical deficiency. Hypersegmented 
neutrophils are not specific for cobalamin or folate deficiency; they are 
found in patients receiving chemotherapeutic drugs such as 5-fluorouracil 
or hydroxyurea, in some patients receiving steroid therapy for Immune 
Thrombocytopenic Purpura , in rare patients with Myelofibrosis or 
Chronic Myelogenous Leukemia, and, possibly, as a benign hereditary 
condition. Macro ovalocytes are large cells (MCV>100fl) and are 
pathognomonic of Megaloblastic anemia. Other features that can be 
present are anisopoikilocytosis, Howell- Jolly bodies, cabot rings, 
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basophilic stippling, nucleated RBCs, leucopenia and 
thrombocytopenia35. Bonemarrow Findings The bone marrow is 
markedly hypercellular with erythroid hyperplasia and a reversal of 
myeloid erythroid ratio. The morphologic hallmark is nuclear-
cytoplasmic dissociation,  best appreciated in precursor cells in the bone 
marrow aspirate. There is a preponderance of megaloblastic changes in 
early and intermediate erythroblasts. Megaloblasts are characterized by a 
large cell size, large, a distinctive fine nuclear chromatin pattern (due to a 
preponderance of euchromatin). Cytoplasmic maturation and hemoglobin 
accumulation proceed at a normal pace, leading to nuclear to cytoplasmic 
asynchrony. Morphologic aberrations apparent in myeloid cells are giant 
metamyelocytes and band forms. Megakaryocytes display unusually large 
and bizarre multilobated nuclei36. 
Apart from vitamin B12/ folate deficiency, liver disease, hemolytic 
anemia, alcoholism, hypothyroidism, aplastic anemia, Myelodysplastic 
syndrome, and cytotoxic chemotherapy also produce macrocytic anemia 
and needs to be distinguished from B12/ folate deficiency. In these 
conditions, MCV rarely exceeds 120fl and the bone marrow reaction is 
normoblastic. 
10. Myelodysplastic Syndrome:  
“Preleukemia” as it was formerly called or Myelodysplastic 
syndrome is fairly an infrequent cause of anemia, but is a more common 
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cause in the aged individuals than in younger patients. Milman N et al 
(1994)37has shown that about 5.8% of the total anemia population had 
Myelodysplastic syndrome (MDS) and 17.2 % of the patients had 
Unexplained anemias. MDS encompass a spectrum of clonal 
hematopoietic stem cell disorders  characterized by cytopenias, 
ineffective hematopoiesis, cytopenias,  clonal chromosomal abnormalities 
and  a risk for acute leukemic transformation in about 30 -35 % of 
patients. The threshold for cytopenias are hemoglobin less than 10g/dl, 
Absolute Neutrophil count less than 1.8x 109/L and platelets less than 100 
x 109/L. MDS arising denovo is termed Primary MDS. Primary or denovo 
MDS predominantly affect older individuals with a median age of onset 
of 60 – 70 years38. Predisposing factors could be genetic or acquired. 
Genetic factors have a role in Pediatric MDS. Secondary MDS is 
diagnosed when a known acquired predisposition is documented. This 
could be due to exposure to benzene, tobacco, radiation or MDS evolving 
from Aplastic anemia and Paroxysmal Nocturnal Hemoglobinuria (PNH). 
Therapy related MDS is seen in patients who have received 
chemotherapy earlier, usually for lymphomas.  
MDS have an estimated annual incidence of approximately 3.5 to 10 per 
100 000 in the elderly population39. The rising frequency and incidence of 
MDS in the US population may be attributed to the growing aging 
population and increasing disease recognition and diagnosis. The etiology 
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and pathogenesis of MDS remain poorly characterized. Underlying the 
marrow failure and peripheral cytopenias is deranged clonal proliferation 
of hematopoietic progenitor cells with inherited or acquired genetic 
mutation. Clonality in MDSs has been supported by cytogenetics, FISH 
and X chromosome inactivation studies. The early proliferative advantage 
of MDS clones may be represented by increased cellular proliferation 
particularly in the myeloid lineage and potentially all hematopoietic 
lineages. Accumulating multiple alterations that may affect cycle 
regulation, transcription factors, growth factor receptors and tumor 
supressors, these clonal cells further expand with abnormal maturation 
and increased rates of apoptosis. Excessive apoptosis of hematopoietic 
progenitor cells may contribute to the defining features of MDSs, 
including dysplastic morphological features, ineffective hematopoiesis 
and marrow failure. Alongside this observation some studies suggest that 
disease progression may be accompanied by decreased rates of apoptosis, 
because susceptibility to intramedullary cell death changes with changing 
phenotype40.  
Laboratory Diagnosis of MDS:  
The diagnosis is established after a careful examination of 
peripheral blood smear and along with a bone marrow aspirate and/or 
biopsy.  Isolated anemia(Hb < 11g/dl) is the most common presentation 
in about 85% of cases but rarely, it can present with isolated 
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thrombocytopenia. An even less common presentation is isolated 
neutropenia41 .The anemia can be Normocytic, Macrocytic or Microcytic 
accompanied by a low reticulocyte count. Other RBC abnormalities that 
can be observed are anisopoikilocytosis, basophilic stippling, Howell-
Jolly bodies, fragmented cells and nucleated red cells. There may be 
monocytosis, basophilia eosinophilia, or lymphocytosis. Cytoplasmic 
hypogranularity and hyposegmented neutrophils (pseudo- pelger Huet 
anomaly) are other characteristic feature. Few circulating Myeloblasts 
may be seen. Platelets can be large and both hypogranular and 
hypergranular forms can be seen. Bone marrow: Marrow is usually 
hypercellular. Cellularity may be decreased and in such cases trephine 
biopsy of marrow is more informative regarding cellularity and 
percentage of blast cells than a marrow aspirate. The hallmark finding is 
dysplasia in all three lineages – Dyserythropoiesis, Dysgranulopoiesis 
and Dysmegakaryopoiesis42. Dysplasia   should be seen in a minimum of 
ten percent or greater of the marrow cells of the concerned lineage. The 
subgroup determination of MDS can be made after taking in to 
consideration the four features such as the percent bone marrow Blasts, 
presence of Auer rods, percent of Ringed Sideroblasts, and absolute 
number of Monocytes in the peripheral blood. Erythroid Lineage: There 
is megaloblastic erythropoiesis. Features of dyserythropoiesis are 
distorted nuclear cytoplasmic maturation, nuclear budding, irregular 
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nuclei, karyorrhexis, intranuclear bridging, multinuclearity. Cytoplasmic 
abnormalities include vacuolization, basophilia and poor 
hemoglobinisation. The other characteristic morphologic feature is 
Ringed Sideroblasts. They have five or more granules/cell and encircling 
more than one third of nucleus and should be more than 15% in the 
Refractory Anemia with Ringed Sideroblast subtype of MDS.   
Erythropoiesis is shifted to left and the number of erythroid precursors 
varies between five to fifty percent.43.  Myeloid series Myeloid 
hyperplasia is usually seen in MDS. There is hypogranularity and 
hyposegmentation of myeloid cells. Other nuclear dysplastic features that 
can be observed are ring shaped nuclei, nuclear sticks and clumping of 
chromatin44 .Platelet Abnormalities In the marrow, there is 
megakaryocytic hyperplasia or the number is normal. The characteristic 
abnormalities are Micromegakaryocytes, Multinucleated megakaryocytes 
and Hypolobated megakaryocytes. Hypolobated megakaryocytes are 
more common in 5q- syndrome.  Micromegakaryocytes(dwarf forms), are  
two times less than the diameter of a neutrophil, and hypolobated 
megakaryocytes are moderate sized with monolobate eccentric nuclei and 
hypogranular cytoplasm45. Blast cell characterization in MDS 
Identification of Blast cells is most important in classification and 
prognostication of MDS. The overall survival and overt leukemic 
progression is determined by the percentage of blast cells in marrow.46 
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Three types of blasts can be recognized that may have prognostic 
significance. Type I blasts:  These cells bear a  resemblance to  pro-
myelocytes,  have a  reticular nuclear chromatin pattern and  one to three 
nucleoli, with a  moderately basophilic cytoplasm. Cytoplasmic granules 
and Auer rods are absent. Type II blasts: These cells contain few 
azurophilic granules and a lower nuclear/ cytoplasmic ratio. Type III 
blasts: these are blast cells with more than or equal to 20 azurophilic 
granules without a golgi zone. 
Table 2: FAB classification of MDS 
Morphologic Subtype Peripheral Blood Bone Marrow MDS Diagnoses, % 
Refractory anemia 
(RA)  Blasts <1% 
 Blasts <5% 
ringed sideroblasts 
<5% 
10 -40 
Refractory anemia 
with 
ringed sideroblasts 
(RARS) 
Blasts <1% 
Blasts <5% 
ringed 
sideroblasts>15% 
10 -35 
Refractory anemia 
with excess 
Blasts(RAEB) 
Blasts <5%    Blasts 5-19% 25 -30 
Refractory anemia 
with excess 
blasts in 
transformation(RAEB-
t) 
Blasts > 5% Or  
Auer rods present 
 Blasts 20- 29% 
Or  Auer 
Rods present 
10 -30 
Chronic 
myelomonocytic 
Leukemia(CMML) 
 Blasts >5% 
<1 x 109/L 
monocytes 
 Blasts <20% 10 – 20 
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Table 3: WHO CLASSIFICATION OF MDS 
MDS Subtype 
(WHO) Peripheral Blood Bone Marrow 
FAB 
Subtype 
Refractory 
cytopenia with 
unilineage 
dysplasia(RCUD) 
Anemia 
Absent/rare blasts 
unilineage dysplasia 
<5% blasts 
<15% ringed 
sideroblasts 
RA 
Refractory anemia 
with ring 
sideroblasts(RARS) 
Anemia 
Absent blasts 
Isolated erythroid 
dysplasia 
<5% blasts 
<15% ringed 
sideroblasts 
RARS 
MDS with isolated 
del 5q 
Anemia 
 Blasts <5% 
Normal to increased 
platelets 
Normal to increased 
megakaryocytes 
with hypolobulated 
nuclei 
<5% blasts 
Absent Auer rods 
Isolated (del)5q 
RA 
Refractory 
cytopenia with 
multilineage 
dysplasia (RCMD) 
Bi/pancytopenia  
No/rare blasts 
No Auer rods 
Monocytes< 1x 
109/L . 
 dysplasia in > 10% of 
the cells of >2 myeloid 
cell 
lines 
<5% blasts 
No  Auer rods 
<15% ringed 
sideroblasts 
RA 
 
RCMD – RS 
Bi/pancytopenia  
No /rare blasts 
No  Auer rods 
Monocytes< 
1x109/L. 
 dysplasia in >10% of 
the cells of >2 myeloid 
cell 
lines 
<5% blasts 
Absent Auer rods 
>15% ringed 
sideroblasts 
RARS 
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Refractory anemia 
with excess blasts – 
1(RAEB -1) 
Cytopenias 
<5% blasts 
No  Auer rods 
Monocytes 
<1x109/L 
Unilineage or 
multilineage dysplasia 
5%–9% blasts 
No  Auer rods 
RAEB 
Refractory anemia 
with excess blasts – 
2(RAEB – 2) 
Cytopenias 
5%–19% blasts 
Auer rods Present 
or absent 
Monocytes<1x109/L 
Unilineage or 
multilineage dysplasia 
10%–19% blasts 
Auer rods Present or 
absent 
RAEB 
MDS – unclassified Cytopenias 
Absent/rare blasts 
Absent Auer rods 
Unilineage dysplasia in 
granulocytes 
of megakaryocytes 
<5% blasts 
Absent Auer rods 
….. 
 
MDS with isolated del 5q syndrome 
  This is a distinct clinical category within the WHO classification of 
MDS. This is a disease of elderly women characterized by 
thrombocytosis with transfusion dependent anemia of macrocytic type 
which is therapy resistant. Marrow demonstrates large number of 
hypolobated forms of megakaryocytes with paucity of erythroid 
precursors. There is mild leucopenia and normal marrow blast count. The 
clinical course is mild and prognosis is good47. 
Trephine biopsy in MDS48 
Bone marrow biopsy in MDS is useful to determine cellularity of 
marrow, Abnormal Localization of Immature Precursors (ALIP), 
Reticulin fibrosis, Megakaryocytic dysplasia, lymphoid aggregates and 
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Hypoplastic MDS. There is increase in number of dysplastic early 
normoblasts and proerythroblasts. The late normoblasts are reduced 
disturbing the normal maturation. Megaloblasts have regular and uniform 
nuclei with linear nucleoli and these should not be mistaken for blasts. 
There is preponderance of early and intermediate megaloblasts and the 
late megaloblasts demonstrate dyserythropoiesis. Clusters of more than 
five blasts are abnormally located in the central parts of the marrow 
(ALIP). Normally the blasts are located in paratrabecular location. The 
higher the number of ALIPs, the worse is prognosis. Megakaryocytes are 
increased in number and many are seen in paratrabecular location. 
Normally they are seen in central parts of the marrow. 
Micromegakaryocytes are characteristics and CD41/CD61 may be used to 
confirm. Hypolobation,giant forms, irregular nuclear lobation and 
maturation are well made out in biopsy. 
Marrow demonstrates increased in Reticulin in 20% of the cases 
and this is associated with increased number of megakaryocytes in the 
marrow. There is increased apoptosis in MDS. Neovascularisation is 
significantly increased and Angiogenesis is correlated with 
transformation to acute leukemia54. 
Differential diagnosis  
  Dysplastic changes in one or two cell lines are seen in some 
conditions which may be difficult to differentiate from MDS. The non 
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malignant hematological conditions that are associated with 
Myelodysplasia are vitamin B12/folic acid deficiency, exposure to 
arsenic and other heavy metals, Congenital Dyserythropoietic anemia, 
Paroxysmal Nocturnal Hemoglobinuria HIV infection parvo virus B19 
infection, G-CSF therapy. Hematological malignancies associated with 
myelodysplasia are Hypoplastic AML, Myeloproliferative disorders, 
AML – therapy related and AML in the elderly, Idiopathic myelofibrosis, 
accelerated phase of CML. 
Vitamin B12 and folic acid deficiencies display morphologic 
alterations in all the hemopoietic cell lines and these revert with 
appropriate therapy. G-CSF therapy induces marked dysplasia of 
neutrophil series with hyper granularity; Dohle bodies and nuclear 
hypolobation and blasts may increase up to 10%. HIV infection results in 
dysplastic hemopoiesis. Lead poisoning leads to microcytic hypochromic 
anemia with basophilic stippling and Sideroblastic erythropoiesis. HIV 
associated dysplasia includes dyserythropoiesis, dysmegakaryopoiesis 
and giant metamyelocytes without hypersegmented neutrophils. 
Following zidovudine therapy erythropoiesis is megaloblastic and 
dysplastic changes are greater. However in HIV infection, blasts are not 
increased. 
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Variants of MDS49 
Hypoplastic MDS:  
Nearly, ten to fifteen percent of cases of Myelodysplastic 
syndromes are of hypocellular MDS type with higher prevalence in 
females. In these cases there are severe cytopenias and cellularity of 
marrow is <30% in adults who are less than 60 years or less than 20% in 
those more than 60 years of age. Majority of patients present with 
Refractory Anemia (RA). The diagnosis of MDS is made when the 
dysplastic features of megakaryocytes/and/or myeloid cells, excess of 
blasts and a cytogenetic abnormality is demonstrable.  
Hypoplastic MDS needs to be demonstrated from Hypocellular 
AML and Aplastic anemia. In MDS fibrosis is more and unlike in aplastic 
anemia megakaryocytes are seen. CD34 is useful for demonstration of 
blasts. In these cases, response to immunosuppressive therapy is better 
than in cases with normo/hypercellular marrow. Prognosis is similar to 
the cases with normo/hypercellular MDS. 
Secondary/therapy related MDS:   
Alkylating agents, radiation, benzene, toxins and HIV infection 
cause secondary MDS. The mean age of presentation is 10 years younger 
than that of primary MDS. Marrow demonstrates normal or increased 
cellularity and there is striking Trilineage dyspoiesis. There is 
pronounced pancytopenia and most of the cases are of RAEB type. 
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Peripheral smear demonstrates marked anisopoikilocytosis and nucleated 
RBCs.  
    Trephine biopsy is valuable in differentiating secondary MDS from 
primary type. Stromal changes like increased reticulin, stromal edema 
and gelatinous marrow transformation are observed. There may be 
necrosis of bone and marrow. In secondary MDS other marrow changes 
include presence of plasma cells, reactive lymphoid nodules and 
granulomas in the trephine biopsy. 
    Therapy related MDS are of two types – MDS occurring after 
many years of alkylating drug intake and are associated with del 7q 
and/or del 5q abnormalities and MDS resulting after more than two years 
of use of topoisomerase II inhibitor drugs. Both these subtypes frequently 
evolve into AML than denovo MDS. Therapy related MDS is very 
aggressive in its clinical course. 
MDS with fibrosis of marrow:  
MDS-f is characterized by marked increase in bone marrow 
reticulin fibres, pancytopenia and minimal organomegaly. They comprise 
nearly 10% of primary MDS cases. There is trilineage dysplasia with 
prominent dysmegakaryopoiesis. Majority of the cases demonstrate 
RAEB type picture. Since there is increased marrow fibrosis, CD34is 
useful in demonstrating blasts in fibrous tissue; which usually are not 
discerned in the bone marrow aspirate. 
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MDS-f should be differentiated from other disease states in which 
there is marrow dysplasia with fibrosis like AML M7, AML with 
multilineage dysplasia, primary myelofibrosis and CML in accelerated 
/blastic phase with marrow fibrosis. 
MDS of childhood:  
MDS of childhood is relatively rare in comparison to MDS of the 
elderly. Most of the childhood MDS cases become symptomatic rather 
early and transform in to AML in a very short span.MDS in children has 
an aggressive clinical course irrespective of the WHO subtype. There are 
many differences between MDS in children and adults.e.g. RARS is 
extremely rare in children. Childhood MDS is more often associated with 
pre-existing marrow failure or congenital abnormalities like Kostmann’s 
syndrome, Schwachmaann- Diamond syndrome, Diamond- Blackfan 
anemia, Fanconi anemia, Down’s syndrome, Neurofibromatosis I and 
Juvenile Xanthogranuloma. Juvenile MyeloMonocytic leukemia (JMML) 
is the commonest. Cytogenetic abnormalities occur in 60-70% of primary 
MDS in children. In primary MDS, monosomy 7 is the most common 
cytogenetic abnormality. 
Prognosis in MDS:   
MDS patients have a reduced life expectancy compared with 
normal controls. This difference is marked in patients who are less than 
60 years. Though the WHO classification of MDS is of prognostic 
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significance, scoring systems provide objective parameters for improved 
reproducibility. International prognostic scoring system (IPSS) is 
computed from three parameters – marrow blast percentage, number of 
lineage affected and bone marrow cytogenetics. Of the different types of 
MDS, pure sideroblastic anemia and the 5q- syndrome are associated 
with an excellent prognosis with a low rate of transformation in to acute 
leukemia.50 
Table 4: International Prognostic Scoring System (IPSS) 
  Risk score 
AML 
Transformation % 
Median survival 
(years) 
Low  0 19 5.7 
Intermediate-1 0.5-1.0  30 3.5 
Intermediate - 2 1.5-2.0 33 1.2 
High  2.5 45 0.4 
 
Management of MDS:  
The only treatment is Allogenic stem cell transplantation. 
Management is individualized and guided by patient’s age, prognosis and 
toxicity of treatment. Low risk MDS is associated with longer survival. 
Hence amelioration of hematological deficits is the therapeutic goal. 
Treatment consists of erythropoietin and combined administration of G-
CSF and GM-CSF, immunosuppressive therapy, antiangiogenic agents 
and management of neutropenia. High risk MDS have risk of leukemic 
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transformation and shorter survival. Hence, prolongation of survival and 
warring of leukemic evolution is the target. 5- azacytidine, a DNA 
hypomethylating/ methyl transferase inhibitor is the most promising 
therapy for improved quality of life in MDS. 
11. Unexplained Anemia of Elder People:  
A mild, normochromic normocytic anemia with a hemoglobin 
concentration usually between 11 and 12 g/dL has been observed in 
people above the age of seventy years.  More than thirty percent of the 
anemias in the older adult might be put under the category of this 
Unexplained anemia51. The pathogenesis of unexplained anemia in 
geriatric patients is poorly characterized, and it is primarily a diagnosis of 
exclusion51. Several possible mechanisms have been put forth to explain 
this type of anemia. These include alterations in hematopoietic stem and 
erythroid progenitor cell number and/or function, hypogonadism, decline 
in renal function with age and/or a reduction in erythropoietin secretion 
and finally the presence of early or overt Myelodysplastic syndromes.  It 
is a hypoproliferative anemia and is characterized by a low absolute 
reticulocyte counts and a low reticulocyte index52. Other associated 
features are low lymphocyte, neutrophil, and platelet counts. One other 
feature that implies that this condition is not   merely a normal age – 
related variant is the increased red blood cell 2, 3 – DPG level present in 
these patients53. Traditionally, it is thought that in response to hemolytic 
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anemia, the bone marrow is able to attain a compensatory increase in 
erythropoiesis of about eight fold in children and about fivefold in adults. 
However this does not hold true for the older adult. Certain other factors 
need to be emphasized   when taking in to account the unexplained 
anemias in the elderly. The first is the undetermined potential impact of 
changes in levels of testosterone or estrogen with age. Next is that, older 
individuals have a tendency for poly pharmaceutical usage. A variety of 
these drugs are capable of suppressing erythropoiesis. Lastly, careful 
inquiring of all considerable co morbid conditions in an older person’s 
medical history is essential in defining and managing unexplained anemia 
in elderly. 
        Myelodysplastic syndrome (MDS) is likely to be the cause of   
anemia in a significant   percentage of elder individuals with Unexplained 
anemia. MDS is primarily a disease of the older adult with a median age 
at diagnosis of 65 years. Approximately 5-15% of elder patients with 
unexplained anemia are liable to have Myelodysplastic syndromes using 
French American British criteria and a further minor subgroup of patients 
may have abnormalities that are suspicious for, but not confirmatory of 
MDS54. Aditional studies are needed to better categorize these patients, 
called pre-MDS category and for better understanding their long term 
prognosis. Emerging molecular techniques to detect clonal hematopoiesis 
are expected to provide a vital part in this category55. Indications for  
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Bone Marrow Aspiration or Biopsy  in these patients are56 (1) peripheral 
blood film with immature white cells or nucleated red cells, (2) 
Pancytopenia, (3) Monoclonal Gammopathy, (4) Suspicion of MDS,  
(5)Indeterminate status of iron stores or (6)Unexplained progressive or 
refractory anemia. 
12. Myeloproliferative/ myelodysplastic(MPD/MDS) neoplasms 
     This group of overlap disorders demonstrates features of both 
myeloproliferation and myelodysplasia and includes chronic 
myelomonocytic leukemia (CMML), atypical chronic myelogenous 
leukemia, juvenile myelomonocytic leukemia (JMML) and unclassifiable 
MPD/MDS neoplasms57. CMML This clonal neoplasm is characterized by 
monocytosis persistent for more than three months. There is ineffective 
hematopoiesis leading to anemia and thrombocytopenia. These cases are 
bcr/abl negative. Monocytosis is almost always more than ten percent of 
the white cells. Blasts and promonocytes are less than twenty percent. 
Bone marrow is hypercellular with myeloid hyperplasia and increased 
monocytes and promonocytes. Mild degree of dyserythropoiesis and 
dysmegakaryopoiesis are present. Monocytic series are confirmed with 
non-specific esterase stain. Reticulin fibrosis is present. The common 
cytogenetic abnormality is t (5; 12) (q33:p13). Atypical CML It is a rare 
Ph negative MPN. Anemia is more severe than CML. Total count is less 
than in typical CML and usually in the range of 24-100x109 /L. 
42 
 
promyelocytes,myelocytes and metamyelocytes are fewer than in CML 
and constitute 10-20% 0f WBCs. Monocytosis is more than typical CML 
but less than in CMML. Platelets are diminished. Bone marrow is hyper 
cellular with myeloid hyperplasia with multilineage dysplasia.  Blasts are 
less than twenty percent. Patients with aCML have a poor prognosis with 
median survival of about two years. JMML This is a bcr/abl negative 
distinct entity seen in very young children aged less than two years and is 
characterized by a prominent monocytic component and is clinically an 
aggressive disease. 
Unclassifiable MDS/MPD neoplasms:  
Cases which are in transition and have not evolved into any distinct 
entity are included in this subgroup. The diagnostic criteria are (i) no 
preceding history of growth factor or cytotoxic therapy or MPN or of 
MDS. (ii) myeloproliferative features like platelet count >450x 109/L, 
splenomegaly and TLC > 13x 109/L. (iii) hematologic and clinical 
findings of one of the categories of MDS with <20% blasts in blood/BM. 
Leukemias in Elderly 
Most Leukemias have a predilection for the adult age group 
possibly with the exception of Acute Lymphoblastic Leukemia (ALL). In 
elderly, the commonest types of leukemia are Acute myeloid Leukemia 
(AML), Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia 
and Acute Lymbhoblastic Leukemia. Other less common forms are Hairy 
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cell leukemia, Large Granular Lymphocytic Leukemia and Adult T-cell 
Leukemia. AML: The incidence of Acute myeloid leukemia increases 
with age. The median age group is around sixty seven years. Men are 
more commonly affected. The subtypes of AML common in elderly age 
group are erythroleukemia (FAB M6), acute megakaryoblastic leukemia 
(FAB M7) and the rare acute panmyelosis with myelofinrosis.anemia and 
thrombocytopenia are present in nearly all cases58. In aleukemic leukemia 
total count is low. In bone marrow, blasts constitute more than 20% of 
non erythroid cells of marrow. Auer rods are the most reliable 
morphological feature of AML. These are prominent in AML M2 and 
AML M3. AML-M6: this is rare leukemia constituting only 3-4% of all 
cases of AML. The criteria for AML- M6 are (i) erythroblasts more than 
50% of bone marrow nucleated cells (ii) blasts more than 20% of bone 
marrow non erythroid cells. In pure erythroid leukemia the early 
erythroblasts are more than 80% of the marrow cells. AML-M7: it is an 
uncommon form of AML accounting for 8-10% of all cases in adults and 
2-3% of cases in children. It is not an uncommon form of blast crisis in 
CML since it occurs in nearly 20% of Ph positive CML cases. AML has a 
dismal prognosis in the elderly. This could be due to the following 
reasons.  
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(i) Elder patients are unable to tolerate the intensive cytotoxic 
chemotherapy.  
(ii) They have a higher incidence of co morbid disorders, poor tolerance 
to infections and a poor organ reserve.  
(iii) It frequently arises from antecedent MPD or MDS which is common 
in elderly and associated with poor prognosis.  
(iv) Higher incidence of unfavourable risk cytogenetics in elderly such as 
inv(3), t(11:19), t(6:9), del5, del 7.59 
ALL: Although commoner in children, a second peak is usually 
seen after the age of fifty years for ALL. The incidence is 1.0 to 1.6/ 
100,000. Advanced age along with increased leucocyte count, 
immunophenotype and cytogenetics is a poor prognostic factor for ALL. 
The Philadelphia positivity status rises with increasing age in these 
patients which is associated with a poor prognosis60. CLL: It usually 
affects adults over the age of fifty five years. It is a low grade malignancy 
with a survival rate of seventy five percent. CML: This is the most 
common leukemia encountered in India. It is a clonal myeloproliferative 
neoplasm arising from neoplastic transformation of stem cell resulting in 
overproduction of normal appearing granulocytes. The hallmark finding 
is the Philadelphia chromosome t (9: 22). CML passes through a triphasic 
course of (i) chronic phase of massive leucocytosis (ii) accelerated phase 
with sudden rise in blast cells and clinical deterioration and (iii) blast 
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crisis with blasts more than twenty percent in bone marrow with rapid 
deterioration clinically. Its incidence increases with age with more than 
50% patients diagnosed at more than or equal to sixty years of age61. 
Survival rate is above ninety percent. Peripheral smear: there is marked 
leucocytosis with total count ranging from 30x 109/L to 500 x 
109/L.neutrophils and myelocytes are the predominant cells in chronic 
phase. Basophils are more in accelerated phase. Presence of tear drop 
cells and anisopoikilocytosis suggests fibrosis of the marrow. 
Thrombocytosis varies from 300 – 600 x 109/L. neutrophil alkaline 
phosphatase score is markedly diminished to 0 – 20. Bonemarrow: 
marrow is hypercellular with replacement of fat by hyperplastic 
hemopoietic cells with marked myeloid hyperplasia and an elevated M: E 
ratio. Blasts are more than 20% in blastic crisis. Pseudo- Gauchers cells 
are macrophages with granular cytoplasm scattered among the marrow 
cells formed due to increased lipid turnover from granulocytic 
membranes and accumulating in the macrophages. Differential diagnosis: 
(i) leukemoid reaction: in CML, marrow is hypercellular with loss of fat, 
while fat spaces are made out in the marrow in a case of leukemoid 
reaction. Lack of basophilia and eosinophilia with high NAP score is 
suggestive of a leukemoid reaction. (ii) Essential thrombocythemia – 
there is marked megakaryocytic hyperplasia with myeloid and erythroid 
proliferation. Clinical picture, blood picture and bcr/abl fusion gene are 
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taken in to account to differentiate essential thrombocythemia from 
CML.(iii) cellular phase of idiopathic myelofibrosis- marrow is 
hypercellular with hyperplasia of all the three cell lines with normal 
maturation. Megakaryocytic proliferation is more marked with many 
immature and dysplastic forms present in clusters.    
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MATERIALS AND METHODS 
        This prospective study was conducted in the Department of 
Pathology, Tirunelveli Medical College & Hospital under due approvals 
of the TVMC Institutional Research Ethics Committee. Patients were 
sourced from the Departments of General Medicine, General Surgery, 
Oncology and Geriatric Medicine over a period of two years from 
September 2010. 
         Geriatric patients of age more than 60 years who are presenting with 
anemia, fulfilling the WHO criteria of anemia (Hemoglobin <13gms/dl in 
males, <12gms/dl in females) were enrolled in the study. Sixty five 
patients were selected non consecutively. Consent was taken from all 
patients. The following were taken as the Inclusion Criteria: namely (1) 
Patients more than 60 years of age (2) Patients of all gender 
predispositions (3) Patients with anemia as per WHO standards. The 
patients were excluded as per the following Exclusion Criteria: (1) 
Patients with a history of recent transfusion (2) Patients who have 
undergone major surgical procedure in the past 3months. (3) Acute and 
Terminally ill patients. 
            Sixty five patients who satisfied our selection criteria were 
selected for the study. A detailed clinical interview was undertaken and 
all details regarding age, gender, occupation, racial characters, socio 
economic milieu, presenting complaints, previous history as pertaining to 
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the presenting complaints, history of exposure to chemicals or drugs, 
dietary habits, co-morbid conditions, were recorded. A detailed clinical 
examination was done and presence of organomegaly, lymphadenopathy, 
clubbing, cyanosis, pedal edema etc as per protocol was recorded. 
             A standardized set of lab investigations were ordered for all these 
patients - Complete Blood Count, Basic Clinical Chemistry, Liver 
Function Tests, Thyroid Profile, Reticulocyte Count and Peripheral Blood 
Film.  Radiological investigations such as roentgenogram, sonographic 
studies, CT scans and MRI were performed based on clinical needs. 
Some patients were given an endoscopic analysis of the upper and lower 
GIT as clinically required.  
            All the patients who were selected for the study were advised a 
bone marrow aspiration study as per standard clinical protocols of our 
hospital. It was advised in patients with blood smear showing microcytic, 
normocytic, macrocytic or dimorphic blood picture, cytopenia, and 
abnormal cellular morphology. Bone marrow was aspirated from the 
sternum or the posterior superior iliac crest, using a Salah needle. 
Aspirated were used to make 8-15 smears. The smears were air-dried, 
fixed in methanol and stained with Leishman’s stain as per standard 
protocol. One smear was saved for perl’s stain. The Bone marrow 
samples were examined and the findings were recorded in a standard 
format.  The smears were assessed for (1)Degree of Cellularity - graded 
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as hypocellular, normocellular or hypercellular (2) Relative distribution 
of erythroid, myeloid, and lymphoid cells (3) Morphological 
abnormalities of the erythroid, granulocytic, and megakaryocytic series 
(4) Presence of other cells. The finding was recorded.  
 The results were tabulated and statistically analyzed.  
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The age of the patients enrolled in our study was between 60 to 85 years. 
The mean age was 66.65 years.  Most of the patients were in the age 
group of 60–69 years (73.84%). 23.08% patients were between 70-
79years and 3.08% above 80years of age. (Table 5) .Of the 65 patients, 
34 (52.31%) were women  and 31 (47.69%) were Men. 22 men and 26 
women were between 60 – 69 years, 8 men and 7 women were between 
70-79 years.(Table 5)(Chart 1)   
Table 6  Distribution of the Presenting Complaints 
Symptoms No of Patients Percentage 
Fatigue 24 36.92 
Dyspnoea 19 29.23 
Pedal edema 13 20.00 
Abdominal pain 9 13.85 
Neurological 3 4.62 
GI Bleed  3 4.62 
Others 8     12.31  
 
The most common presenting complaint was Fatigue found in 
24(36.92%) patients. The next common symptom was Exertional 
dyspnoea which was present in 19(29.23%) patients. These were 
followed by pedal edema and abdominal pain which was present in 
13(20%) and 9(13.85%) patients respectively. 3(4.62%) patients 
presented with neurological symptoms and another 3(4.62%) patients 
with bleeding diathesis. Other less common symptoms accounted for 
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12.31%.  Many patients had overlapping symptoms amongst these.  
(Table 6)  
Table 7 Co-morbid Conditions in the Study Group 
Condition No Of Patients Percentage 
Hypertension 21 32.31 
Diabetes 12 18.46 
Renal disease 7 10.77 
Tuberculosis 6 9.23 
Bleeding diathesis 6 9.23 
CAHD 5 7.69 
Malignancy 5 7.69 
Liver disease 4 6.15 
 APD 2 3.08 
Hypothyroid 1 1.54 
 
The co-morbid conditions associated with our study group were 
Hypertension(HT) seen in 21(32.31%) patients, Diabetes mellitus(DM) in 
12(18.46%) patients and  Renal  disease  in 7(7.69%) patients. 6(9.23%) 
patients had a history of Tuberculosis(PT) and another 6(9.23%) patients 
had a history of gastrointestinal and/or  genitourinary bleed. An H/O 
coronary artery heart disease (CAHD) was present in 5(7.69%) patients.  
Liver disease was present in 4(6.15%) patients. H/O of solid organ 
malignancy was present in 5(7.69%) patients, 2(3.08%) had H/O Acid 
Peptic Disease (APD) and 1(1.54%) patient was a hypothyroid.  (Table 
7). Overlapping features were present in many patients. 
 Table 8
Endoscopic Findings
Mucosal Erosions
Congestion 
Normal 
Ulceration –Stomach
Mucosal  Prolapse
Grade II Varices
Growth 
Total 
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Out of the total 65 patients, 29 patients underwent Upper Gastro 
intestinal endoscopy. Endoscopy revealed normal findings in 4(13.79%) 
patients, mucosal erosions in 10(34.48%) patients, congestion in 
9(31.03%patients) and gastric ulcers in 3(10.34%) patients. Esophageal 
varices was present in 1(3.44%) case, an ulceroproliferative gastric 
growth in 1(3.44%) patient and mucosal prolapse in 1(3.44%) of our 
patients. (Table 8)(Chart 2). 
 
Table 9 Severity of Anemia 
Severity Gender No of Patients Total Percentage 
Mild 
Men 2 (3.08%) 
7 10.77 
Women   5 (7.69%) 
Moderate 
Men 13 (20%) 
24 36.92 Women   11 (16.92%) 
Severe 
Men  16 (24.62) 
34 52.31 
Women  18 (27.69) 
Total 65 100 
 
 
 
 
  
  
Hemoglobin estimation done in all patients revealed mild anemia 
in 7(10.77%) patients, a moderate degree of anemia in 24(36.92%) 
patients and severe anemia in 34(52.31%) patients. Out of the 7 cases of 
mild anemia, 5 were 
moderate anemia, 13 were men and 11 were women. Out of the 34 cases 
of severe anemia, 16 were men and 18 were women
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 Table 10 Peripheral Smear Findings
Type of anemia
Microcytic
Dimorphic
Normocytic
Macrocytic
Pancytopenia
Total
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5(7.69%) patients. (Table 10)(
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 32 49.23 
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 10 15.38 
 6 9.23 
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hypochromic anemia (MCHC) was observed in 
anemia (DA) in 12(18.46%) patients, a 
NA) in 10(15.38%) patients and a Macrocytic 
Chart 4).  
Dimorphic Normocytic Macrocytic Pancytopenia
18.46
15.38
9.23
7.69
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Table 11 Bone Marrow Cellularity 
Marrow Cellularity No of Patients Percentage 
Normocellular 30 46.15 
Hypocellular 7 10.77 
Hypercellular 28 43.08 
Total 65 100 
 
Bone marrow aspiration was done in all patients. It showed 
Normocellular marrow in 30(46.15%) patients, Hypocellular marrow in 
7(10.77%) patients and Hypercellular marrow in 28(43.08%) patients. 
(Table 11). 
Table 12 BM Diagnosis 
Diagnosis No of cases Percentage 
Non-malignant 
Hematological 
Disorders 
55 84.62 
Hematologic 
malignancies 
10 15.38 
Total 65 100 
 
Overall, non- malignant hematologic disorders were observed in 
55(84.62%) patients and hematologic malignancies were observed in 10 
(15.38%) patients. (Table 12) 
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Table 13 Spectrum of Bone Marrow Aspiration Findings 
S.No Marrow Findings Men Women Total % 
1. Reactive Erythroid wth  
Hyperplasia of Marrow 
Micronormoblastic 
Erythroid Maturation  
12 15 27 41.54 
2. Megaloblastic Marrow  7 6 13 20.0 
3. Reactive Erythroid with 
Hyperplasia of Marrow 
Micro and 
Macronormoblastic 
Erythroid Maturation  
6 4 10 15.38 
4. Megaloblastoid Marrow 
with Unilineage 
dysplasia. (MDS) 
1 0 1 1.54 
5. Megaloblastoid Marrow 
with. Bi/multilineage 
dysplasia 
3 1 4 6.15 
6. Megaloblastoid Marrow 
with Multilineage 
Dysplasia and Excess of 
Myeloblasts  
0 1 1 1.54 
7. Acute Meylogenous 
Leukemia AML M1 
0 1 1 1.54 
8. Chronic Myelogenous 
Leukemia (Chronic 
Phase) 
0 1 1 1.54 
9. Chronic Myelogenous 
Leukemia (Accelerated 
Phase) 
1 1 2 3.08 
10 Possibly MDS 1 4 5 7.69 
 Total 31 34 65 100 
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diagnosed in 1(1.54%) female patient, Chronic Myeloid leukemia in 
3(4.63%) patients. Among them 1 was a male and 2 were women.  A 
possibility of a probable MDS was suggested in 5(7.69%) patients. (Table 
13)(Chart 5).  
Table 14 Comparison of Co morbidities and bone marrow diagnosis 
Co-morbid 
Conditions 
REH 
micronormo 
blastic 
maturation 
REH 
Micro and 
macro 
Normo 
blastic 
maturation 
Megalobl
astic 
anemia 
MDS Leukmia P/O MDS 
HT 9 3 5 3 - 1 
DM 4 1 3 2 1 1 
CAHD 2 1 -- 1 - 1 
Renal  Disease 3 -- 3 - 1 - 
Liver  Disease 2 1 1 - - - 
Old PT 3 1 2 .. - - 
APD … … 1 1 - - 
Hypothyroid 1 - - - - - 
Malignancy 3 -- 1 - - 1 
 
In patients with Reactive Erythroid Hyperplasia (REH) of marrow 
with micronormoblastic maturation, Hypertension was present in 9 
patients. Diabetes mellitus was present in 4 patients.  A  H/O GI/GU 
bleed was present in 5 patients of which one had oesophageal varices on 
endoscopy. H/O Renal disease was present in 3 patients and a H/O Liver 
disease was present in 2 patients. Of these two, 1 had evidence of 
hemolysis. UGI endoscopy detected malignancy in 1 patient. H/O 
pulmonary tuberculosis (PT) was present in 2 patients. Associated solid 
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organ malignancies were present in 3 cases and they had H/O 
chemotherapy/ radiotherapy. (Table 14) 
 In patients with reactive erythroid hyperplasia (REH) of marrow, 
with micro and macro normoblastic maturation. Hypertension was 
present in 3 patients. H/O Diabetes and CAHD was present each in one 
patient.  A H/o liver disease was present in one patient. (Table 14) 
In patients with megaloblastic anemia, 5patients had h/o 
hypertension, 3 had  Diabetes mellitus and one had a h/o CAHD.  One 
patient was hypothyroid. One patient had H/O chemotherapy for 
carcinoma breast. Renal parameters were elevated in three patients and 
liver disease was present in one patient. 2 patients had h/o old PT, and I 
patient had APD. (Table 14) 
           Out of the 6 patients with the diagnosis of MDS, no underlying 
liver or renal disease were found. The other associated co morbid 
conditions in these patients were CAHD in 1 patient, DM in 2 and HT in 
3 patients. (Table 14). In the patients with acute and chronic leukemia, an 
associated renal disease was present in one patient and DM in one patient.            
Among 5 patients with the diagnosis of a possibility of MDS, one patient 
was a case of carcinoma breast with H/O chemotherapy. One had a 
history of diabetes and treatment for PT and another one patient was a 
known case of CAHD. (Table 14) 
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Table 15 Comparison of the RBC Morphology and MCV in patients 
with Iron Deficiency Anemia 
 
Sl. 
No 
Anemia 
Grade 
Hb 
g% 
MCV 
Retic 
% 
WBC 
x103/mm3 
Platelet 
Count 
x105/mm3 
Peripheral 
Smear 
Iron 
Stores 
1 I 10.3 88.7 1.5 6.5 2.98 Normocytic  Absent  
2 III 6.5 72.8 1 4.2 1.1 Normocytic Absent 
3 I 10.4 97.4 1 5.8 90 Normocytic Absent  
4 I 11.2 77.6 0.5 3.8 1.06 Normocytic  Absent  
5 II 7.7 86.6 0.5 4.1 1.52 Normocytic Absent 
6 III 6.3 93.6 3 4.2 0.41 Dimorphic Absent 
7 II 7.5 86.4 1.3 7.3 1.50 MCHC Absent 
8 I 10.2 66.6 0.5 6.6 3.32 MCHC Absent 
9 II 8.9 78.9 1.2 6.3 4.32 MCHC Absent 
10 III 6.2 68.7 0.5 5.2 2.13 MCHC Absent 
11 II 8.3 56.5 1 7.3 2.65 MCHC Absent 
12 III 6.4 72.5 1 11 0.19 MCHC Absent 
13 III 5.7 73.5 0.6 6 3.8 MCHC Absent 
14 III 5.8 66.4 <0.5 10.6 3.55 MCHC Absent 
15 II 8.7 72.9 1.1 9.9 4.1 MCHC Absent 
16 III 5.7 76.9 0.5 9.2 1.48 MCHC Absent 
17 II 7.4 77.2 1 4.7 3.96 MCHC Absent 
18 II 7.1 65.5 0.5 5.4 2.31 MCHC Absent 
19 III 6.3 92.7 0.5 4.3 1.35 MCHC Absent 
20 III 5.3 64.3 0.4 5 2.98 MCHC Absent 
21 III 5.9 63.2 1.3 7.8 2.95 MCHC Absent 
22 III 6.8 79 1 6.4 3.35 MCHC Absent 
23 III 6.4 73.4 0.5 5.3 2.05 MCHC Absent 
24 II 8.2 69.6 0.6 5.6 2.29 MCHC Absent 
25 III 6.9 74.8 1 6.1 3.41 MCHC Absent 
26 III 5.7 62.9 0.5 2.9 1.13 MCHC Absent 
27 III 6.3 59.7 0.3 5.3 2.73 MCHC Absent 
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            The 27 patients with   REH   with   micronormoblastic maturation 
were given a diagnosis suggestive of a probable Iron deficiency Anemia. 
(IDA).  There was a severe anemia in 15 cases, moderate degree of 
anemia in 8 cases and a mild degree of anemia in 4 cases. MCV was 
normal in 6 cases,   < 80fl    in 21 cases and increased in none. 
Reticulocyte count was normal in 25 cases, decreased in 2 cases. 
Peripheral smear showed microcytic hypochromic blood picture in 21 
cases, normocytic in 5 cases and dimorphic anemia in 1 case. The marrow 
was hypercellular in 8 cases and normocellular in 19 cases. Perl’s stain 
showed absent iron stores in all cases. (Table 15) 
Table 16 Comparison of the RBC Morphology and MCV in patients 
with Combined Deficiency Anemia 
No Anemia 
Grade 
HB 
g% 
MCV Retic 
% 
WBC 
X103/
mm3 
Platelet  
Count 
x105/mm3 
   Blood  
   Film 
Iron 
Stores 
1 III 5.6 89.3 0.3 6.9 2.5 Dimorphic  Low 
2 III 6.2 74 1 10.5 1.8 MCHC Low 
3 III 5.1 70.8 2 7.3 1.42 MCHC Low 
4 II 9.3 87.4 0.5 4.7 3.16 Normocytic Low 
5 I 10.8 90.4 0.5 5.3 2.84 Normocytic Normal 
6 II 7.5 83.2 1.4 7.8 2.78 MCHC Normal 
7 II 8.3 86.5 0.5 6.5 3.26 MCHC Low 
8 II 8.7 82.6 1.6 7.4 2.53 Dimorphic Low 
9 I 10.4 88.3 1 4.9 1.79 MCHC normal 
10 II 6.8 81.7 1.2 6.3 1.85 Dimorphic Low 
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The 10 patients with REH with micro and macro normoblastic 
maturation were given a diagnosis as suggestive of a probable combined 
B12/ iron deficiency.  The anemia was severe in 3 patients, moderate in 5 
cases and mild in 2 cases. MCV < 80fl in 2 patients was observed in cases 
and was normal in 8 cases. Reticulocyte count was normal in 7 cases and 
decreased in 1 case and increased in 2 cases. Blood film showed 
microcytic hypochromic picture in 5 cases, dimorphic picture in 3 cases 
and normocytic in 2 cases. Marrow was normocellular in 6 cases, 
hypercellular in 4 cases. Perl’s stain showed low iron stores in 7 cases, 
normal iron stores in 3cases (Table 16) 
Table 17 Comparison of the RBC Morphology and MCV in patients 
with Megaloblastic Anemia 
No 
 
Anemia 
Grade 
HB 
g% 
MCV Retic 
% 
Platelet 
Count 
WBC 
x103/mm3 
   Blood 
    Film 
Iron 
Stores 
1 II 8.1 116.9 1.5 1.73 11.4 Macrocytic increased  
2 II 7.6 84.7 0.5 2.45 4.8 Normocytic  Increased 
3 II 8.3 98.4 0.5 2.11 6.4 Dimorphic  Low  
4 III 6.1 102.4 0.5 1.5 6.2 Macrocytic  Normal   
5 II 9.1 89.4 <0.5 3.3 12 Dimorphic  Normal 
6 III 6.6 94 1 2.69 4.3 Macrocytic  increased  
7 II 8.2 99.6 0.5 2.31 4.5 Dimorphic  Increased 
8 III 4.8 83.3 0.5 0.71 2.9 Dimorphic  Normal 
9 II 9.1 100.4 1 2.94 5.9 Dimorphic  Increased 
10 III 6.8 92.5 0.5 0.9 3.2 Pancytopenia   Increased 
11 II 7.0 66 <0.5 4.22 4.5 Macrocytic  Increased  
12 II 7.7 104 0.5 1.27 1.2 macrocytic Normal  
13 III 6.8 128 1.2 0.4 3.2 pancytopenia Increased  
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Of the 13 patients with megaloblastic anemia, the anemia was 
severe in 5 cases and of moderate degree in 8 cases. MCV was >100 fl in 
5 cases and was normal in 7 cases and decreased in 1 case. Reticulocyte 
count was normal in 11 cases, decreased in 2 cases. Blood film revealed 
dimorphic picture in 5 cases, macrocytic in 5 cases, normocytic in 1 case 
pancytopenia in two cases. The marrow was hypercellular in 8 cases and 
normocellular in 5 cases. Perl’s stain showed increased iron stores in8 
cases and normal iron stores in 4 cases. (Table 17) 
Table 18 Comparison of the RBC Morphology and MCV in patients 
with MDS 
No Grade 
HB 
g% 
MCV Retic 
WBC 
count 
x103/mm3 
Platelet 
count 
x105/mm3 
Blood 
Film 
Iron 
Stores 
1 III 4.9 129.3 1 2.5 0.3 Pancytopenia Increased 
2 III 4.7 90.1 0.5 4 0.105 Pancytopenia Normal   
3 III 6.5 91 1 3.2 0.33 Pancytopenia  Increased 
4 III 5.4 132.4 1.5 11.9 3.54 MCHC Increased  
5 III 6.8 65.3 0.5 5.8 2.92 Dimorphic Increased  
6 III 5.6 76.4 1 3.9 2.12 Dimorphic Increased  
 
Out of the 6 patients with MDS, the anemia was severe in all 
patients. MCV normal in 2 patients, <80fl in 2 patients and >80fl in 2 
patients. Reticulocyte count was normal in all cases.  Peripheral smear 
showed a pancytopenic blood picture in 3 cases, a dimorphic picture in 2 
cases and a microcytic hypochromic anemia in 1 patient. The marrow was 
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hypercellular in 4 patients and hypocellular in 2 patients. Perl’s stain 
showed increased iron stores in 5 patients and normal iron stores in one 
patient. (Table 18) 
Table 19 Comparison of the RBC Morphology and MCV in patients 
with Anemia: Possibly due to AML 
No Severity 
Grade 
HB 
Value 
MCV WBC 
Count 
x103cells/mm3 
Platelet 
Count 
x105cells/mm3 
Blood 
Film 
1 III 6.9 85.9 145 0.28 
MCHC 
Anemia/ 
 
The one patient with possible AML was a female with severe 
anemia. MCV was decreased.  Blood film was suggestive of acute 
leukemia with Microcytic Hypochromic anemia and Thrombocytopenia. 
(Table 19) 
Table 20: Comparison of the RBC Morphology and MCV in patients 
with CML 
No Severity 
Grade 
HB 
g% 
MCV WBC 
Count 
x103cells/mm3 
Platelet  
Count 
x105cells/mm3 
Blood 
Film 
1 II 7.7 83.3 125 3.19 MCHC 
Anemia 
2 III 6.7 106 153 3.24 Macrocytic 
Anemia 
3 II 8.9 63.7 90 1.74 MCHC 
Anemia 
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Of the 3 patients with CML, the anemia was of moderate degree in 
2 cases and was severe in one case. MCV was normal in one, increased in 
one and was reduced in the remaining one patient. Peripheral smear 
showed Microcytic hypochromic anemia in 2 cases and was Macrocytic 
anemia in one patient. One patient was in chronic phase and 2 were in 
accelerated phase. (Table 20) 
Table 21: Comparison of the RBC Morphology and MCV in patients 
with Anemia: Possibly due to MDS 
No Grade 
HB 
g% 
MCV 
Retic 
% 
WBC 
Count 
x103cells/
mm3
 
Platelet  
Count 
x105cells/mm3 
Blood Film 
1 III 5.9 78.2 2 7.8 2.3 Dimorphic  
2 II 9.1 107.3 0.5 3.7 1.93 Dimorphic 
3 I 11.1 97.5 1 5.4 3.15 Normocytic  
4 III 6.6 72.3 0.5 8.6 2.64 Microcytic  
5 II 7.9 86.6 0.5 9.1 2.32 Microcytic  
 
Of the five patients with the possible diagnosis of MDS, the 
anemia was severe in two patients, moderate in two patients and was of 
mild degree in one patient. MCV was decreased in two patients, normal 
in two patients and increased in one. Reticulocyte count was increased in 
one and normal in the remaining four patients. Total count was normal in 
three and increased in two patients. Platelet count was normal in all five. 
Peripheral smear showed dimorphic anemia in two cases, microcytic in 
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two and normocytic anemia in one patient. Bone marrow was 
hypocellular in three patients and hypercellular in two patients.  
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DISCUSSION 
Anemia is common in older age group. A cause for anemia needs 
to be determined in each patient.  The etiology of anemia in elderly is 
often multifactorial and is due to Nutritional deficiency in one-third of 
cases, Anemia of Chronic disease in one-third and Unexplained anemia in 
remaining  one-third.  In elderly,  a  Bone marrow examination is 
required for the diagnosis and management of Hematological disorders. 
In the present study we analyzed the Bone marrow findings and the 
clinical and laboratory parameters of geriatric patients with anemia. 
A total of 65 geriatric patients with anemia were evaluated in our 
study. The patients were in the age group between 60 to 85 years with a 
mean age of 66.65 years.(Table 5). The majority of the patients were 
between 60-69 years. This is similar to the observations of  Bhasin A et 
al.,(2011)62 and Choi CW et al.,(2004)63 where the mean age was found to 
be 70.51 years and 70 years respectively.  
In the present study, Anemia was observed in 52.31% of 
women.(Table 5). This is in concordance with    Petrosvan I et 
al.,(2012)64 who showed 52.6% prevalence in women. The present study 
recorded  47.69% men with anemia.  Ania BJ et al.,(1997)65 and Beghe C 
et al.,loc.cit.(2004) showed a similar observation whereas   Bhasin A et 
al.,loc.cit.(2011 ) in their study showed a higher percentage (52%) of men 
with anemia. 
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The most common presenting complaint in the present study was 
fatigue (36.92%), followed by exertional dyspnoea (29.23%) (Table 6). 
The presenting signs and symptoms in our study were usually attributed 
to anemia with or without congestive heart failure. 
In the present study, the anemia was severe in majority (52.31%) 
of the patients.(Table 9).  Artz AS et al.,(2011)66 and Elzen.et.al.,(2008)67 
had shown a lower percentage of patients with severe anemia.  Mild 
anemia was observed in only 10.77% of patients in the present study. In 
contrast,  Mauro T et al.,(2010)68 and Elzen WP et al.,loc.cit(2008) had 
shown a higher (27.4%) percentage of mild anemias in elderly.  
Anemia is a disease of multiple causation and its scientific 
management requires an exact classification which can be done only after 
a complete study of blood. A complete blood count including the 
reticulocyte count and a peripheral blood film examination is an initial 
indispensable tool in the evaluation of anemia. They have a decisive role 
in the diagnosis and classification of anaemia.  
In the present study, Normocytic anemia was found in 15.38% of 
patients.(Table 10). This contrasts with those of Elis et al.,loc.cit(1996)  
and Ania et al.,loc.cit(1997 ) who had shown a higher percentage of   
Normocytic anemia was  in elderly indiviuals . The   present study 
showed Microcytic Hypochromic anemia as the most common type of 
anemia found in 49.23% of patients.  Bhasin A et al.,loc.cit (2011) and 
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Mauro T et al.,loc.cit (2010)  had shown that Microcytic anemia 
accounted for 30%  and 16.9% of the anemic individuals respectively in 
their studies.  A higher occurrence of Microcytic Hypochromic anemia in 
our study could be attributed to the increased number of patients from 
rural areas and of low socio-economic status.  
Bone marrow studies, though invasive is a safe and simple 
procedure and is the most frequently carried out investigation in the 
evaluation of hematological disorders.   In geriatric patients  Bone 
marrow examination is important particularly in the diagnosis of  
Myelodysplastic syndromes. 
The cellularity of marrow decreases with age. In the present study, 
Bone marrow examination of all the 65 geriatric patients with anemia 
showed normocellular marrow in 46.15%, hypercellular marrow in 
43.08% and hypocellular marrow in 10.77%.(Table 11).  
In the present study, the  Bone marrow aspiration findings were   
broadly categorized into malignant and non- malignant hematological 
disorders. Non-malignant hematological disorders formed the major 
group   comprising 84.62%.(Table 12). The majority of cases was of REH 
of Marrow Micronormoblastic Erythroid Maturation, suggestive of a 
probable IDA and was present in 41.54% of patients.  In the study by 
Bhasin A et al.,loc.cit(2011) IDA accounted for 69% of patients which is 
higher when compared to the present study. 
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In our study, in patients with REH of marrow, Normocytic anemia 
was seen in 5(18.52%) patients.(Table 15). Apart from iron deficiency,  
AOCD   most often presents as normocytic normochromic, anaemia. In 
the present study, the co-morbid illnesses associated in this group of 
patients were Liver disease, Renal disease, CAHD, GI bleed and Solid 
organ malignancies.(Table 14). Hence, in elderly patients with 
microcytic/ normocytic anemia, apart from  nutritional iron deficiency,  
other causes of anemia needs to be determined through endoscopic 
evaluation of GIT for evidence of blood loss or evaluation for  an 
underlying Renal or Liver disease  is necessary. In our study UGI 
endoscopy done in 29 patients, detected lesions in 82.75% of patients in 
our study and malignancy in 1 patient. (Table 8). This correlates with    
Sanchez F et al., (2000)69 who had shown that UGI lesions were the most 
frequent cause for iron deficiency.  
In the present study, REH of Marrow Micro and 
Macronormoblastic Erythroid Maturation suggestive of a probable  
combined B12/ iron deficiency accounted for  15.38% of patients.(Table 
13). This is similar (17%) to the observations of Tahlan A et.al., (2008)70 
in their study.  
In the present study, Megaloblastic anemia was observed in 20% of 
patients.(Table 13). This is similar to that shown by pudasini S et al., 
(2009)71 who had shown a 18.3% of patients with Megaloblastic anemia. 
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However  Al-Ghazaly J et al., (2006)72 and Tahlan A et al.loc.cit(2008) 
showed a high prevalence of  Megaloblastic anemia  in their studies. In 
the present study, the patients with Megaloblastic anemia presented with 
a Dimorphic anemia in 45.45% of cases and Microcytic anemia in 9.09% 
of cases(Table 17). Seward SJet al.,loc.cit. (1990) in their study have 
highlighted that a normocytic or even microcytic anemia can be 
associated in a significant proportion of elderly patients with B12/folate 
deficiency.  In our study Macrocytic anemia was present in 38.46% of 
patients.(Table 17).  Khanduri U et al., (2007)73 and Mukiibi JM et al., 
(1992)74 had shown a higher percentage of macrocytic anemia in patients 
with Megaloblastic anemia.87,88 In our study,   Pancytopenia was present 
in 15.38% of patients with Megaloblastic anemia. This relatively 
correlates with Kumar et al., (2001)75 who have shown a 20.3% of 
pancytopenia, whereas     Tilak V et al., (1999)76 and Jha et al., (2008)77 
have shown a higher association of pancytopenia in Megaloblastic 
anemia.  
Malignant hematological disorders comprised 15.38% cases in the 
present study.(Table 12). This is akin with the observations in the studies 
by Al-Ghazaly J et al.,loc.cit(2006) and Tahlan A et al.,loc,cit(2008 ) in 
which malignant hematological disorders comprised 18.% of cases. Artz 
et al.,loc.cit(2011) recorded a lower percentage (7.5%) of patients with 
hematological malignancies. Acute and chronic leukemias accounted for 
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7.70% of cases in our study.(Table 13). However, Mukiibi JM., et 
al.,loc.cit (1992) in their study have shown a higher (17.5%) occurrence 
of Leukemias in elderly.   
In the present study, 1(1.54%) patient had a probable diagnosis of 
AML.(Table 19). Grünewald K et al., (1982)78 in his study had observed 
an increased frequency of Acute Myeloid leukemia in older patients with 
dismal prognosis. 
In the present study 3(4.64%) patients were diagnosed with CML, 
one in chronic phase and two patients in accelerated phase.(Table 20). 
Similar study by Joosten et al.,(1992)79  had shown that chronic 
leukemias accounted for 5% of anemia in elderly.   
In anemic elderly, MDS is almost certainly an under diagnosed 
condition since the evaluation of anemia is less likely to include a bone 
marrow evaluation in all cases.   The prevalence of Myelodysplastic 
syndrome (MDS) increases in people aged 70 years and older. In the 
United States, the incidence has been estimated to be 3.5/100,000 to 
12.6/100,000 per year40 .The median age at diagnosis is between 60 and 
80years51. The diagnosis of the Myelodysplastic syndromes (MDSs)   
relies on combining the clinical history, morphologic features of the 
peripheral blood and/or bone marrow sample, and cytogenetic 
information. 
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A total of 6 patients were given a diagnosis of MDS (9.23%) in the 
present study.(Table 13). This is comparable with 5.5% of cases of MDS 
observed by Joosten et al. (1998)80 in their study.  Marrow iron stores 
were normal or increased in these patients. The mean age of these 
patients was 70.5 years. This correlates well with the observations by 
Mukiibi JM et al.,(1994)81 who had shown a mean age of 69 years in their 
study. However  Malo JP et al.,(2001)82  in their study had shown a 
higher mean age of 78 years in a group of MDS patients. The 6 patients 
with MDS in the present study included   4 men and 2 women. This is 
similar to the results of Mukiibi JM et al.,loc.cit.(1994) who had also 
shown a male preponderance in MDS patients. 
Anemia and correlated signs and symptoms are the most relevant, 
disease-specific manifestation and are the most frequent presenting 
symptoms of MDS patients. Frequently they can be asymptomatic. In the 
present study, all patients diagnosed with MDS were symptomatic 
(100%). However Khalifa MS et al.,(2003)83 and Malo JP et 
al.,loc.cit.(2001) had shown that only  81% and 80%of patients 
respectively were symptomatic. In the present study, 
Hepatosplenomegaly and skin manifestations were present in 16.67% of 
the patients. A similar observation has been made by Khalifa  MS et 
al.,loc.cit(2003) who recorded hepato splenomegaly and skin 
manifestations in 25% of cases.  
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In the present study, in patients with MDS, co morbid illnesses 
were present in 66.67% of patients.(Table 14) Wang et al., (2009)84 had 
shown a lower (51%) percentage of patients with co morbid disorders. 
At presentation, the most common laboratory finding, present in 
nearly all patients with MDS, is anemia and reticulocytopenia. The 
anemia is typically Macrocytic but may also be normocytic.  Microcytic 
hypochromic anemia is rarely associated with MDS. In the present study, 
Anemia associated with MDS was Microcytic in 16.67% of patients. 
Several series by Barzi A et al.,(2010)85 Juneja et al.,(1983)86 Nguyen P et 
al.,(2009)87 had shown that Microcytic anemia can be associated with 
MDS. In the present study, all the MDS patients had severe degree of 
anemia.(Table 18). Irfan M et al.,(1998)88 similarly had observed a severe 
degree of anemia in MDS patients. 
Anemia may be accompanied by neutropenia and/or 
thrombocytopenia, with pancytopenia found in approximately 50% of all 
cases. Isolated neutropenia or thrombocytopenia is reported in _5% of 
cases. In the present study Pancytopenia was associated with 50% of 
MDS patients. A similar (52%) observation has been reported by Chen 
PH et al., (1992)89 in their analysis of MDS patients.  However  studies by 
 Dewulf et al.,loc.cit.(2004)90 and Irfan M et al.,loc.cit(1998) had shown a 
lower association of pancytopenia with MDS patients , accounting for 
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18% and 9%  repectively. The higher the degree and number of cell lines 
decreased, the worse the prognosis. 
In the bone marrow, the minimum diagnostic criterion  for MDS is 
dysplasia in _10% of any of the myeloid lineages and less than 20% blast 
cells of all nucleated cells in the bone marrow unless there are 
cytogenetic abnormalities suggestive of the diagnosis of MDS as per the 
World Health Organization (WHO).   
The dysplastic features commonly observed in MDS are 
megaloblastosis, multinuclearity, nuclear budding, intranuclear bridging, 
karyorrhexis and karyopyknosis and hypolobated megakaryocytes. . In 
the present study, in MDS patients, Bilineage dysplasia (66.67%) was 
more common than Unilineage dysplasia (16.67%). This is comparable 
with the reports of other studies by Dewulf G et al.,loc.cit(2004) and Irfan 
M et al.,loc.cit.(1998) who  had shown a similar observation in MDS 
patients. However,  other  studies by Mukiibi JM et al., loc.cit.(1994) and 
Malo JP et al.,loc.cit(2001) had shown a lower percentage of patients 
with Unilineage and Bilineage dysplasia.  In  the present study,  MDS 
with Multilineage dysplasia and Excess Blasts was seen in  16.67% of 
cases. This  is comparable with the results of Mukiibi JM et 
al.,loc.cit(1994)   and Malo JP et al.,loc.cit.(2001) who had shown 21.4% 
and 24.44% of cases with Refractory anemia with Excess Blasts(RAEB). 
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However Dewulf et al.,loc.cit.(2004) had encountered only 8% cases in 
their study.  
In the present  study five  patients, with bone marrow aspiration 
findings suggesting a possibility of MDS  are on follow up studies for 
further evaluation. 
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SUMMARY AND CONCLUSION 
Anemia in elderly patients should never be regarded as a normal 
physiological  response to aging. The main categories of anemia in older 
patients are the nutritional anemia attributed to iron deficiency, including 
blood loss, folate and vitamin B12 deficiency, and Anemia of chronic 
disease in patients with cancer, infections and other chronic 
inflammation. MDS is more common in elderly individuals  and is also a 
cause for Unexplained anemia in elderly.  
In the present study, we analysed the pattern of Anemia  in 65 
geriatric patients and found that the anemia was of  severe degree in most 
patients as per WHO criteria. It was often multifactorial. Bone marrow 
examination  done in  these patients showed  a Reactive Erythroid 
Hyperplasia of marrow with micronormoblastic maturation suggestive of 
a probable Iron deficiency in 41.54% of  patients. The other less common 
patterns were  Megaloblastic anemia found in 20% patients and  Reactive 
Erythroid Hyperplasia of marrow with micro and macronormoblastic 
maturation suggestive of a combined B12/iron deficiency in 15.38% of 
patients. We also encountered 4(7.70%) incidental cases of leukemia in 
these patients. The present study identified Myelodysplastic syndrome as 
a cause of Geriatric Anemia in 9.23% of  patients.   
Thus to conclude, all  Elderly patients with Anemia should always 
be evaluated for an underlying cause. Indiscriminate administration of 
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iron to a geriatric patient with an unevaluated anemia is not appropriate 
and may  contribute to  iron overload especially in AOCD and MDS. 
Hence a Bone marrow examination is necessary in all cases of geriatric 
anemia for establishing a diagnosis, particularly in MDS. 
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APPENDIX - I 
Tirunelveli Medical College Hospital 
Tirunelveli – 11 
Hematology case record 
NAME  LAB NO  
AGE  SEX  IP NO  
WARD  UNIT   
ADDRESS  
 
 
 
COMPLAINTS  
 
 
 
 
HISTORY OF 
PRESENT 
ILLNESS 
 
 
 
 
 
PAST HISTORY Diabetes                                               Chronic drug ingestion 
Hypertension                                       Chemotherapy/ Radiotherapy       
Acid peptic disease                              Renal/Liver Disease 
Old PT                                                  Others 
  
GENERAL 
EXAMINATION 
Build                                                               Lymph nodes 
Pallor                                                              Skin   
Icterus                                                             ENT     
Pedal edema                                                   Musculoskeletal 
Vital signs: 
Pulse 
B.P 
RR 
SYSTEM 
EXAMINATION 
CVS: 
 
RS: 
 
GIT: 
 
RES: 
 
CNS: 
INVESTIGATIONS X-ray 
USG 
CT 
MRI 
 
INVESTIGATIONS 
BASIC 
LABORATORY 
    CP 
 
INVESTIGATIONS 
BASIC 
LABORATORY 
  BIOCHEMISTRY 
 
INVESTIGATIONS 
BASIC 
LABORATORY 
 OTHERS 
 
HEMATOLOGY 
TESTS 
BONE MARROW 
ASPIRATION 
PROCEDURE :     PSIC               STERNUM  
Process  :            leishman’s stain  
                            Pearl’s stain        
                            others                 
REPORTS 
PERIPHERAL 
 
 
SMEAR 
STUDY 
 
 
BONE MARROW 
SMEAR STUDY 
Cellularity  
M:E ratio  
Erythroid series 
 
 
Myeloid series  
 
 
Megakaryocytic series 
 
 
Lymphoid series 
 
 
Monocytic series 
 
 
Others 
 
 
Impression 
 
 
 
Marrow iron  
 
DISCUSSION: 
 
 
FINAL DIAGNOSIS: 
 
 
 
 
  
APPENDIX II 
  
APPENDIX III 
Staining Procedures  
1. Leishman’s Stain 
Reagents 
(i) Leishman powder - 0.15gm 
(ii) Methyl Alocohol (acetone free ) – 100ml. 
Procedure  
1. Air dry the smears.  
2. Flood the slide  with Leishman’s stain and allow to stand for  2 
minutes. 
3. Dilute with double the volume of buffer water and stain for 7- 10 
minutes. 
4. Wash off the stain  in a stream of buffered water until it  a pinkish 
tinge is obtained. 
5. Air dry the slides. 
2. Reticulocyte Stain  
Reagents  
Brilliant cresyl blue  –  1.0g. 
Phosphate buffer   –  100ml. 
  
Procedure  
1. Add 2-3 drops of dye solution in to a small bottle. 
2. Add 2-4 volumes of patient’s EDTA- anticoagulated blood to the dye 
solution and mix. 
3. Keep the mixture at 37.C for 15 – 20 minutes. 
4. Resuspend the cells by gentle mixing and make films in the usual way. 
 
3. Perl’s Stain 
Reagents   
4% potassium ferrocyanide  - 25 ml. 
4% hydrochloric acid          -  25 ml. 
Procedure 
1. Bone marrow smears are fixed in methanol for 10 minutes. 
2. Incubate  the smears in freshly prepared acid ferrocyanide solution for 
10 -15 minutes. 
3. Wash in distilled water. 
4. Lightly stain the nuclei with 0.5% aqueous neutral red. 
 
 
 
 
 
 
ID No Name Age sex Presenting Complaints
Present Co-
morbidities
1-DM
2-HT
3-CRD
4-CLD
5-APD
6-Immune Dis
8-GI Bleeds
10-TB
11-Thyroid Dis
12-Cancer
13-GU Bleed
15-Others
Systems Radiology Endoscopy TRBC
x106cells/
cumm
TLC
x103cells/cu
mm
PLC
x105cells/cu
mm
HB
gms/dl HCT MCV   MCH   MCHC Retic C
ESR
1Hr BSR BUN SCR
PSS-RBC
Describe RBC
PSS-RBC
Impression
PSS-WBC
Impression
PSS-PL
Impression
Marrow
Cellularity
0-Normal
1-Hypo
2-Hyper
Marrow 
Erythroid
Describe
Marrow Myeloid 
Describe
Marrow Megk
Describe
Marrow Impression
Describe
marrow 
iron
1.5654 saraswathy 77 F
dyspnoea, 
pedal edema 
decreased 
urine output
1 mild 
hepatomegaly
, B/L crepts NAD normal 3.1 6.2 1.5 6.1 18 102.4 23.2 26.8 0.5 52 35 3 28 1.3
number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia Normal normal 2
number 
increased 
megaloblastic 
maturation
number 
increased 
giant 
metamyelocyt
es
normal 
number n 
morphology
megaloblastic 
anemia normal
2.6784 saraswathy 65 F
mass P/V 
urinary 
disturbances
1
NAD NAD not done 2.5 6.9 2.5 5.6 16 89.3 23.6 27.9 0.3  30 50 106 22 1.1
number 
decreased 
normocytic 
n 
microcytic 
RBCs 
anisopoikil
ocytosis
dimorphic 
anemia RN
reactive 
thromboc
ytosis 0
 number 
increased  
micro n 
macro 
normoblastic  
maturation 
incresed in 
number 
normal 
maturation
normal in 
number n 
morphology
reactive marrow 
with micro n 
macronormoblastic 
maturation  low
3.1364 seetha 65 F
dyspnoea on 
exertion
5
hemic murmur NAD not done 3 10.5 1.8 6.2 26 74 22 22 1
 55 
120 148 24 0.8
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia 
anisopoikiloc
ytosis RN normal 2
 number 
increased 
micro n 
macro 
normoblasti 
maturation 
normal in 
number n 
morphology
normal in 
number n 
morphology
REH with micro n 
macro normoblastic 
maturation  low
4.4798 esther 62 F
abdominal 
pain dyspnoea
1,,2. 15
NAD
cardiomegal
y mild 
splenomegal
y 
 mucosal erosions1.82 2.5 30000 4.9 16.7 129.3 41.5 32.1 1 28/50 128 30 1.1
 number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia leucopenia
thromboc
ytopenia 2
number 
decreased 
micro n 
macronormob
lastic 
maturation 
dividing cells 
dyserythropoi
esis 
number 
increased 
myeloblasts 
promyelocyte
s mature 
forms variable
MDS multilinege 
dysplasia increased
5 .15779 kosalai 65 F fatigue
1,2,3 hemic 
murmur, 
splenomegaly splenomegaly not done 2.2 145 0.28 6.9 18.9 85.9 31.5 36.5 . . . 92 65 3
 number 
decreased  
microcytic 
hypochrom
ic RBCs
MCHC 
anemia
acute 
leukemia
thromboc
ytopenia 2
 number 
decreased 
micronormob
lastic 
maturation
increased in 
number 
myeloblasts 
>90% decreased AML-M1  - -
6 .4471 santhivinayagam 65 M ulcer leg
..
moderate 
splenomegaly
 splenomegalynot done 2.12 90,000 1.74 8.9 20.9 63.7 21.3 27.4 . .
98 
130 70 30 1.1
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia
CML - 
chronic 
phase 
thromboc
ytosis 2
number 
decreased 
micronormob
lastic 
maturation
increase in 
myeloblasts 
promyelocyte
s 
metamyelocyt
es 
normal  
number n 
morphology CML chronic phase
 - -
7 ..9578 bagavathy 66 F fatigue
5, 8 splenomegaly
, tender 
hepatomegaly
splenomegal
y, renal 
calculi congested GI mucosa2.7 11 0.19 6.4 19.3 72.5 21.3 31.1 1
100  
150 104 29 0.9
number 
decreased 
microcytic  
hypochrom
ic RBCs
MCHC 
anemia RNL
thromboc
ytopenia 2
number 
normal 
micronormob
lastic 
maturation
increase in 
metamyelocyt
es, band 
forms, mature 
neutrophils
normal  
number n 
morphology
reactive erythroid 
micronormoblastic 
maturation absent
8 .2039 mariyal 63 F
giddiness 
exertional 
dyspnoea
1,2,, 6
NAD fatty liver not done 2.39 4.3 2.69 6.6 22.1 94 23.8 27.4 0.5 . . 146 38 1.1
number 
decreased 
normocytic 
n 
macrocytic 
RBCs
macrocytic 
anemia Normal normal 0
number 
increased 
megaloblastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
megaloblastic 
anemia increased
9 ..43923 gnanam 69 F
abdominal 
pain dyspnoea
6
anemia ….. …. 2.47 9.1 1.02 7.9 36 86.6 24.8 33.2 0.5 99 38 0.7 1.1
number 
decreased
MCHC 
anemia RN decreased 1
normal 
number 
dividing cells normal
megaloblastic 
dysmegakary
opoiesis ?MDS
10 .17294 meenakshi 60 F giddiness
…
anemia .. not done 2.67 6.1 3.41 6.9 28.5 74.8 23.6 29.2 1 55 81 21 0.7
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia normal normal 0
number 
normal 
nicronormobl
astic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
reactive erythroid 
with 
micronormoblastic 
maturation absent
11 .17356 santhanam 60 M
exertional 
dyspnoea
1
submandibul
ar lymph 
nodes NAD not done 2.2 7.8 2.78 7.5 34 83.2 27 28.4 1.4 100 78 22 0.9
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia RN normal 0
number 
increased 
micro n 
macro 
normoblastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
REH with micro n 
macro 
normoblastimaturat
ion  normal
12 .32901 selvaraj 62 M
easy 
fatiguability 
loss of apetite
, ,
epigastric tenderness NAD erosion 2.9 7.2 1.79 10.4 26.5 88.3 22.3 26.6 1 90 101 28 0.7
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia mild 
anisocytosis RN normal 0
number 
normal micro 
n macro 
normoblastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
REH with micro n 
macro normoblastic 
maturation  normal
13 .30148 valliammal 74 F
giddiness, 
chestpain 
palpitation
..
anemia . not done 2.2 4.1 1.52 7.7 23 86.6 26.1 33.2 0.5 .. 64 13 0.5
number 
decreased 
normocytic 
RBCs 
normocytic 
anemia normal normal 0
micronormob
lastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
hyperplastic 
marrow with 
micronormoblastic 
maturation absent
14 .41267 meenambal 73 F
pedal eema 
chest pain 
fatigue
15
NAD NAD not done 3.3 5.3 2.84 10.8 90.4 43 31.7 0.5 65 96 20 0.8
number 
decreased 
normocytic 
RBCs 
normocytic 
anemia Normal normal 0
number 
normal micro 
n macro 
normoblastic 
maturation
normal 
maturation
normal 
number n 
morphology
REH with micro n 
macro normoblasti 
maturation normal
15 .44321 thangapandi 61 M giddiness
. .
anemia NAD not done 2.6 4.7 3.16 9.3 36 87.4 24.1 29.2 0.5 .. 74 16 0.4
number 
decreased 
normocytic 
RBCs 
normocytic 
anemia RN normal 0
number 
increased 
micronormob
lastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
REH with micro  
normoblastic 
maturation absent
16 .54902 velu 67 F
giddiness loss 
of apetite 
fever
, ,
NAD NAD not done 1.68 2.9 1.13 5.7 27.9 62.9 24.3 28.6 0.5 60 77 16 0.8
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia normal normal 0
number 
increased 
micronormob
lastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
REH 
micronormoblastic 
maturation absent
17 . 55798sudalaimuthu 73 M giddiness
4
hepatomegaly hepatomegaly congested GI mucosa2.8 7.4 2.53 8.7 28.8 82.6 24.2 29.3 1.2 40 92 14 0.3
number 
decreased 
micro n 
macrocytic 
RBC
dimorphic 
anemia RN normal 2
number 
increased 
micro n 
macro 
normoblastic 
maturation
number 
increased
number 
increased 
normal 
morphology
REH with micro n 
macro normoblastic 
maturation low
18 .62071 akilandeswari 81 F
loss of apetite 
vomiting 
fatigue
..
anemia NAD not done 2.9 6.3 1.85 6.8 28.1 81.7 26.3 31.4 1.2 110 81 28 1.1
number 
decreased 
anisopoikil
ocytosis
dimorphic 
anemia normal normal 2
number 
increased 
micro n 
macro 
normoblastic 
maturation
number 
increased
normal 
number n 
morphology
REH with micro n 
macro normoblasti 
maturation absent
19 .64721 jeyarani 61 F
fatigue chest 
pain giddiness
1
DM/ gastritis NAD not done 2.06 5.3 2.73 6.3 26.5 59.7 25.3 29.7 0.3 88 92 23 0.7
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia normal normal 0
number 
increased 
micronormob
lastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
 reactive erythroid 
micronormoblastic 
maturation absent
20 . 
60969 lakshmi 66 F fatigue diarrhoea
14
hepatomegaly hepatomegaly erosion 1.96 10.6 3.55 5.8 20.1 66.4 21.2 29.6 < 0.5
55 
100 137 44 1
 number 
decreased 
microcytic 
and 
macrocytic 
RBCs 
MCHC 
anemia normal
reactive 
thromboc
ytosis 2
 number 
increased 
micro n 
macro 
normoblastic 
maturation
normal  
number n 
morphology
normal  
number n 
morphology
hyperplastic 
marrow with 
micronormoblastic 
maturation absent
21. 54734 pandaram 69 M
poor apetite 
giddiness
5
NAD normal  ulceration 2.47 6.4 5.63 6.9 19.6 79 23.5 29.6 1
50 
100 96 25 0.8
 number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia normal
reactive 
thromboc
ytosis 2
 number 
increased 
micronormob
lastic 
maturation 
normal  
number n 
morphology
normal  
number n 
morphology
REH 
micronormoblastic 
maturation absent
22. 43705 madasamy 70 M
pedal edema 
dyspnoea
2, 3
tender hepatomegaly
B/L medical 
renal disease 
type III RPD 
changes normal 2.68 4.5 2.31 8.2 24.7 99.6 30.6 30.8 0.5
20 
130 157 150 5.4
 number 
decreased 
microcytic 
and 
macrocycyt
ic RBCs
dimorphic 
anemia RN normal 2
 number 
increased 
megaloblastic 
maturation 
increase in 
metamyelocyt
es giant band 
forms
normal in 
number n 
morphology
megaloblastic 
anemia increased
23 . 45911madathi 65 F
hemoptysis, 
fever
. .
hemic 
murmur, B/L 
crepts, 
splenomegaly
old PT, 
Splenomegal
y, increased 
renal cortical 
echoes not done 1.8 125 3.19 7.7 21.3 83.3 26.1 31.3 . . . . 68 20 0.8
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia 
NRBC
CML- 
accelerat
ed phase
thromboc
ytosis 2
 number 
decreased 
micronormob
lastic 
maturation
increase in 
myeloblasts 
promyelocyte
s 
metamyelocyt
es basophils
number 
increased 
normal 
morphology
CML - accelerated 
phase
 - - 
24 . 
43507 gurusamy 70 M dyspnoea
3,8,10
systolic 
murmur B/L 
crepts
old PT B/L 
medical 
renal disease 
type I RPD 
changes
 mucosal erosions2.5 3.2 0.4 6.8 22.4 128 27 32 1.2
150 
165 138 54 2
number  
decreased 
macrocytic 
n 
normocytic 
RBCs
dimorphic 
anemia leucopenia
thromboc
ytopenia 1
 number 
increased 
megaloblastic 
maturation 
dividing cells
megaloblastic 
maturation
normal  
number n 
morphology megaloblastianemia
increase
d
25 . 
61113 shanmugasundaram 62 M
cough 
palpitation 
pedal edema
5 , 10 epigatric 
tenderness 
hepatomegaly old PT not done 2.28 7.8 2.95 5.9 14.4 63.2 14.9 23.6 1.3 10 22 115 34 1.5
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia Normal normal 2
number 
increased 
micronormob
lastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
REH with micro 
normoblasti 
maturation absent
26 . 
42094 subbiah 60 M
dyspnoea 
decreased 
urine output
2
hemic murmur
cardiomegal
y 
mildsplenom
egaly,B/L  
moderate PE 
ulcer, 
incompetent 
GEJ 1.36 11.9 3.5 5.4 18 132.4 26.7 30 1
100 
130 114 44 1.2
number 
decreased 
microcytic  
hypochrom
ic RBCs
MCHC 
anemia
reactive 
neutrophi
a
thromboc
ytopenia 2
dividing cells 
dyserythropoi
esis
dysmyelopois
is
normal 
morphology
MDS multilinege 
dysplasia increased
27 . 
44867 mariappan 62 M
pedal edema 
facial 
puffiness
2
hemic murmur
cardiomegal
y moderate 
splenomegal
y not done 1.95 7.3 1.42 5.1 13.8 70.8 16.4 23.2 2 30 60 146 21 0.8
number 
decreased  
microcytic  
hypochrom
ic RBCs
MCHC 
anemia normal normal 2
 number 
increased, 
micro and 
macro 
normoblasti 
maturation 
normal  
number n 
morphology
normal  
number n 
morphology
REH with micro n 
macro 
normoblastimaturat
ion and 
plasmacytosis absent
28 . 
49305 arumugam 76 M
facial 
puffiness 
pedal edema
1,5
b/l crepts
cardiomegal
y  mild 
pleural 
effusion 
minimal 
ascitis congested GI mucosa1.01 5.8 2.92 6.8 16.6 65.3 15.8 24.2 0.5 32 60 98 63 1.2
number 
decreased 
microcytic 
n 
normocytic
dimorphic 
anemia normal normal 1
micro 
normoblastic 
maturation 
dyserythropoi
esis
normal 
maturation
dysmorphic 
megks
MDS with 
plasmacytosis increased
29. 46728 esakki 72 M weakness limbs
2
spastic quadriparesis
non 
compressive 
myelopathy not done 1.63 1200 1.27 7.7 25.6 104 31.3 30.1 0.5 10 40 135 23 0.8
number 
decreased 
microcytic 
n 
macrocytic 
RBCs
macrocytic 
anemia leucopenianormal 1
number 
decreased 
megaloblastoi
d maturation
number 
decreased 
dysmyelopoie
sis normal
megaloblastic 
anemia normal
30. 50914 esakkkiammal 66 F mass abdomen
5, 8
liver just 
palpable 
massivesplen
omegaly
cardiomegal
y 
splenomegal
y dilated 
portal vein
esophageal 
varices 
severe PHT/ 
gastropathy 2.22 4.2 0.41 6.3 18.4 93.6 18.4 22.3 3 26 80 76 16 0.6
number 
decreased 
microcytic 
hypochrom
ic  RBCs 
dimorphic 
anemia normal
thromboc
ytopenia 0
number 
increased 
micronormob
lastic 
maturation
normal in 
number n 
morphology
normal in 
number n 
morphology
Reactive marrow 
with micro 
normoblasti 
maturation absent
31 . 
40029 veeramariammal 70 F
fever 
abdominal 
pain
2,5,
hemic murmur
mild 
cardiomegal
y congested GI mucosa3.3 12 3.3 9.1 36 89.4 23.6 30.1 <0.5
55 
110 86 40 0.8
number 
decreased 
microcytic 
n 
macrocytic 
RBCs
dimorphic 
anemia
reactive 
neutrophi
lia normal 2
 number 
increased 
megaloblastic 
maturation
increased 
giant 
metamyelocyt
es band forms
normal  
number n 
morphology
megaloblastic 
anemia normal
32 . 
45982 srinivasan 74 M
giddiness 
swaying while 
walking
2
NAD
cerebral 
atrophy not done 2.2 3 0.3 6.5 20.1 91 29.4 32.3 1
100 
130 65 50 1
number 
decreased 
microcytic 
n 
normocytic 
RBCs 
dimorphic 
anemia leucopenia
thromboc
ytopenia 1
number 
decreased 
dyserythropoi
esis
number 
decreased 
dysmyelopoie
sis
normal 
number 
dysmorphic 
megks
MDS multilinege 
dysplasia increased
33 . 47881paramasivan 62 M
exertional 
dyspnoea 
pedal edema 
1,2 ESM, 
hepatospleno
megaly
mild 
cardiomegal
y congested GI mucosa2.19 4.3 1.35 6.3 20.3 92.7 28.8 31.1 0.5
50 
105 117 76 1.4
 number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia normal normal 0
number 
increased 
micronormob
lastic 
maturation
normal in 
number n 
maturation
normal  
number n 
morphology
reactive marrow 
with micro 
normoblasti 
maturation s/o IDA absent
34 . 48220murugan 63 M fever
. .
NAD NAD not done 3.2 5.8 90 10.4 33.7 97.4 32.9 33.8 1
80 
120 78 36 0.9
number 
decreased 
normocytic 
normochro
mic RBCs 
normocytic 
anemia
reactive 
neutrophi
lia
thromboc
ytopenia 0
 number 
increased 
normal 
maturation
number 
increased 
normal 
maturation
normal  
number n 
morphology
reactive marrow 
with micro 
normoblasti 
maturation s/o IDA absent
35 . 
32431 poothathan 65 M
abdominal 
pain dyspnoea
2,.15
splenomegaly
splenomegal
y 
cholelithiasis 
renal calculi
mucosal 
erosions 2.26 34.5 1.1 6.5 27.6 72.8 17.8 24.5 1 15 30 60 44 1.2
number 
decreased 
normocytic 
normochro
mic RBCs 
occassional 
macrocyte
normocytic 
anemia
reactive 
neutrophi
lic 
leucocyto
sis normal 2
number 
normal early 
megaloblastic 
maturation
 increase in 
band forms
normal in 
number n 
morphology
normocellular 
marrow with 
micronormoblastic 
maturation absent
36 . 
33513 vellathai 65 F
abdominal 
pain icterus
4,11
mild splenomegaly
fatty liver 
mild 
splenomegal
y congested GI mucosa1.19 11.4 1.73 8.1 24.9 116.9 32.7 31.3 1.5
110 
150 106 29 0.8
number 
decreased 
normocytic 
n 
macrocytic 
RBCs
macrocytic 
anemia
reactive 
neutrophi
lia normal 0
number 
increased 
megaloblastic 
maturation
normal 
number  
normal 
maturation
normal  
number n 
morphology
megaloblastic 
anemia increased
37 . 
14794 sundar raj 69 M giddiness 
2, 10
systolic murmur NAD congested GI mucosa2.34 5.3 2.05 6.4 28.1 73.4 24.5 26.2 0.5
50 
100 110 28 0.8
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia normal normal 0
number 
increased 
micronormob
lastic 
maturation
normal 
number  
normal 
maturation
normal 
number n 
morphology
REH 
micronormoblastic 
maturation absent
38 . 6858 gandhi 85 M hematemesis
. . hemic 
murmur, 
thyromegaly
B/L MRD 
type I CKD stomach - ulceration2.1 3.9 2.12 5.6 24 76.4 21.6 28.8 1
50, 
105 96 129 2.2
number 
decreased 
microcytic 
and 
macrocytic 
RBCs
dimorphic 
anemia normal normal 2
number 
increased 
megaloblastic 
maturation
number 
increased 
dysmyelopoie
sis
normal in 
number n 
morphology  MDS-RA increased
39 . 9806 ramar 67 M paraparesis
1, 10
ESM normal not done 2.89 3.7 1.93 9.1 31 107.3 31.5 20.4 0.5 12, 45 178 56 1.5
number 
decreased 
microcytic 
n 
macrocytic 
RBCs
dimorphic 
anemia normal
reactive 
thromboc
ytosis 2
number 
increased 
micro n 
macro 
normoblastic 
maturation 
dividing cells
normal in 
number n 
morphology
normal 
number n 
morphology  ? MDS  -
40 . 
15364 patrakali 66 F
exertional 
dyspnoea
. .
mild hepatomegaly
consolidatio
n lung early 
type I MRD 
mild 
hepatomegal
y congested GI mucosa1.27 4 10000 4.7 13.9 90.1 32.2 35.8 0.5
100 
150 125 22 1
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia leucopenia
thromboc
ytopenia 2
number 
decreased 
dyserythropoi
esis
number 
increased 
dysmyelopoie
sis
reduced 
number 
dysmorphic 
forms
MDS trilineage 
dysplasia -RAEB normal
41. 50536 kanchana 61 F
abdominal 
pain icterus
1,2,4,6
jaundice 
hepatomegaly
splenomegal
y calculous 
cholecystitis congested GI mucosa3.2 9.9 4.1 8.7 30.6 72.9 19.6 26.9 1.1 10 22 137 27 0.7
number 
decreased 
schistocyte
s
hemolytic 
blood picture 
MCHC RN
reactive 
thromboc
ytosis 0
number 
increased 
micronormob
lastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
florid erythroid 
hyperplasia with 
micronormoblastic 
maturation absent
42 . 
47768 muthukrishnan 72 M
giddiness 
pedal edema
2,3,6
NAD
mild 
splenomegal
y not done 1.92 2.9 71000 4.8 16 83.3 24.5 29.4 1 45, 85 65 41 1.2
number 
decreased 
microcytic 
n 
macrocytic 
RBCs
dimorphic 
anemia normal normal 0
number 
increased 
megaloblastic 
maturation
megaloblastic 
maturation
normal 
number n 
morphology
megaloblastic 
anemia normal
43 . 
49335 manoharan 65 M
fever, 
abdominal 
pain
1,2,3
moderate 
splenomegaly 
tender 
hepatomegaly
hepatospleno
megaly not done 2.67 7.3 1.56 7.5 23 86.4 28.1 34.6 1.3
100 
132 132 95 4.3
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia
reactive 
neutrophi
lia normal 0
number 
increased 
normal 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
erythroid 
hyperplasiamicrono
rmoblastic 
maturation absent
44 . 
16214 navaneetham 71 F
exertional 
dyspnoea 
vomiting 
malena
15
venous hum NAD erosion 1.96 7.8 2.3 5.9 18.8 78.2 20.5 25.7 2
100 
130 126 29 1.1
number 
decreased 
microcytic 
n 
macrocytic 
RBCs
dimorphic 
anemia normal normal 2
number 
increased 
megaloblastoi
d maturation  
dividing cells
number 
increased 
normal in 
number n 
morphology ? MDS low
45 . 
42317 ganapathy 66 M
loss of apetite 
fatigue
. .
moderate 
splenomegaly 
hepatospleno
megaly not done 1.83 1.53 3.24 6.7 22.1 106 23.2 26.9 . . 60 73 38 1.2
number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia
CML - 
acc.phase
reactive 
thromboc
ytosis 2
number 
decreased 
micro n 
macronormob
lastic 
maturation  
increase in 
myeloblasts 
promyelocyte
s myelocytes 
band forms 
mature 
neutrophils 
normal in 
number n 
morphology CML - accc. phase
 - -
46 . 4632 rajeshwari 63 F
easy 
fatiguability 
loss of apetite
12, 14
ca breast NAD not done 2.2 6.5 2.98 10.3 32.3 88.7 25.6 32.1 1.5
50, 
100 74 24 0.8
number 
decreased 
normoctic 
normochro
mic RBCs
normocytic 
anemia normal normal 0
number 
normal 
normoblastic 
maturation
number 
increased 
normal 
maturation
normal 
number n 
morphology
erythroid 
hyperplasia 
micronormoblastic 
maturation absent
47 . 
38421 guruvammal 60 F
exertional 
dyspnoea
12
k/c/o ca breast NAD not done 2.91 5.4 3.15 11.1 26.8 97.5 24.3 31.7 1 10 40 90 21 0.8
number 
decreased 
normoctic 
normochro
mic RBCs
normocytic 
anemia normal normal 1
number 
increased 
megaloblastic 
maturation
dysmyelopois
is
normal 
number n 
morphology ? MDS ..
48 . 
19917 ramani 67 m loss of apetite
12
k/c/o ca alveolus NAD not done 2.88 6.5 3.32 10.2 33.1 66.6 26.2 29.7 0.5
55 
100 146 20 0.8
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia normal normal 2
number 
increased 
normal 
maturation
number 
increased 
normal 
maturation
normal 
number n 
morphology
REH with 
micronormoblastic 
maturation absent
49 . 
37152 lakshmi 60 F
abdominal 
pain vomiting
8
epigastric mass
antral 
growth 
simple 
hepatic cyst 
proliferative 
growth 
pylorus 
erosion 3.1 6000 3.8 5.7 19.4 73.5 22.7 28.5 0.6 40 85 89 32 0.9
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia 
anisopoikiloc
ytosis normal normal 0
number 
increased 
normal 
maturation
number 
increased 
normal 
maturation
normal 
number n 
morphology
erythroid 
hyperplasia with 
micronormoblastic 
maturation absent
50. 31693 kannimalar 70 M giddiness
2, 3, 10
NAD
old PT B/L 
small 
kidneys
 mucosal erosions2.09 5.4 2.31 7.1 26.4 65.5 16.7 25.1 0.5 42 60 48 1.3
number 
decreased 
microcytic 
n  
macrocytic  
RBCs
MCHC 
anemia
reactive 
neutrophi
lia normal 2
number 
increased 
micronormob
lastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
reactive marrow 
micronormoblastic 
maturation absent
51 . 
14794 soundarajan 62 M
exertional 
dyspnoea 
palpitation
8 hemic 
murmur, 
haemorrhoids NAD erosion 2.99 6.3 4.32 8.9 30.1 78.9 21.2 32.2 1.2 60 97 20 0.9
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia normal
reactive 
thromboc
ytosis 0
number 
increased 
micro n 
macro 
normoblastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
REH with 
micronormoblastic 
maturation absent
52 . 3904 velayutham 65 M
chestpain 
giddiness
. .
NAD cardiomegaly not done 2.63 5.9 2.94 9.1 29.6 100.4 22.6 28.3 0.5 50 94 23 0.9
number 
decreased 
microcytic 
n  
macrocytic  
RBCs
dimorphic 
anemia normal normal 0
number 
normal 
megaloblastic 
maturation
number 
normal giant 
metamyelocyt
es band forms
normal 
number n 
morphology
megaloblastic 
anemia increased
53 . 3422 shanmugathammal 65 F
exertional 
dyspnoea 
pedal edema
2, 5, 6
mild splenomegaly
splenomegal
y 
cardiomegal
y normal 1.78 4.7 3.96 7.4 23.5 77.2 19.3 27.4 1 130 112 35 1.1
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia normal
reactive 
thromboc
ytosis 0
number 
increased 
micronormob
lastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
Reactive marrow 
with micronormo 
blastic maturation absent
54 . 3398 sudalaimadan 61 M
abdominal 
pain malena
8, 12, 14
k/c/o ca stomach NAD not done 2.26 5.2 2.13 6.2 24.8 68.7 23.2 25.7 0.5 50 76 28 0.6
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia Normal normal 0
number 
increased 
normal 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
REH with 
micronormoblastic 
maturation absent
55 . 4954 krishnan 69 M
giddiness 
pedal edema
10
hemic murmur
old PT 
cardiomegal
y not done 1.56 3.2 0.9 6.8 19.6 92.5 18.7 26.6 0.5 40 92 19 1
number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia leucopenia
thromboc
ytopenia 2
number 
increased 
megaloblastic 
maturation
number 
increased 
megaloblastic 
maturation
normal 
number n 
morphology
megaloblastic 
anemia increased
56 . 3490 jesumichel 65 M
pedal edema 
loss of weight
2,4
jaundice 
hepatomegaly
hepatospleno
megaly erosion 2.99 7.3 2.65 8.3 30.2 56.5 19.3 22.4 1 48 66 22 0.8
number 
decreased 
microcytic 
hypochrom
ic RBCs 
MCHC 
anemia Normal normal 0
number 
increased 
micro n 
macronormob
lastic 
maturation 
normal 
number n 
maturation
normal 
number n 
morphology
REH 
micronormoblastic 
maturation absent
57 . 
76231 subbulakshmi 61 F vomiting fever
1
ca breast on treatment NAD not done 3.11 4.8 2.45 7.6 22.3 84.7 24.5 30.2 0.5 110 102 36 0.9
number 
decreased 
normocytic 
BBCs
normocytic 
anemia 
NRBC Normal normal 0
number 
increased 
megaloblastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
megaloblastic 
anemia increased
58 . 
50267 ponnammal 66 F
exertional 
dyspnoea 
palpitation
15
b/l crepts
pneumonitic 
changes mild 
cardiomegal
y not done 1.87 9.2 1.48 5.7 19.4 76.9 21.5 27.3 0.5 55 64 21 0.6
number 
decreased 
microcytic 
hypochrom
ic RBCs
MCHC 
anemia
reactive 
neutrophi
lia normal 0
number 
increased 
micronormob
lastic 
maturation
number 
increased 
normal 
maturation
normal 
number n 
morphology
reactive marrow 
with micro 
normoblasti 
maturation absent
59 . 1400 pathmanaban 61 M
pedal edema 
abdominal 
pain
2
NAD
mild 
splenomegal
y
gastric 
mucosal 
prolapse 3.47 5 2.98 5.3 22.3 64.3 15.3 23.8 0.5 30 50 112 42 0.9
 number 
decreased  
microcyti 
hypochrom
ic RBCs
MCHC 
anemia Normal normal 2
 number 
increased 
micro 
normoblastic  
maturation 
normal in 
number n 
morphology
normal in 
number n 
morphology
REH 
micronormoblastic 
maturation absent
60 . 
22754 saroja 68 F
pedal edema 
facial 
puffiness
15
systolic murmur
cardiomegal
y B/L 
minimal PE not done 2.23 6.4 2.11 8.3 20.6 98.4 22.1 28.4 0.5 100 75 41 1.1
number 
decreased 
microcytic 
n 
macrocytic 
RBCs
dimorphic 
anemia Normal normal 2
number 
increased 
megaloblastic 
maturation
number 
increased 
megaloblastic 
maturation
normal 
number n 
morphology
megaloblastic 
anemia low
61 . 14865mangaiyarkarasi 63 F
chest pain, 
exertional 
dyspnoea not done 1.88 6.5 3.26 8.3 36.8 86.5 22.6 28.7 0.5 .. 113 43 0.6
number 
decreased 
microcytic 
hypochrom
ic
MCHC 
anemia Normal normal 0
micro 
normoblastic 
maturation normal normal
REH with micro n 
macro normoblasti 
maturation
62 . 33871parvathy 66 F fatigue
3
NAD NAD not done 2.93 5.6 2.29 8.2 31.6 69.6 25.3 30.4 0.6 90 89 23 0.6
number 
decreased 
MCHC 
anemia normal
reactive 
thromboc
ytosis 0
number 
increased 
micronormob
lastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
hyperplastic 
marrow with 
micronormoblastic 
maturation absent
63 . 6297 muthulakshmi 71 F fatigue vomiting
. .
epigastric tenderness NAD mucosal erosions3.06 3.8 1.06 11.2 33.6 77.6 25.2 31.7 0.5 100 95 26 0.7
number 
decreased
normocytic 
anemia normal normal 0
micro 
normoblastic 
maturation normal normal
reactive hyperplasia 
micronormoblastic 
maturation absent
64. 14709 sagunthala 76 F
fatigue, 
cough, 
constipation
….
anemia …. ….. 2.3 8.6 2.64 6.6 32 72.3 22.7 31.1 0.5 63 20 1 .. .
MCHC 
anemia RN normal 1
megaloblastic 
Yserythropoi
esis normal normal ? MDS
65 . 12487subramanian 65 M
dyspnoea 
chestpain
2
NAD cardiomegaly normal 3 4.5 4.22 7 24 66 18.7 22.6 <0.5 5, 20 75 16 1.3
 number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia Normal normal 2
 number 
increased 
megaloblastic 
maturation
 number 
increased 
myelocyte 
metamyelocyt
e giant band 
forms
normal in 
number n 
morphology
megaloblastic 
anemia increased
1.5654 saraswathy 77 F
dyspnoea, 
pedal edema 
decreased 
urine output
1
7
10.2039 mariyal 63 F
giddiness 
exertional 
dyspnoea
1,2,10, 6
3, 7
13. 43705 madasamy 70 M
pedal edema 
dyspnoea
2, 3
7
15. 43507 gurusamy 70 M dyspnoea
3,8,10,15
7
22. 40029 veeramariammal 70 F
fever 
abdominal 
pain
2,5,7
7
27. 33513 vellathai 65 F
abdominal 
pain icterus
4,11
7
33. 47768 muthukrishnan 72 M
giddiness 
pedal edema
2,3,6
7
43. 3904 velayutham 65 M
chestpain 
giddiness
15
7
46. 4954 krishnan 69 M
giddiness 
pedal edema
5, 10, 15
7
50. 22754 saroja 68 F
pedal edema 
facial 
puffiness
15
7
7. 12487 subramanian 65 M
dyspnoea 
chestpain
2, 15
7
2 0 3 0 0 0 1 1 0
2 0 1 0 0 0 0 1 0
2 3 2 0 1 0 1 1 0
2 3 3 0 0 0 0 1 0
2 3 1 0 0 0 0 0 0
2 0 2 0 1 1 0 0 0
2 2,3 1 0 1 0 0 1 0
2 2,3 1 0 0 0 0 1 0
2 3 3 0 0 0 0 1 0
2 3 1 0 0 0 0 1 0
2 2,3 3 0 0 0 0 0 0
0 76 110/70 22
mild 
hepatomegal
y, B/L crepts NAD pale upperGImucosa
0 66 130/100 26 NAD fatty liver normal
0 78 160/100 23 tender hepatomegaly
B/L medical 
renal disease 
type III RPD 
changes normal
0 85 120/ 70 18
systolic 
murmur B/L 
crepts
old PT B/L 
medical 
renal disease 
type I RPD 
changes pale upper GI mucosa
4 68 130/90 24 hemic murmur
mild 
cardiomegal
y normal
0 71 140/70 19 mild splenomegaly
fatty liver 
mild 
splenomegal
y congested GI mucosa
0 93 140/70 22 NAD
mild 
splenomegal
y normal
0 88 120/70 22 NAD cardiomegaly normal
0 68 140/90 20 hemic murmur
old PT 
cardiomegal
y pale UGI mucosa
0 80 150/70 14 systolic murmur
cardiomegal
y B/L 
minimal PE pale UGI mucosa
0 84 130/70 20 NAD cardiomegaly normal
3.1 6.2 1.5 6.1 18 102.4 23.2 26.8
2.39 4.3 2.69 6.6 22.1 94 23.8 27.4
2.68 4.5 2.31 8.2 24.7 99.6 30.6 30.8
2.5 3.2 0.4 6.8 22.4 128 27 32
3.3 12 3.3 9.1 36 89.4 23.6 30.1
1.19 11.4 1.73 8.1 24.9 116.9 32.7 31.3
1.92 2.9 71000 4.8 16 83.3 24.5 29.4
2.63 5.9 2.94 9.1 29.6 100.4 22.6 28.3
1.56 3.2 0.9 6.8 19.6 92.5 18.7 26.6
2.23 6.4 2.11 8.3 20.6 98.4 22.1 28.4
3 4.5 4.22 7 24 56 18.7 22.6
0.5 52 35 3 28 1.3 0.6 18 22 86
0.5 50 130 146 38 1.1 0.6 18 29 107
0.5 20 130 157 150 5.4 1.1 46 39 114
0.5 150 165 138 54 2 0.7 22 28 101
<0.5 55 110 86 40 0.8 0.9 21 32 97
1.5 110 150 106 29 0.8 0.9 32 21 96
0.5 45, 85 65 41 1.2 3.8 48 24 65
0.5 50 94 23 0.9 0.6 34 36 102
0.5 40 92 19 1 1.1 16 21 76
0.5 100 75 41 1.1 1.2 37 44 107
0.5 5, 20 75 16 1.3 0.5 18 21 88
5.8 3.1 1.1 83 0.7
number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia 3
normal 
number n 
morphology
5.3 2.2 1.1 86 0.7
number 
decreased 
normocytic n 
macrocytic 
RBCs
macrocytic 
anemia 3
normal 
number n 
morphology
4.8 2.8 0.7 74 1.9
 number 
decreased 
microcytic 
and 
macrocycytic 
RBCs
dimorphic 
anemia 4
increase in 
neutrophils
5.6 3 1.3 88 0.3
number  
decreased 
macrocytic n 
normocytic 
RBCs
dimorphic 
anemia 4
number 
decreased
6.2 2.9 1.9 52 3.5
number 
decreased 
microcytic n 
macrocytic 
RBCs
dimorphic 
anemia 4
number 
increased 
shift to left
6.2 3.2 68 4.5 2.1
number 
decreased 
normocytic n 
macrocytic 
RBCs
macrocytic 
anemia 3
increase in 
neutrophils
6.7 3.2 1.2 89 2.3
number 
decreased 
microcytic n 
macrocytic 
RBCs
dimorphic 
anemia 4
normal in 
number n 
morphology
5.4 3 1.2 66 0.4
number 
decreased 
microcytic n  
macrocytic  
RBCs
dimorphic 
anemia 4
normal 
number n 
morphology
6.2 3.1 1.2 65 0.7
number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia 3
number 
decreased
5.6 3.2 0.5 79 0.4
number 
decreased 
microcytic n 
macrocytic 
RBCs
dimorphic 
anemia 4
normal 
number n 
morphology
5.9 2.7 1.3 78 0.3
 number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia 3
normal in 
number n 
morphology
Normal 0
 normal 
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
number 
increased 
giant 
metamyelocy
tes
normal 
number n 
morphology
Normal 0
normal 
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
normal 
number n 
maturation
normal 
number n 
morphology
RN 1
normal  
number and 
morphology normal 0 0
 number 
increased 
megaloblasti
c maturation 
increase in 
metamyelocy
tes giant 
band forms
normal in 
number n 
morphology
leucopenia
 number 
reduced 
giant 
platelets
thrombocyto
penia 3 0
 number 
increased 
megaloblasti
c maturation 
dividing 
cells
megaloblasti
c maturation
normal  
number n 
morphology
reactive 
neutrophilia 1
normal  
number n 
morphology normal 0 0
 number 
increased 
megaloblasti
c maturation
increased 
giant 
metamyelocy
tes band 
forms
normal  
number n 
morphology
reactive 
neutrophilia 1
normal  
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
normal 
number  
normal 
maturation
normal  
number n 
morphology
normal
normal in 
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
megaloblasti
c maturation
normal 
number n 
morphology
normal 0
normal 
number n 
morphology normal 0 0
number 
normal 
megaloblasti
c maturation
number 
normal giant 
metamyelocy
tes band 
forms
normal 
number n 
morphology
leucopenia
number 
decreased 
normal 
morphology
thrombocyto
penia 2 0
number 
increased 
megaloblasti
c maturation
number 
increased 
megaloblasti
c maturation
normal 
number n 
morphology
Normal 0
normal 
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
number 
increased 
megaloblasti
c maturation
normal 
number n 
morphology
Normal 0
normal in 
number n 
morphology normal 1 0
 number 
increased 
megaloblasti
c maturation
 number 
increased 
myelocyte 
metamyelocy
te giant band 
forms
normal in 
number n 
morphology
megaloblasti
c anemia
megaloblasti
c anemia
megaloblasti
c anemia
megaloblasti
c 
dyserythropo
iesis
megaloblasti
c anemia
megaloblasti
c maturation
megaloblasti
c anemia
megaloblasti
c anemia
megaloblasti
c anemia
megaloblasti
c anemia
megaloblasti
c anemia
4.4798 esther 62 F
abdominal 
pain 
dyspnoea
1,2, 15
7
15. 43507 gurusamy 70 M dyspnoea
3,8,10,15
7
17. 42094 subbiah 60 M
dyspnoea 
decreased 
urine output
2, 15
7
19. 49305 arumugam 76 M
facial 
puffiness 
pedal edema
1,5,15
7
20. 46728 esakki 72 M weakness limbs
2
7
23. 45982 srinivasan 74 M
giddiness 
swaying 
while 
walking
2, 10, 15
7
29. 6858 gandhi 85 M hematemesis
8
7
31. 15364 patrakali 66 F
exertional 
dyspnoea
4, 15
7
2 0 3 0 0 1 0 0 0
2 3 3 0 0 0 0 1 0
2 1,2,3 3 0 0 0 0 1 0
2 1,2,3 1 0 0 0 0 1 0
2 1, 2, 3 2 0 0 0 0 1 0
2 2,3 3 0 0 0 0 1 0
2 3 3 0 0 0 0 0 0
2 3 3 0 0 0 1 1 0
0 86 140/80 20 NAD
cardiomegal
y 
splenomegal
y normal
0 85 120/ 70 18
systolic 
murmur B/L 
crepts
old PT B/L 
medical 
renal disease 
type I RPD 
changes pale upper GI mucosa
0 94 160/90 22 hemic murmur
cardiomegal
y 
mildsplenom
egaly,B/L  
moderate PE 
ulcer, 
incompetent 
GEJ
0 76 140/70 16 b/l crepts
cardiomegal
y  mild 
pleural 
effusion 
minimal 
ascitis normal
0 80 150/80 18 spastic quadriparesis
non 
compressive 
myelopathy pale UGI mucosa
0 74 120/80 16 NAD
cerebral 
atrophy normal
0 70 11o /70 23
hemic 
murmur, 
thyromegaly
B/L MRD 
type I CKD normal
1, 2 100 110/70 20 mild hepatomegaly
consolidatio
n lung early 
type I MRD 
mild 
hepatomegal
y pale UGI mucosa
1.82 2.5 30000 4.9 16.7 129.3 41.5 32.1
2.5 3.2 0.4 6.8 22.4 128 27 32
1.36 11.9 3.5 5.4 18 132.4 26.7 30
1.01 5.8 2.92 6.8 16.6 65.3 15.8 24.2
1.63 1200 1.27 7.7 25.6 104 31.3 30.1
2.2 3 0.3 6.5 20.1 91 29.4 32.3
2.1 3.9 2.12 5.6 24 76.4 21.6 28.8
1.27 4 10000 4.7 13.9 90.1 32.2 35.8
1 28/50 128 30 1.1 2.1 21 28 90
0.5 150 165 138 54 2 0.7 22 28 101
1 100 130 114 44 1.2 2.4 19 22 85
0.5 32 60 98 63 1.2 2.7 105 123 197
0.5 10 40 135 23 0.8 1.1 62 28 84
1 100 130 65 50 1 1 38 27 79
1 50, 105 96 129 2.2 1.2 36 26 206
0.5 100 150 125 22 1 0.6 31 31 85
4.6 2.5 1.3 103 1.1
 number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
 number 
decreased
5.6 3 1.3 88 0.3
number  
decreased 
macrocytic n 
normocytic 
RBCs
dimorphic 
anemia 4
number 
decreased
5.3 2.2 1.7 89 1
number 
decreased 
microcytic  
hypochromic 
RBCs
MCHC 
anemia 2
increase in 
neutrophils 
toxic 
vacuoles
5.8 3 1.5 61 0.5
number 
decreased 
microcytic n 
normocytic
dimorphic 
anemia 4
normal in 
number n 
morphology
6 2.7 1.6 81 1
number 
decreased 
microcytic n 
macrocytic 
RBCs
macrocytic 
anemia 3
number 
decreased
6.3 3.2 2 92 3.3
number 
decreased 
microcytic n 
normocytic 
RBCs 
dimorphic 
anemia 4
number 
decreased
5.3 2.6 1.3 86 0.6
number 
decreased 
microcytic 
and 
macrocytic 
RBCs
dimorphic 
anemia 4
normal in 
number n 
morphology
7.9 4.4 1.2 89 1
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
number 
decreased
leucopenia
 number 
reduced 
normal 
morphology
thrombocyto
penia 2 2
number 
decreased 
micro n 
macronormo
blastic 
maturation 
dividing 
cells 
dyserythropo
iesis 
number 
increased 
myeloblasts 
promyelocyt
es mature 
forms variable
leucopenia
 number 
reduced 
giant 
platelets
thrombocyto
penia 3 0
 number 
increased 
megaloblasti
c maturation 
dividing 
cells
megaloblasti
c maturation
normal  
number n 
morphology
reactive 
neutrophia 1
 number 
reduced 
normal 
morphology
thrombocyto
penia 2 2
dividing 
cells 
dyserythropo
iesis
dysmyelopoi
sis
normal 
morphology
normal 0
normal in 
number n 
morphology normal 0 1
dyserythropo
iesis
normal 
maturation
dysmorphic 
megks
leukopenia
normal 
number n 
morphology normal 0 1
number 
decreased 
megaloblasto
id maturation
number 
decreased 
dysmyelopoi
esis normal
leucopenia
number 
decreased 
normal 
morphology
thrombocyto
penia 3 1
number 
decreased 
dyserythropo
iesis
number 
decreased 
dysmyelopoi
esis
normal 
number 
dysmorphic 
megks
normal 0
normal in 
number n 
morphology normal 0 2
number 
increased 
megaloblasti
c maturation
number 
increased 
dysmyelopoi
esis
normal in 
number n 
morphology
leucopenia
number 
decreased
thrombocyto
penia 2 2
number 
decreased 
dyserythropo
iesis
number 
increased 
dysmyelopoi
esis
reduced 
number 
dysmorphic 
forms
MDS RAEB
megaloblasti
c 
dyserythropo
iesis
MDS
plasmacytosi
s MDS
MDS
MDS
MDS
MDS 
trilineage 
dysplasia -
RAEB
AGE GENDER PRESENTING COMPLAINTS
dyspnoea -     16
60 - 69 yrs   39 females   -  22
70 - 79 yrs   10 males    -    28
pedal edema   - 12
>80 yrs          1 abdominal pain  - 6
neuro. Sym  -  3
CO- MORBID CONITIONS
bleeding sym  - 3
DM  -   11
HT  -    19
liver  -   6
renal -  6
PT  -  10
APD  -  10
CA  -  5
thyroid - 1
bleeding  - 7
immune - 4
PRESENTING COMPLAINTS DIET PALLOR SPLEEN PEDAL EEMA
dyspnoea -     16
veg -  5 sclera -22 no   - 36 yes  -  32
fatigue -    6
non veg  - 45 tongue - 11 mild  -  7 no  -  18
pedal edema   - 12
both - 17 moderate  -  5 
abdominal pain  - 6 HABITS marked - 2
giddiness - 8 no  -   12 L.N
neuro. Sym  -  3
alcohol   - 7 no  -  41 LIVER
bleeding sym  - 3
smoking  - 16 isolated - 9 no    -   38
others  -  8 tea  - 30 mild  -  10
moderate - 2
PEDAL EEMA
anemia severity
mild - 3
moderate- 18
severe - 29

normocytic - 5 
microcytic - 25
macrocytic - 7
dimorphic - 13
pancytopenia - 5
PERIPHERAL SMEAR BONE MARROW
RBC WBC PLATELETS CELLULARITY
normocytic - 5 normal - 29 normal - 30 normo -36
microcytic - 25 reactive - 11 high  - 10 hypo - 4
macrocytic - 7 leucopenia -6 low   - 4 hyper - 10
dimorphic - 13 leukemia - 4
     acute - 1
    chronic - 3
pancytopenia - 5
AML - 1
megaloblasti
c anemia - 
14
neoplasms - 
10 CML -  3
non 
neoplastic - 
40
    chronic phase - 2 meg. dYsmyelopoiesis - 2elopoie is - 1
    accelerate phase - 1 meg. dYserythropoiesis  - 1
MDS  -  6
reactive 
marrow - 26
     RA-     1
 hyperplastic  
- 10
     RAEB- 2 IDA  -  11
     RCMD- 3 combined -  3
possibility of  MDS - 2
p/Omds
35. 16214 navaneetham 71 F
exertional 
dyspnoea
15
7 1
20. 46728 esakki 72 M weakness limbs
2
7 2
30. 9806 ramar 67 M paraparesis
1, 10
7 2
15. 43507 gurusamy 70 M dyspnoea
3,8,10,15
7 2
38. 38421 guruvammal 60 F
exertional 
dyspnoea
12
2 2
61 gnanam 69 F
52 76 F
0 3 0 0 0 0 1 0 0
1, 2, 3 2 0 0 0 0 1 0 0
2,3 1 0 0 0 0 1 0 0
3 3 0 0 0 0 1 0 0
0 1 0 0 0 0 0 0 0
68 110/ 80 14 venous hum NAD normal 1.96
80 150/80 18 spastic quadriparesis
non 
compressive 
myelopathy pale UGI mucosa 1.63
88 120/80 14 ESM normal normal 2.89
85 120/ 70 18
systolic 
murmur B/L 
crepts
old PT B/L 
medical 
renal disease 
type I RPD 
changes pale upper GI mucosa2.5
64 130/ 80 14 ca breast NAD normal 2.91
7.8 2.3 5.9 18.8 78.2 20.5 25.7 2
1200 1.27 7.7 25.6 104 31.3 30.1 0.5
3.7 1.93 9.1 31 107.3 31.5 20.4 0.5
3.2 0.4 6.8 22.4 128 27 32 1.2
5.4 3.15 11.1 26.8 97.5 24.3 31.7 1
100 130 126 29 1.1 0.9 32 40 112 6
10 40 135 23 0.8 1.1 62 28 84 6
12, 45 178 56 1.5 0.6 46 37 99 7.5
150 165 138 54 2 0.7 22 28 101 5.6
10 40 90 21 0.8 0.8 24 21 108 6.2
2.9 1.2 69.1 0.6
number 
decreased 
microcytic n 
macrocytic 
RBCs
dimorphic 
anemia 4
number 
normal 
hypersegmen
ted 
neutrophils normal
2.7 1.6 81 1
number 
decreased 
microcytic n 
macrocytic 
RBCs
macrocytic 
anemia 3
number 
decreased leukopenia
3.5 0.6 60 0.5
number 
decreased 
microcytic n 
macrocytic 
RBCs
dimorphic 
anemia 4
normal in 
number n 
morphology normal
3 1.3 88 0.3
number  
decreased 
macrocytic n 
normocytic 
RBCs
dimorphic 
anemia 4
number 
decreased leucopenia
3.1 1.8 92 0.6
number 
decreased 
normoctic 
normochrom
ic RBCs
normocytic 
anemia 1
normal 
number n 
morphology normal
0normal in 
number n 
morphology normal 0 0
number 
increased 
micro n 
macronormo
blastic 
maturation 
dividing 
cells
number 
increased 
dysmyelopoi
esis
normal in 
number n 
morphology
normal 
number n 
morphology normal 0 1
number 
decreased 
megaloblasto
id maturation
number 
decreased 
dysmyelopoi
esis normal
0
number 
increased 
giant 
platelets
reactive 
thrombocyto
sis 3 0
number 
increased 
micro n 
macro 
normoblastic 
maturation 
dividing 
cells
normal in 
number n 
morphology
normal 
number n 
morphology
 number 
reduced 
giant 
platelets
thrombocyto
penia 3 0
 number 
increased 
megaloblasti
c maturation 
dividing 
cells
megaloblasti
c maturation
normal  
number n 
morphology
0
normal 
number n 
morphology normal 0 1
number 
increased 
megaloblasti
c maturation
dysmyelopoi
sis
normal 
number n 
morphology
REH with 
micro n 
macro 
normoblasti
maturation 
with features 
s/o 
myelodyspla
sia p/o MDS
p/o MDS
p/o MDS 
dyserythropo
iesis
reactive 
marrow with 
micro n 
macronormo
blastic 
maturationpo
ssibility of 
MDSmay be 
thought of
p/o MDS 
dyserythropo
iesis
megaloblasti
c 
dyserythropo
iesis
p/o MDS 
meg 
dyserythro
megaloblasti
c 
ysmyelopoie
sis
p/o MDS 
meg 
dysmyelo
megaloblasti
c 
dysmegakary
opoiesis
meg. 
Yserythropoi
esis
meg. 
Yserythropoi
esis
ID No Name Age Gender
Presenting 
Complaints Code
Present Co-
morbidities
1-DM
2-HT
3-Chronic 
Renal Dis
4-Chr Liver 
Dis
5-APD
6-Chr 
Immune Dis
7-Menstrual 
Dis
8-Chr GI 
Bleeds
9-Splenic 
Enlargments
10-TB
11-Thyroid 
Dis
12-Cancer
13-GU 
Bleeding
14-Diarrhoea
15-Others
Treatment 
for Co-
Morbidities
1-RT
2-CT
3-Steroids
4-
AntiThyroid
5-
Hemodialysi
s
6-OCD
7-Others
Dietary 
History
1-Vegan
2-Non 
Vegan
6.15779 kosalai 65 F fatigue
1,2,3
7 2
36. 42317 ganapathy 66 F
loss of 
apetite 
fatigue
15
7 2
8.4471 santhivinayagam 65 M ulcer leg
10
7 2
14. 45911 madathi 65 F
hemoptysis, 
fever
15
7 2
33. 47768 muthukrishnan 72 M
giddiness 
pedal edema
2,3,6
7 2
43. 3904 velayutham 65 M
chestpain 
giddiness
15
7 2
10.2039 mariyal 63 F
giddiness 
exertional 
dyspnoea
1,2,10, 6
3, 7 2
48. 76231 subbulakshmi 61 F vomiting fever
1, 10
1, 2 2
27. 33513 vellathai 65 F
abdominal 
pain icterus
4,11
7 2
50. 22754 saroja 68 F
pedal edema 
facial 
puffiness
15
7 2
1.5654 saraswathy 77 F
dyspnoea, 
pedal edema 
decreased 
urine output
1
7 2
7. 12487 subramanian 65 M
dyspnoea 
chestpain
2, 15
7 2
22. 40029 veeramariammal 70 F
fever 
abdominal 
pain
2,5,7
7 2
13. 43705 madasamy 70 M
pedal edema 
dyspnoea
2, 3
7 2
46. 4954 krishnan 69 M
giddiness 
pedal edema
5, 10, 15
7 2
19. 49305 arumugam 76 M
facial 
puffiness 
pedal edema
1,5,15
7 2
23. 45982 srinivasan 74 M
giddiness 
swaying 
while 
walking
2, 10, 15
7 2
29. 6858 gandhi 85 M hematemesis
8
7 2
31. 15364 patrakali 66 F
exertional 
dyspnoea
4, 15
7 2
4.4798 esther 62 F
abdominal 
pain 
dyspnoea
1,2, 15
7 2
17. 42094 subbiah 60 M
dyspnoea 
decreased 
urine output
2, 15
7 2
66 63 F
60 73 F
63 60 M
67 selvaraj 62 M
56 61 M
2.6784 saraswathy 65 F
mass P/V 
urinary 
disturbances
15
7 2
18. 44867 mariappan 62 M
pedal edema 
facial 
puffiness
4
7 2
57 sudalaimuthu 73 M
3.1364 seetha 65 F
dyspnoea on 
exertion
5
7 2
12. 54734 pandaram 69 M
poor apetite 
giddiness
5, 12
7 2
Habits
0-No
1-Alcohol
2-Smoking
3-Tea/Cofee 
excess intake
Palor
1-Sclrea
2-Tongue
3- Both
Cyanosis
0-No
1-Yes
2-Marked
Lymphad
enopathy
0-No
1-Isolated
2-
Generalized
Spleen
0-No
1-Minimal
2-Moderate
3-Marked
Liver
0-No
1-Mild
2-Moderate
3-Marked
Pedal Edema
0-No
1-Yes
Clubbing
0-No
1-Yes
Skin 
Changes
0-No
1-Petichiae
2-Purpura
3-
Hyperpigme
ntation
4-
Hypopigmen
tation
5-Sclerosis
0 3 0 0 2 0 0 0 0
2 1 0 1 2 0 1 0 0
1, 3 2 0 0 3 0 1 0 3
3 1 0 0 2 0 1 0 0
2,3 1 0 1 0 0 1 0 0
2,3 1 0 0 0 0 1 0 0
0 1 0 0 0 0 1 0 0
0 2 0 0 0 0 0 0 0
0 2 0 1 1 0 0 0 0
3 1 0 0 0 0 1 0 0
0 3 0 0 0 1 1 0 0
2,3 3 0 0 0 0 0 0 0
3 1 0 0 0 0 0 0 4
3 2 0 1 0 1 1 0 0
3 3 0 0 0 0 1 0 0
1,2,3 1 0 0 0 0 1 0 0
2,3 3 0 0 0 0 1 0 0
3 3 0 0 0 0 0 0 0
3 3 0 0 0 1 1 0 1, 2
0 3 0 0 1 0 0 0 0
1,2,3 3 0 0 0 0 1 0 0
3 3 0 0 0 0 0 0 3
3 1 0 0 0 1 1 0 4
3 1 0 0 0 0 0 0 0
2,3 2 0 0 0 0 1 0 0
Peripheral 
Pulses BP
Resp
Rate
Systems
Describe 
Changes
Code
Changes
Radiology
Describe
Changes
Code
 Changes
Endoscopy
Describe
TRBC
x106cells/cu
mm
86 130/90 22
hemic 
murmur, 
splenomegal
y splenomegaly normal 2.2
70 130/80 20
moderate 
splenomegal
y 
hepatospleno
megaly normal 1.83
92 150/80 14 massive splenomegaly  splenomegaly normal 2.12
76 110/60 14
hemic 
murmur, B/L 
crepts, 
splenomegal
y
old PT, 
Splenomegal
y, increased 
renal cortical 
echoes
pale upper 
GI mucosa 1.8
93 140/70 22 NAD
mild 
splenomegal
y normal 1.92
88 120/70 22 NAD cardiomegaly normal 2.63
66 130/100 26 NAD fatty liver normal 2.39
82 110/80 16 ca breast NAD normal 3.11
71 140/70 19 mild splenomegaly
fatty liver 
mild 
splenomegal
y congested GI mucosa1.19
80 150/70 14 systolic murmur
cardiomegal
y B/L 
minimal PE pale UGI mucosa 2.23
76 110/70 22
mild 
hepatomegal
y, B/L crepts NAD pale upperGImucosa3.1
84 130/70 20 NAD cardiomegaly normal 3
68 130/90 24 hemic murmur
mild 
cardiomegal
y normal 3.3
78 160/100 23 tender hepatomegaly
B/L medical 
renal disease 
type III RPD 
changes normal 2.68
68 140/90 20 hemic murmur
old PT 
cardiomegal
y pale UGI mucosa 1.56
76 140/70 16 b/l crepts
cardiomegal
y  mild 
pleural 
effusion 
minimal 
ascitis normal 1.01
74 120/80 16 NAD
cerebral 
atrophy normal 2.2
70 11o /70 23
hemic 
murmur, 
thyromegaly
B/L MRD 
type I CKD normal 2.1
100 110/70 20 mild hepatomegaly
consolidatio
n lung early 
type I MRD 
mild 
hepatomegal
y pale UGI mucosa 1.27
86 140/80 20 NAD
cardiomegal
y 
splenomegal
y normal 1.82
94 160/90 22 hemic murmur
cardiomegal
y 
mildsplenom
egaly,B/L  
moderate PE 
ulcer, 
incompetent 
GEJ 1.36
78 120/70 18 NAD NAD pale UGImucosa 2.5
96 130/80 15 hemic murmur
cardiomegal
y moderate 
splenomegal
y pale upper GI mucosa1.95
84 130/80 16 hemic murmur NAD pale upperGImucosa3
94 140/80 16 NAD normal
growth body 
fundus of 
stomach up 
to LES 2.47
TLC
x103cells/cu
mm
PLC
x105cells/cu
mm
HB
gms/dl HCT MCV   MCH   MCHC RDW-SD Retic C
145 0.28 6.9 18.9 85.9 31.5 36.5 0.5
1.53 3.24 6.7 22.1 106 23.2 26.9 0.5
119 1.74 8.9 20.9 63.7 21.3 27.4 0.5
125 3.19 7.7 21.3 83.3 26.1 31.3 1
2.9 71000 4.8 16 83.3 24.5 29.4 1
5.9 2.94 9.1 29.6 100.4 22.6 28.3 0.5
4.3 2.69 6.6 22.1 94 23.8 27.4 0.5
4.8 2.45 7.6 22.3 84.7 24.5 30.2 0.5
11.4 1.73 8.1 24.9 116.9 32.7 31.3 1.5
6.4 2.11 8.3 20.6 98.4 22.1 28.4 0.5
6.2 1.5 6.1 18 102.4 23.2 26.8 0.5
4.5 4.22 7 24 66 18.7 22.6 <0.5
12 3.3 9.1 36 89.4 23.6 30.1 <0.5
4.5 2.31 8.2 24.7 99.6 30.6 30.8 0.5
3.2 0.9 6.8 19.6 92.5 18.7 26.6 0.5
5.8 2.92 6.8 16.6 65.3 15.8 24.2 0.5
3 0.3 6.5 20.1 91 29.4 32.3 1
3.9 2.12 5.6 24 76.4 21.6 28.8 1
4 10000 4.7 13.9 90.1 32.2 35.8 0.5
2.5 30000 4.9 16.7 129.3 41.5 32.1 1
11.9 3.5 5.4 18 132.4 26.7 30 1
6.5 3.26 8.3 78.5 0.5
5.3 2.84 10.8 90.4 0.5
7.8 2.78 7.5 83.2 1.4
7.2 1.79 10.4 88.3 1
4.7 3.16 9.3 87.4 0.5
6.9 2.5 5.6 16 89.3 23.6 27.9 0.3
7.3 1.42 5.1 13.8 70.8 16.4 23.2 2
7.4 2.53 8.7 82.6 1.2
10.5 1.8 6.2 26 74 22 22 1
6.4 5.63 6.9 19.6 79 23.5 29.6 1
ESR
1Hr BSR BUN SCR SBRT SGOT SGPT ALP SPROT
10 50 92 65 3 0.8 28 26 84 6.2
60 73 38 1.2 0.5 62 66 110 4.9
98 130 70 30 1.1 0.7 20 22 102 4.6
50 100 68 20 0.8 0.9 18 23 96 7.3
45, 85 65 41 1.2 3.8 48 24 65 6.7
50 94 23 0.9 0.6 34 36 102 5.4
50 130 146 38 1.1 0.6 18 29 107 5.3
110 102 36 0.9 1 26 28 88 6.2
110 150 106 29 0.8 0.9 32 21 96 6.2
100 75 41 1.1 1.2 37 44 107 5.6
52 35 3 28 1.3 0.6 18 22 86 5.8
5, 20 75 16 1.3 0.5 18 21 88 5.9
55 110 86 40 0.8 0.9 21 32 97 6.2
20 130 157 150 5.4 1.1 46 39 114 4.8
40 92 19 1 1.1 16 21 76 6.2
32 60 98 63 1.2 2.7 105 123 197 5.8
100 130 65 50 1 1 38 27 79 6.3
50, 105 96 129 2.2 1.2 36 26 206 5.3
100 150 125 22 1 0.6 31 31 85 7.9
28/50 128 30 1.1 2.1 21 28 90 4.6
100 130 114 44 1.2 2.4 19 22 85 5.3
 30 50 106 22 1.1 0.6 36 29 99 5.3
30 60 146 21 0.8 1.1 41 44 118 4.8
 55 120 148 24 0.8 1 40 36 104 5.7
50 100 96 25 0.8 0.4 19 41 98 6.6
ALB T3 T4 TSH
PSS-RBC
Describe 
RBC
PSS-RBC
Impression
PSS-RBC
1-
Normocytic
2-Microcytic
3-Macrocytic
4-Dimorphic
5-Others
PSS-WBC
Describe
PSS-WBC
Impression
3.3 1.7 88 0.8
 number 
decreased  
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
increased 
myelolasts leukemia
2.2 0.9 78 0.7
number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia 3
number 
increased 
mature 
neutrophils, 
band forms 
myelocytes 
occasssional 
blasts
CML - 
chronic 
phase
2.7 1.6 82 0.9
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
increased in 
neutrophils 
band forms 
occassional 
blasts
CML - 
chronic 
phase
4.3 1 92 3
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
increase in 
mature 
neutrophil, 
band forms, 
myelocyt 
basophils
CML- 
accelerated 
phase
3.2 1.2 89 2.3
number 
decreased 
microcytic n 
macrocytic 
RBCs
dimorphic 
anemia 4
normal in 
number n 
morphology normal
3 1.2 66 0.4
number 
decreased 
microcytic n  
macrocytic  
RBCs
dimorphic 
anemia 4
normal 
number n 
morphology normal
2.2 1.1 86 0.7
number 
decreased 
normocytic n 
macrocytic 
RBCs
macrocytic 
anemia 3
normal 
number n 
morphology Normal
2.9 0.7 74 1.9
number 
decreased 
normocytic 
BBCs
normocytic 
anemia 1
normal 
number n 
morphology Normal
3.2 68 4.5 2.1
number 
decreased 
normocytic n 
macrocytic 
RBCs
macrocytic 
anemia 3
increase in 
neutrophils
reactive 
neutrophilia
3.2 0.5 79 0.4
number 
decreased 
microcytic n 
macrocytic 
RBCs
dimorphic 
anemia 4
normal 
number n 
morphology Normal
3.1 1.1 83 0.7
number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia 3
normal 
number n 
morphology Normal
2.7 1.3 78 0.3
 number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia 3
normal in 
number n 
morphology Normal
2.9 1.9 52 3.5
number 
decreased 
microcytic n 
macrocytic 
RBCs
dimorphic 
anemia 4
number 
increased 
shift to left
reactive 
neutrophilia
2.8 0.7 74 1.9
 number 
decreased 
microcytic 
and 
macrocycytic 
RBCs
dimorphic 
anemia 4
increase in 
neutrophils RN
3.1 1.2 65 0.7
number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia 3
number 
decreased leucopenia
3 1.5 61 0.5
number 
decreased 
microcytic n 
normocytic
dimorphic 
anemia 4
normal in 
number n 
morphology normal
3.2 2 92 3.3
number 
decreased 
microcytic n 
normocytic 
RBCs 
dimorphic 
anemia 4
number 
decreased leucopenia
2.6 1.3 86 0.6
number 
decreased 
microcytic 
and 
macrocytic 
RBCs
dimorphic 
anemia 4
normal in 
number n 
morphology normal
4.4 1.2 89 1
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
number 
decreased leucopenia
2.5 1.3 103 1.1
 number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
 number 
decreased leucopenia
2.2 1.7 89 1
number 
decreased 
microcytic  
hypochromic 
RBCs
MCHC 
anemia 2
increase in 
neutrophils 
toxic 
vacuoles
reactive 
neutrophia
MCHC 
anemia 2 Normal
normocytic 
anemia 1 Normal
MCHC 
anemia 2 RN
MCHC 
anemia 2 n RN
normocytic 
anemia 1 RN
2.8 0.9 78 0.9
number 
decreased 
normocytic n 
microcytic 
RBCs 
anisopoikilo
cytosis
dimorphic 
anemia 4
increase in 
neutrophils RN
2.6 1.8 88 0.6
number 
decreased  
microcytic  
hypochromic 
RBCs
MCHC 
anemia 2
normal  
number n 
morphology normal
dimorphic 
anemia 4 RN
3.1 1.6 82 1.2
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
normal in 
number n 
morphology RN
3.2 1.8 76 0.3
 number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
normal in 
number n 
morphology normal
PSS-WBC
0-Normal
1-Reactive
2-Suspicious
3-
Malignancy
4-
Inconclusive
PSS-PL
Describe
PSS-PL
Impression
PSS-PL
0-Normal
1-High
2-Low
3-Giant Pl
Marrow
Cellularity
0-Normal
1-Hypo
2-Hyper
Marrow 
Erythroid
Describe
Marrow 
Myeloid 
Describe
Marrow 
Megk
Describe
Marrow 
Others
Describe
3
 number 
reduced 
thrombocyto
penia 2 2
 number 
decreased 
micronormo
blastic 
maturation
increased in 
number 
myeloblasts 
>90% decreased
3
number 
increased 
normal in  
morphology
reactive 
thrombocyto
sis 1 2
number 
decreased 
micro n 
macronormo
blastic 
maturation  
increase in 
myeloblasts 
promyelocyt
es 
myelocytes 
band forms 
mature 
neutrophils 
normal in 
number n 
morphology
3
 number 
increased 
normal 
morphology
thrombocyto
sis 1 2
number 
decreased 
micronormo
blastic 
maturation
increase in 
myeloblasts 
promyelocyt
es 
metamyelocy
tes 
normal  
number n 
morphology
3
 number 
increased 
normal 
morphology
thrombocyto
sis 1 2
 number 
decreased 
micronormo
blastic 
maturation
increase in 
myeloblasts 
promyelocyt
es 
metamyelocy
tes basophils
number 
increased 
normal 
morphology
0normal in 
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
megaloblasti
c maturation
normal 
number n 
morphology
0
normal 
number n 
morphology normal 0 0
number 
normal 
megaloblasti
c maturation
number 
normal giant 
metamyelocy
tes band 
forms
normal 
number n 
morphology
0
normal 
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
normal 
number n 
maturation
normal 
number n 
morphology
0
normal 
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
normal 
number n 
maturation
normal 
number n 
morphology
1
normal  
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
normal 
number  
normal 
maturation
normal  
number n 
morphology
0
normal 
number n 
morphology normal 0 2
number 
increased 
megaloblasti
c maturation
number 
increased 
megaloblasti
c maturation
normal 
number n 
morphology
0
 normal 
number n 
morphology normal 0 2
number 
increased 
megaloblasti
c maturation
number 
increased 
giant 
metamyelocy
tes
normal 
number n 
morphology
0
normal in 
number n 
morphology normal 0 2
 number 
increased 
megaloblasti
c maturation
 number 
increased 
myelocyte 
metamyelocy
te giant band 
forms
normal in 
number n 
morphology
1
normal  
number n 
morphology normal 0 2
 number 
increased 
megaloblasti
c maturation
increased 
giant 
metamyelocy
tes band 
forms
normal  
number n 
morphology
1
normal  
number and 
morphology normal 0 2
 number 
increased 
megaloblasti
c maturation 
increase in 
metamyelocy
tes giant 
band forms
normal in 
number n 
morphology
2number 
decreased 
normal 
morphology
thrombocyto
penia 2 2
number 
increased 
megaloblasti
c maturation
number 
increased 
megaloblasti
c maturation
normal 
number n 
morphology
0
normal in 
number n 
morphology normal 0 1
micro 
normoblastic 
maturation 
dyserythropo
iesis
normal 
maturation
dysmorphic 
megks
plasmacytosi
s
2
number 
decreased 
normal 
morphology
thrombocyto
penia 2 1
number 
decreased 
dyserythropo
iesis
number 
decreased 
dysmyelopoi
esis
normal 
number 
dysmorphic 
megks
0
normal in 
number n 
morphology normal 0 2
number 
increased 
megaloblasti
c maturation
number 
increased 
dysmyelopoi
esis
normal in 
number n 
morphology
2
number 
decreased
thrombocyto
penia 2 2
number 
decreased 
dyserythropo
iesis
number 
increased 
dysmyelopoi
esis
reduced 
number 
dysmorphic 
forms
2
 number 
reduced 
normal 
morphology
thrombocyto
penia 2 2
number 
decreased 
micro n 
macronormo
blastic 
maturation 
dividing 
cells 
dyserythropo
iesis 
number 
increased 
myeloblasts 
promyelocyt
es mature 
forms variable
1
 number 
reduced 
normal 
morphology
thrombocyto
penia 2 2
dividing 
cells 
dyserythropo
iesis
dysmyelopoi
sis
normal 
morphology
0 n normal 0 0
0 normal 0 0
1 normal 0 0
1 normal 0 0
1 n normal 0 0
1number 
increased 
normal in  
morphology
reactive 
thrombocyto
sis 1 0
 number 
increased  
micro n 
macro 
normoblastic  
maturation 
incresed in 
number 
normal 
maturation
normal in 
number n 
morphology
0
normal  
number n 
morphology normal 0 2
 number 
increased, 
micro and 
macro 
normoblasti 
maturation 
normal  
number n 
morphology
normal  
number n 
morphology
plasmacytosi
s
1 normal 0 2
1
normal in 
number n 
morphology normal 0 2
 number 
increased 
micro n 
macro 
normoblasti 
maturation 
normal in 
number n 
morphology
normal in 
number n 
morphology
0
 number 
increased 
normal  
morphology
reactive 
thrombocyto
sis 1 2
 number 
increased 
micronormo
blastic 
maturation 
normal  
number n 
morphology
normal  
number n 
morphology
Marrow 
Impression
Describe diagnosis
AML-M1 AML
CML - 
chronic 
phase CML
CML 
chronic 
phase CML acc.
CML - 
accelerated 
phase CML
megaloblasti
c anemia meg ane
megaloblasti
c anemia meg ane
reactive 
marrow with 
megaloblasti
c maturation meg ane
megaloblasti
c anemia meg ane
erythroid 
hyperplasia 
withmegalob
lastic 
maturation 
consistent 
with 
megaloblasti
c anemia meg ane
megaloblasti
c anemia meg ane
megaloblasti
c anemia meg ane
megaloblasti
c anemia meg ane
megaloblasti
c anemia meg ane
megaloblasti
c anemia meg ane
megaloblasti
c anemia meg ane
MDS with 
plasmacytosi
s - RCMD
MDS RCMD
megaloblasti
c marrow 
with 
dysmyelopoi
esis s/o MDS-
RA
MDS 
trilineage 
dysplasia -
RAEB
MDS RCMD
MDS RCMD
combined 
deficiency combined
combined 
deficiency combined
combined 
deficiency combined
combined 
deficiency combined
combined 
deficiency combined
reactive 
marrow with 
micro n 
macronormo
blastic 
maturation  
s/o combined 
deficiency combined
REH with 
micro n 
macro 
normoblasti
maturation 
and 
plasmacytosi
s combined
combined 
deficiency combined
REH with 
micro n 
macro 
normoblastic 
maturation  
s/o combinrd 
deficiency combined
REHs/o IDA combinedIDA
6.15779 kosalai 65 F fatigue
1,2,3
7 . 0
14. 45911 madathi 65 F
hemoptysis, 
fever
15
7 2 3
8.4471 santhivinayagam 65 M ulcer leg
..
7 2 1, 3
36. 42317 ganapathy 66 M
loss of 
apetite 
fatigue
15
7 2 2
4.4798 esther 62 F
abdominal 
pain 
dyspnoea
1,2, 15
7 . 0
31. 15364 patrakali 66 F
exertional 
dyspnoea
. .
7 2 3
17. 42094 subbiah 60 M
dyspnoea 
decreased 
urine output
2, 15
7 2 1
23. 45982 srinivasan 74 M
giddiness 
swaying 
while 
walking
2
7 2 2,3
19. 49305 arumugam 76 M
facial 
puffiness 
pedal edema
1,5
7 2 . .
29. 6858 gandhi 85 M hematemesis
. .
1 . .
20. 46728 esakki 72 M weakness limbs
2
7 2 1, 2, 3
15. 43507 gurusamy 70 M dyspnoea
3,8,10,15
7 2 3
48. 76231 subbulakshmi 61 F vomiting fever
1
1, 2 2 0
10.2039 mariyal 63 F
giddiness 
exertional 
dyspnoea
1,2,, 6
3, 7 2 0
27. 33513 vellathai 65 F
abdominal 
pain icterus
4,11
7 2 0
50. 22754 saroja 68 F
pedal edema 
facial 
puffiness
15
7 2 3
22. 40029 veeramariammal 70 F
fever 
abdominal 
pain
2,5,
7 2 . .
1.5654 saraswathy 77 F
dyspnoea, 
pedal edema 
decreased 
urine output
1
7 . . 0
43. 3904 velayutham 65 M
chestpain 
giddiness
15
7 . . 2
7. 12487 subramanian 65 M
dyspnoea 
chestpain
2, 15
7 . . 2,3
46. 4954 krishnan 69 M
giddiness 
pedal edema
10, 15
7 2 3
13. 43705 madasamy 70 M
pedal edema 
dyspnoea
2, 3
7 2 . .
33. 47768 muthukrishnan 72 M
giddiness 
pedal edema
2,3,6
7 2 .?
66 63 F
chest pain, 
exertional 
dyspnoea
2.6784 saraswathy 65 F
mass P/V 
urinary 
disturbances
1
7 2 3
3.1364 seetha 65 F
dyspnoea on 
exertion
5
7 2 3
60 73 F
pedal eema 
chest pain 
fatigue
15
63 60 M
exertional 
dyspnoea
1
56 61 M giddiness
. .
18. 44867 mariappan 62 M
pedal edema 
facial 
puffiness
2
7 2 3
67 selvaraj 62 M
easy 
fatiguability 
loss of 
apetite
, ,
57 sudalaimuthu 73 M giddiness
4
62 81 F
loss of 
apetite 
vomiting 
fatigue
..
5. 1400 pathmanaban 61 M
pedal edema 
abdominal 
pain
2
7 1 0
24. 47881 paramasivan 62 M
exertional 
dyspnoea 
pedal edema 
1,2
7 2 2
16. 61113 shanmugasundaram 62 M
cough 
palpitation 
pedal edema
5 , 10
7 2 0
25. 48220 murugan 63 M fever
15
7 2 2
28. 14794 sundar raj 69 M giddiness 
2, 10
7 2 1
41. 31693 kannimalar 70 M giddiness
2, 3, 10
7 1 3
21. 50914 esakkkiammal 66 F mass abdomen
5, 8
7 2 3
49. 50267 ponnammal 66 F
exertional 
dyspnoea 
palpitation
15
7 2 3
54 66 F fatigue
3
58 velu 67 F
giddiness 
loss of 
apetite fever
, ,
68 71 F fatigue vomiting
. .
65 74 F
giddiness, 
chestpain 
palpitation
40. 37152 lakshmi 60 F
abdominal 
pain 
vomiting
8
2 2 1
37. 4632 rajeshwari 63 F
easy 
fatiguability 
loss of 
apetite
12, 14
1,2, 7 2 3
9.9578 bagavathy 66 F fatigue
5, 8
7 . . 3
11. 60969 lakshmi 66 F fatigue diarrhoea
14
7 2 3
39. 19917 ramani 67 F loss of apetite
12
2 2 1
45. 3398 sudalaimadan 61 M
abdominal 
pain malena
8, 12, 14
2, 7 2 2
42. 14794 soundarajan 62 M
exertional 
dyspnoea 
palpitation
8
7 2 2
34. 49335 manoharan 65 M
fever, 
abdominal 
pain
1,2,3
7 2 3
26. 32431 poothathan 65 M
abdominal 
pain 
dyspnoea
2,.15
7 , , . .
47. 3490 jesumichel 65 M
pedal edema 
loss of 
weight
2,4
7 2 2,3
55 60 F giddiness
…
2 ,
32. 50536 kanchana 61 F
abdominal 
pain icterus
1,2,4,6
3, 7 1 0
64 61 F
fatigue chest 
pain 
giddiness
1
44. 3422 shanmugathammal 65 F
exertional 
dyspnoea 
pedal edema
2, 5, 6
7 1 0
62 81 F
loss of 
apetite 
vomiting 
fatigue
..
3 0 2 0 0 86 130/90 22
hemic 
murmur, 
splenomegal
y splenomegaly 
1 0 2 0 1 76 110/60 14
hemic 
murmur, B/L 
crepts, 
splenomegal
y
old PT, 
Splenomegal
y, increased 
renal cortical 
echoes
2 0 2 0 1 92 150/80 14
moderate 
splenomegal
y
 splenomegaly
1 1 2 0 0 70 130/80 20
moderate 
splenomegal
y 
hepatospleno
megaly
3 0 1 0 0 86 140/80 20 NAD
cardiomegal
y mild 
splenomegal
y 
3 0 0 1 1 100 110/70 20
mild 
hepatomegal
y
consolidatio
n lung early 
type I MRD 
mild 
hepatomegal
y
3 0 0 0 1 94 160/90 22
hemic 
murmur
cardiomegal
y 
mildsplenom
egaly,B/L  
moderate PE 
3 0 0 0 1 74 120/80 16 NAD
cerebral 
atrophy
1 0 0 0 1 76 140/70 16 b/l crepts
cardiomegal
y  mild 
pleural 
effusion 
minimal 
ascitis
3 0 0 0 0 70 11o /70 23
hemic 
murmur, 
thyromegaly
B/L MRD 
type I CKD
2 0 0 0 1 80 150/80 18
spastic 
quadriparesis
non 
compressive 
myelopathy
3 0 0 0 1 85 120/ 70 18
systolic 
murmur B/L 
crepts
old PT B/L 
medical 
renal disease 
type I RPD 
changes
2 0 0 0 0 82 110/80 16
ca breast on 
treatment NAD
1 0 0 0 1 66 130/100 26 NAD fatty liver 
2 1 1 0 0 71 140/70 19
mild 
splenomegal
y
fatty liver 
mild 
splenomegal
y
1 0 0 0 1 80 150/70 14
systolic 
murmur
cardiomegal
y B/L 
minimal PE
1 0 0 0 0 68 130/90 24
hemic 
murmur
mild 
cardiomegal
y
3 0 0 1 1 76 110/70 22
mild 
hepatomegal
y, B/L crepts NAD
1 0 0 0 1 88 120/70 22 NAD cardiomegaly
3 0 0 0 0 84 130/70 20 NAD cardiomegaly
3 0 0 0 1 68 140/90 20
hemic 
murmur
old PT 
cardiomegal
y
2 1 0 1 1 78 160/100 23
tender 
hepatomegal
y
B/L medical 
renal disease 
type III RPD 
changes
1 1 0 0 1 93 140/70 22 NAD
mild 
splenomegal
y
3 0 0 0 0 78 120/70 18 NAD NAD
1 0 0 0 0 84 130/80 16 hemic murmur NAD
1 0 0 1 1 96 130/80 15
hemic 
murmur
cardiomegal
y moderate 
splenomegal
y
3 0 0 0 1 96 140/90 26 NAD
mild 
splenomegal
y
2 0 1 1 1 73 170/100 20
ESM, 
hepatospleno
megaly
mild 
cardiomegal
y
1 0 0 2 1 84 110/80 14
epigatric 
tenderness 
hepatomegal
y old PT
1 0 0 0 0 104 140/80 26 NAD NAD
1 0 0 0 1 110 130/80 22
systolic 
murmur NAD
2 1 0 0 0 63 120/80 16 NAD
old PT B/L 
small 
kidneys
1 0 3 1 0 88 100/70 18
liver just 
palpable 
massivesplen
omegaly
cardiomegal
y 
splenomegal
y dilated 
portal vein
3 0 0 0 1 78 140/80 23 b/l crepts
pneumonitic 
changes mild 
cardiomegal
y
1 0 0 0 0 74 130/90 22 epigastric mass
antral growth 
simple 
hepatic cyst 
1 0 0 0 0 84 120/ 80 18 ca breast NAD
2 1 2 1 1 72 120/60 15
splenomegal
y, tender 
hepatomegal
y
splenomegal
y, renal 
calculi
1 1 0 2 1 90 120/80 16 hepatomegaly hepatomegaly
1 0 0 0 0 68 14/ 80 18 k/c/o ca alveolus NAD
1 1 0 0 0 62 140/60 19 k/c/o ca stomach NAD
3 0 0 0 0 78 150/60 21
hemic 
murmur, 
haemorrhoid
s NAD
2 0 2 1 1 90 120/80 16
moderate 
splenomegal
y tender 
hepatomegal
y
hepatospleno
megaly
3 0 1 0 1 66 150/90 22 splenomegaly
splenomegal
y 
cholelithiasis 
renal calculi
1 0 1 1 1 92 120/80 22
jaundice 
hepatomegal
y
hepatospleno
megaly
2
2 0 1 1 1 94 130/80 16
jaundice 
hepatomegal
y
splenomegal
y calculous 
cholecystitis 
3 1 1 0 1 76 110/80 16 mild splenomegaly
splenomegal
y 
cardiomegal
y
not done 2.2 145 0.28 6.9 18.9 85.9 31.5 36.5
not done 1.8 125 3.19 7.7 21.3 83.3 26.1 31.3
not done 2.12 90,000 1.74 8.9 20.9 63.7 21.3 27.4
not done 1.83 1.53 3.24 6.7 22.1 106 23.2 26.9
not done 1.82 2.5 30000 4.9 16.7 129.3 41.5 32.1
pale UGI mucosa1.27 4 10000 4.7 13.9 90.1 32.2 35.8
ulcer, 
incompetent 
GEJ 1.36 11.9 3.5 5.4 18 132.4 26.7 30
not done 2.2 3 0.3 6.5 20.1 91 29.4 32.3
normal 1.01 5.8 2.92 6.8 16.6 65.3 15.8 24.2
normal 2.1 3.9 2.12 5.6 24 76.4 21.6 28.8
not done 1.63 1200 1.27 7.7 25.6 104 31.3 30.1
pale upper GI mucosa2.5 3.2 0.4 6.8 22.4 128 27 32
not done 3.11 4.8 2.45 7.6 22.3 84.7 24.5 30.2
not done 2.39 4.3 2.69 6.6 22.1 94 23.8 27.4
congested GI mucosa1.19 11.4 1.73 8.1 24.9 116.9 32.7 31.3
pale UGI mucosa2.23 6.4 2.11 8.3 20.6 98.4 22.1 28.4
not done 3.3 12 3.3 9.1 36 89.4 23.6 30.1
pale upperGImucosa3.1 6.2 1.5 6.1 18 102.4 23.2 26.8
not done 2.63 5.9 2.94 9.1 29.6 100.4 22.6 28.3
normal 3 4.5 4.22 7 24 66 18.7 22.6
not done 1.56 3.2 0.9 6.8 19.6 92.5 18.7 26.6
normal 2.68 4.5 2.31 8.2 24.7 99.6 30.6 30.8
not done 1.92 2.9 71000 4.8 16 83.3 24.5 29.4
1.88 6.5 3.26 8.3 36.8 86.5 22.6 28.7
not done 2.5 6.9 2.5 5.6 16 89.3 23.6 27.9
not done 3 10.5 1.8 6.2 26 74 22 22
not done 5.3 2.84 10.8 90.4
not done 7.8 2.78 7.5 83.2
not done 4.7 3.16 9.3 87.4
not done 1.95 7.3 1.42 5.1 13.8 70.8 16.4 23.2
7.2 1.79 10.4 88.3
7.4 2.53 8.7 82.6
not done 6.3 1.85 6.8 79
gastric 
mucosal 
prolapse 3.47 5 2.98 5.3 22.3 64.3 15.3 23.8
congested GI mucosa2.19 4.3 1.35 6.3 20.3 92.7 28.8 31.1
2.28 7.8 2.95 5.9 14.4 63.2 14.9 23.6
normal 3.2 5.8 90 10.4 33.7 97.4 32.9 33.8
pale UGI mucosa2.34 5.3 2.05 6.4 28.1 73.4 24.5 26.2
pale UGI mucosa2.09 5.4 2.31 7.1 26.4 65.5 16.7 25.1
esophageal 
varices 
severe PHT/ 
gastropathy 2.22 4.2 0.41 6.3 18.4 93.6 18.4 22.3
not done 1.87 9.2 1.48 5.7 19.4 76.9 21.5 27.3
not done 5.6 2.29 8.2 69.6
not done 2.9 1.13 5.7 62.9
not done 3.8 1.06 11.2 77.6
4.1 1.52 7.7 86.6
proliferative 
growth 
pylorus 3.1 6000 3.8 5.7 19.4 73.5 22.7 28.5
not done 2.2 6.5 2.98 10.3 32.3 88.7 25.6 32.1
2.7 11 0.19 6.4 19.3 72.5 21.3 31.1
1.96 10.6 3.55 5.8 20.1 66.4 21.2 29.6
not done 2.88 6.5 3.32 10.2 33.1 66.6 26.2 29.7
not done 2.26 5.2 2.13 6.2 24.8 68.7 23.2 25.7
not done 2.99 6.3 4.32 8.9 30.1 78.9 21.2 32.2
not done 2.67 7.3 1.56 7.5 23 86.4 28.1 34.6
pale  UGI 
mucosa 2.26 34.5 1.1 6.5 27.6 72.8 17.8 24.5
2.99 7.3 2.65 8.3 20.2 56.5 19.3 22.4
6.1 3.41 6.9 74.8
3.2 9.9 4.1 8.7 30.6 72.9 19.6 26.9
not done 5.3 2.73 6.3 59.7
normal 1.78 4.7 3.96 7.4 23.5 77.2 19.3 27.4
not done 6.3 1.85 6.8 81.7
. . . 92 65 3 . . . . ..
. . 60 73 38 1.2 0.5 62 66
. . . . 68 20 0.8 . . .
. . 98 130 70 30 1.1 0.7 20 22
0.5 .. 113 43 0.6 .. . .
0.5
1.4
0.5 74
1
1.2
1.5 110 150 106 29 0.8 0.9 32 21
1.1 10 22 137 27 0.7 2.4 63 54
1.2
0.6
0.5
1 28/50 128 30 1.1 2.1 21 28
1 100 130 114 44 1.2 2.4 19 22
1 100 130 65 50 1 1 38 27
0.5 100 150 125 22 1 0.6 31 31
0.5 32 60 98 63 1.2 2.7 105 123
1.2 150 165 138 54 2 0.7 22 28
0.5 10 40 135 23 0.8 1.1 62 28
0.5 110 102 36 0.9 1 26 28
0.5 . . 146 38 1.1 0.6 18 29
0.5 100 75 41 1.1 1.2 37 44
<0.5 55 110 86 40 0.8 0.9 21 32
0.5 52 35 3 28 1.3 0.6 18 22
0.5 50 94 23 0.9 0.6 34 36
<0.5 5, 20 75 16 1.3 0.5 18 21
0.5 40 92 19 1 1.1 16 21
0.5 20 130 157 150 5.4 1.1 46 39
1 45, 85 65 41 1.2 3.8 48 24
1 50, 105 96 129 2.2 1.2 36 26
0.5
0.6 40 85 89 32 0.9 0.8 34 28
1.5 50, 100 74 24 0.8 1 42 36
1 100  150 104 29 0.9 0.8 41 36
< 0.5 55 100 137 44 1 1.6 25 41
1.3 100 132 132 95 4.3 0.6 40 20
1 48 66 22 0.8 0.7 34 42
10.3
1 15 30 60 44 1.2 0.8 17 24
0.5
0.5 42 60 48 1.3 0.7 28 33
0.3  30 50 106 22 1.1 0.6 36 29
3 26 80 76 16 0.6 1.2 34 22
0.5 55 64 21 0.6 0.9 18 26
0.5 50 105 117 76 1.4 0.6 26 26
1 80 120 78 36 0.9 1.1 . .
1 130 112 35 1.1 1.2 26 41
0.5 30 50 112 42 0.9 1.1 20 24
1  55 120 148 24 0.8 1 40 36
2 30 60 146 21 0.8 1.1 41 44
1.3 10 22 115 34 1.5 0.4 34 42
0.5 55 100 146 20 0.8 0.9 40 36
0.5 50 76 28 0.6 0.9 18 21
1.2 60 97 20 0.9 0.7 19 22
0.5 50 100 110 28 0.8 . . .
1.2
. . . . . . 0 0 0
 number 
decreased  
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
110 4.9 2.2 . . .
number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia 3
. . . . 0 0 0
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 
NRBC 2
102 4.6 2.7 . . .
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
. . . . . .
MCHC 
anemia 2
normocytic 
anemia 1
MCHC 
anemia 2
normocytic 
anemia 1
MCHC 
anemia mild 
anisocytosis 2
dimorphic 
anemia 4
96 6.2 3.2 68 4.5 2.1
number 
decreased 
normocytic n 
macrocytic 
RBCs
macrocytic 
anemia 3
109 4.8 3.1 0.5 78 0.9
number 
decreased 
schistocytes
hemolytic 
blood picture 
MCHC 2
0.7
dimorphic 
anemia 4
1.3
MCHC 
anemia 2
0.4
normocytic 
anemia 1
90 4.6 2.5 . . .
 number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
85 5.3 2.2 1.7 89 1
number 
decreased 
microcytic  
hypochromic 
RBCs
MCHC 
anemia 2
79 6.3 3.2 2 92 3.3
number 
decreased 
microcytic n 
normocytic 
RBCs 
dimorphic 
anemia 4
85 7.9 4.4 . . 1
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
197 5.8 3 1.5 61 0.5
number 
decreased 
microcytic n 
normocytic
dimorphic 
anemia 4
101 5.6 3 1.3 0.3
number  
decreased 
macrocytic n 
normocytic 
RBCs
dimorphic 
anemia 4
84 6 2.7 1.6 81 1
number 
decreased 
microcytic n 
macrocytic 
RBCs
macrocytic 
anemia 3
88 6.2 2.9 0.7 74 1.9
number 
decreased 
normocytic 
BBCs
normocytic 
anemia 
NRBC 1
107 5.3 2.2 1.1 86 0.7
number 
decreased 
normocytic n 
macrocytic 
RBCs
macrocytic 
anemia 3
107 5.6 3.2 . . .
number 
decreased 
microcytic n 
macrocytic 
RBCs
dimorphic 
anemia 4
97 6.2 2.9 . . . . 3.5
number 
decreased 
microcytic n 
macrocytic 
RBCs
dimorphic 
anemia 4
86 5.8 3.1 1.1 83 0.7
number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia 3
102 5.4 3 1.2 66 0.4
number 
decreased 
microcytic n  
macrocytic  
RBCs
dimorphic 
anemia 4
88 5.9 2.7 1.3 78 0.3
 number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia 3
76 6.2 3.1 . . 0.7
number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia 3
114 4.8 2.8 . . .
 number 
decreased 
microcytic 
and 
macrocycytic 
RBCs
dimorphic 
anemia 4
65 6.7 3.2 1.2 89 2.3
number 
decreased 
microcytic n 
macrocytic 
RBCs
dimorphic 
anemia 4
206 5.3 2.6 1.3 86 0.6
number 
decreased 
microcytic 
and 
macrocytic 
RBCs
dimorphic 
anemia 4
0.8
MCHC 
anemia 2
116 6.1 2.9 . . .
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 
anisopoikilo
cytosis 2
151 8.6 4.6 . . .
number 
decreased 
normoctic 
normochrom
ic RBCs
normocytic 
anemia 1
112 5.2 2.9 0.5 74 0.8
number 
decreased 
microcytic  
hypochromic 
RBCs
MCHC 
anemia 2
109 7 4 1.4 70 0.5
 number 
decreased 
microcytic 
and 
macrocytic 
RBCs 
MCHC 
anemia 2
104 7.1 3 . . 1.1
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
92 5.8 2.7 1.1 83 0.7
number 
decreased 
microcytic 
hypochromic 
RBCs 
MCHC 
anemia 2
0.6
MCHC 
anemia 2
1.7
MCHC 
anemia 2
89 5.4 2.3 . . .
number 
decreased 
normocytic 
normochrom
ic RBCs 
occassional 
macrocyte
normocytic 
anemia 1
1.9
normocytic 
anemia 1
89 5.6 2.8 . . .
number 
decreased 
microcytic n  
macrocytic  
RBCs
MCHC 
anemia 2
99 5.3 2.8 . . .
number 
decreased 
normocytic n 
microcytic 
RBCs 
anisopoikilo
cytosis
dimorphic 
anemia 4
107 6.1 3 1.3 91 0.4
number 
decreased 
microcytic 
hypochromic  
RBCs 
dimorphic 
anemia 4
100 4.9 2.7 0.9 91 0.3
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
145 5.9 2.5
 number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
. . . . . .
number 
decreased 
normocytic 
normochrom
ic RBCs 
normocytic 
anemia 1
101 6.3 3.2 1.5 61 0.5
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
88 5.3 3.2
 number 
decreased  
microcyti 
hypochromic 
RBCs
MCHC 
anemia 2
104 5.7 3.1 1.6 82 1.2
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 
anisopoikilo
cytosis 2
118 4.8 2.6 1.8 88 0.6
number 
decreased  
microcytic  
hypochromic 
RBCs
MCHC 
anemia 2
98 6.1 3.1 1.2 83 0.5
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
106 5.2 3.2 0.8 88 1.2
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
87 5.4 2.5 1.3 91 0.4
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
94 6.1 3.2 1.2 76 0.6
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
. . . 1.2 65 0.7
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
0.7
dimorphic 
anemia 4
increased 
myelolasts
acute 
leukemia 3
 number 
reduced 
thrombocyto
penia 2 2
 number 
decreased 
micronormo
blastic 
maturation
increased in 
number 
myeloblasts 
>90%
number 
increased 
mature 
neutrophils, 
band forms 
myelocytes 
occasssional 
blasts
CML - 
acc.phase 3
number 
increased 
normal in  
morphology
reactive 
thrombocyto
sis 1 2
number 
decreased 
micro n 
macronormo
blastic 
maturation  
increase in 
myeloblasts 
promyelocyt
es 
myelocytes 
band forms 
mature 
neutrophils 
increase in 
mature 
neutrophil, 
band forms, 
myelocyt 
basophils
CML- 
accelerated 
phase 3
 number 
increased 
normal 
morphology
thrombocyto
sis 1 2
 number 
decreased 
micronormo
blastic 
maturation
increase in 
myeloblasts 
promyelocyt
es 
metamyelocy
tes basophils
increased in 
neutrophils 
band forms 
occassional 
blasts
CML - 
chronic 
phase 3
 number 
increased 
normal 
morphology
thrombocyto
sis 1 2
number 
decreased 
micronormo
blastic 
maturation
increase in 
myeloblasts 
promyelocyt
es 
metamyelocy
tes 
Normal 0 n normal 0 0
Normal 0 normal 0 0
RN 1 normal 0 0
RN 1 n normal 0 0
n RN 1 normal 0 0
RN 1 normal 0 2
increase in 
neutrophils
reactive 
neutrophilia 1
normal  
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
normal 
number  
normal 
maturation
normal 
number n 
morphology RN 1
number 
increased
reactive 
thrombocyto
sis 1 0
number 
increased 
micronormo
blastic 
maturation
normal 
number n 
maturation
normal 0 normal 0 2
normal 0 reactive thrombocytosis1 0
normal 0 normal 0 0
 number 
decreased leucopenia 2
 number 
reduced 
normal 
morphology
thrombocyto
penia 2 2
number 
decreased 
micro n 
macronormo
blastic 
maturation 
dividing 
cells 
dyserythropo
iesis 
number 
increased 
myeloblasts 
promyelocyt
es mature 
forms
increase in 
neutrophils 
toxic 
vacuoles
reactive 
neutrophia 1
 number 
reduced 
normal 
morphology
thrombocyto
penia 2 2
dividing 
cells 
dyserythropo
iesis
dysmyelopoi
sis
number 
decreased leucopenia 2
number 
decreased 
normal 
morphology
thrombocyto
penia 2 1
number 
decreased 
dyserythropo
iesis
number 
decreased 
dysmyelopoi
esis
number 
decreased leucopenia 2
number 
decreased
thrombocyto
penia 2 2
number 
decreased 
dyserythropo
iesis
number 
increased 
dysmyelopoi
esis
normal in 
number n 
morphology normal 0
normal in 
number n 
morphology normal 0 1
micro 
normoblastic 
maturation 
dyserythropo
iesis
normal 
maturation
number 
decreased leucopenia 2
 number 
reduced 
giant 
platelets
thrombocyto
penia 2 1
 number 
increased 
megaloblasti
c maturation 
dividing 
cells
megaloblasti
c maturation
number 
decreased leucopenia 2
normal 
number n 
morphology normal 0 1
number 
decreased 
megaloblasto
id maturation
number 
decreased 
dysmyelopoi
esis
normal 
number n 
morphology Normal 0
normal 
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
normal 
number n 
maturation
normal 
number n 
morphology Normal 0
normal 
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
normal 
number n 
maturation
normal 
number n 
morphology Normal 0
normal 
number n 
morphology normal 0 2
number 
increased 
megaloblasti
c maturation
number 
increased 
megaloblasti
c maturation
number 
increased 
shift to left
reactive 
neutrophilia 1
normal  
number n 
morphology normal 0 2
 number 
increased 
megaloblasti
c maturation
increased 
giant 
metamyelocy
tes band 
forms
normal 
number n 
morphology Normal 0
 normal 
number n 
morphology normal 0 2
number 
increased 
megaloblasti
c maturation
number 
increased 
giant 
metamyelocy
tes
normal 
number n 
morphology normal 0
normal 
number n 
morphology normal 0 0
number 
normal 
megaloblasti
c maturation
number 
normal giant 
metamyelocy
tes band 
forms
normal in 
number n 
morphology Normal 0
normal in 
number n 
morphology normal 0 2
 number 
increased 
megaloblasti
c maturation
 number 
increased 
myelocyte 
metamyelocy
te giant band 
forms
number 
decreased leucopenia 2
number 
decreased 
normal 
morphology
thrombocyto
penia 2 2
number 
increased 
megaloblasti
c maturation
number 
increased 
megaloblasti
c maturation
increase in 
neutrophils RN 1
normal  
number and 
morphology normal 0 2
 number 
increased 
megaloblasti
c maturation 
increase in 
metamyelocy
tes giant 
band forms
normal in 
number n 
morphology normal 0
normal in 
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
megaloblasti
c maturation
normal in 
number n 
morphology normal 0
normal in 
number n 
morphology normal 0 2
number 
increased 
megaloblasti
c maturation
number 
increased 
dysmyelopoi
esis
normal 0 normal 0 0
normal 
number n 
morphology normal 0
normal 
number n 
morphology normal 0 0
number 
increased 
normal 
maturation
number 
increased 
normal 
maturation
normal 
number n 
morphology normal 0
normal 
number n 
morphology normal 0 0
number 
normal 
normoblastic 
maturation
number 
increased 
normal 
maturation
increase in 
neutrophils 
toxic 
vacuoles n 
granules RNL 1
number 
reduced 
normal 
morphology
thrombocyto
penia 2 2
number 
normal 
micronormo
blastic 
maturation
increase in 
metamyelocy
tes, band 
forms, 
mature 
neutrophils
normal in 
number n 
morphology normal 0
 number 
increased 
normal  
morphology
reactive 
thrombocyto
sis 1 2
 number 
increased 
micro n 
macro 
normoblastic 
maturation
normal  
number n 
morphology
increase in 
neutrophils
reactive 
neutrophilia 1
normal in 
number n 
morphology normal 0 0
number 
increased 
normal 
maturation
normal 
number n 
maturation
normal 
number n 
morphology Normal 0
normal 
number n 
morphology normal 0 0
number 
increased 
micro n 
macronormo
blastic 
maturation 
normal 
number n 
maturation
normal 0 normal 0 0
normal 0 normal 0 0
increase in 
neutrophils 
shift to left
reactive 
neutrophilic 
leucocytosis 1
normal  
number n 
morphology normal 0 2
number 
normal early 
megaloblasti
c maturation
 increase in 
band forms
normal normal 0 normal 0 0
increase in 
neutrophils
reactive 
neutrophilia 1
normal 
number n 
morphology normal 0 2
number 
increased 
micronormo
blastic 
maturation
normal 
number n 
maturation
increase in 
neutrophils RN 1
number 
increased 
normal in  
morphology
reactive 
thrombocyto
sis 1 0
 number 
increased  
micro n 
macro 
normoblastic  
maturation 
incresed in 
number 
normal 
maturation
normal  
number n 
morphology normal 0
reduced in 
number
thrombocyto
penia 2 0
number 
increased 
micronormo
blastic 
maturation
normal in 
number n 
morphology
increase in 
number shift 
to left
reactive 
neutrophilia 1
normal 
number n 
morphology normal 0 0
number 
increased 
micronormo
blastic 
maturation
number 
increased 
normal 
maturation
normal  
number n 
morphology normal 0
normal  
number n 
morphology normal 0 0
number 
increased 
micronormo
blastic 
maturation
normal in 
number n 
maturation
increase in 
neutrophils
reactive 
neutrophilia 1
number 
decreased 
giant 
platelets
thrombocyto
penia 2 0
 number 
increased 
normal 
maturation
number 
increased 
normal 
maturation
normal 
number n 
morphology normal 0
 number 
increased  
giant 
platelets
reactive 
thrombocyto
sis 1 0
number 
increased 
micronormo
blastic 
maturation
normal 
number n 
maturation
normal in 
number n 
morphology Normal 0
normal in 
number n 
morphology normal 0 2
 number 
increased 
micro 
normoblastic  
maturation 
normal in 
number n 
morphology
normal in 
number n 
morphology RN 1
normal in 
number n 
morphology normal 0 2
 number 
increased 
micro n 
macro 
normoblasti 
maturation 
normal in 
number n 
morphology
normal  
number n 
morphology normal 0
normal  
number n 
morphology normal 0 2
 number 
increased, 
micro and 
macro 
normoblasti 
maturation 
normal  
number n 
morphology
normal 
number n 
morphology Normal 0
normal 
number n 
morphology normal 0 2
number 
increased 
micronormo
blastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology normal 0
normal 
number n 
morphology normal 0 2
number 
increased 
normal 
maturation
number 
increased 
normal 
maturation
normal in 
number n 
morphology Normal 0
normal 
number n 
morphology normal 0 0
number 
increased 
normal 
maturation
normal 
number n 
maturation
normal 
number n 
morphology normal 0
 number 
increased  
normal 
morphology
reactive 
thrombocyto
sis 1 0
number 
increased 
micro n 
macro 
normoblastic 
maturation
normal 
number n 
maturation
rphologynor
mal number 
n mo normal 0
normal 
number n 
morphology normal 0 0
number 
increased 
micronormo
blastic 
maturation
normal 
number  
normal 
maturation
normal 0 normal 0 2
decreased AML-M1 AML
normal in 
number n 
morphology
CML - accc. 
phase CML
number 
increased 
normal 
morphology
CML - 
accelerated 
phase CML
normal  
number n 
morphology
CML 
chronic 
phase CML
combined 
deficiency combined
combined 
deficiency combined
combined 
deficiency combined
combined 
deficiency combined
combined 
deficiency combined
combined 
deficiency combined
normal  
number n 
morphology
erythroid 
hyperplasia 
withmegalob
lastic 
maturation 
consistent 
with 
megaloblasti
c anemia
normal 
number n 
morphology
florid 
erythroid 
hyperplasia 
with 
micronormo
blastic 
maturations/
o IDA 
hyperplastic 
marrow with 
micronormo
blastic 
maturation
hyperplastic 
marrow with 
micronormo
blastic 
maturation
hyperplastic 
marrow with 
micronormo
blastic 
maturation
variable MDS RCMD MDS
normal 
morphology MDS RCMD MDS
normal 
number 
dysmorphic 
megks
MDS- 
RCMD MDS
reduced 
number 
dysmorphic 
forms
MDS 
trilineage 
dysplasia -
RAEB MDS
dysmorphic 
megks
plasmacytosi
s
MDS with 
plasmacytosi
s MDS
normal  
number n 
morphology
megaloblasti
anemia
normal
megaloblasti
c anemia
normal 
number n 
morphology
megaloblasti
c anemia
normal 
number n 
morphology
megaloblasti
c anemia
normal 
number n 
morphology
megaloblasti
c anemia
normal  
number n 
morphology
megaloblasti
c anemia
normal 
number n 
morphology
megaloblasti
c anemia
normal 
number n 
morphology
megaloblasti
c anemia
normal in 
number n 
morphology
megaloblasti
c anemia
normal 
number n 
morphology
megaloblasti
c anemia
normal in 
number n 
morphology
megaloblasti
c anemia
normal 
number n 
morphology
megaloblasti
c anemia
normal in 
number n 
morphology
megaloblasti
c marrow 
with 
dysmyelopoi
esis s/o MDS-
RA MDS
micronormo
blastic 
maturation 
normal 
number n 
morphology
micronormo
blastic 
maturation 
normal 
number n 
morphology
micronormo
blastic 
maturation 
normal  
number n 
morphology
micronormo
blastic 
maturation 
normal  
number n 
morphology
micronormo
blastic 
maturation 
normal 
number n 
morphology
micronormo
blastic 
maturation 
normal 
number n 
morphology
micronormo
blastic 
maturation 
micronormo
blastic 
maturation 
micronormo
blastic 
maturation 
normal in 
number n 
morphology
normocellula
r marrow 
with 
micronormo
blastic 
maturation
reactive 
hyperplasia 
micronormo
blastic 
maturation
normal 
number n 
morphology
reactive 
marrow s/o 
IDA
normal in 
number n 
morphology
reactive 
marrow with 
micro n 
macronormo
blastic 
maturation  
s/o combined 
deficiency combined
normal in 
number n 
morphology
Reactive 
marrow with 
micro 
normoblastic 
maturation
normal 
number n 
morphology
reactive 
marrow with 
micro 
normoblastic 
maturation
normal  
number n 
morphology
reactive 
marrow with 
micro 
normoblastic 
maturation 
s/o IDA
normal  
number n 
morphology
reactive 
marrow with 
micro 
normoblastic 
maturation 
s/o IDA
normal 
number n 
morphology
Reactive 
marrow with 
micronormo 
blastic 
maturation
normal in 
number n 
morphology
REH s/o 
IDA
normal in 
number n 
morphology
REH with 
micro n 
macro 
normoblastic 
maturation  
s/o combinrd 
deficiency combined
normal  
number n 
morphology
plasmacytosi
s
REH with 
micro n 
macro 
normoblasti
maturation 
and 
plasmacytosi
s combined
normal 
number n 
morphology
REH with 
micro 
normoblastic 
maturation 
s/o IDA
normal 
number n 
morphology
REH with 
micronormo
blastic 
maturation
normal 
number n 
morphology
REH with 
micronormo
blastic 
maturation
normal 
number n 
morphology
REH with 
micronormo
blastic 
maturation
normal 
number n 
morphology REHs/o IDA
combined 
deficiency
ID No Name Age Gender
Presenting 
Complaints
Present Co-
morbidities
1-DM
2-HT
3-Chronic 
Renal Dis
4-Chr Liver 
Dis
5-APD
6- Immune 
7-Menstrual 
8-Chr GI 
Bleeds
9-Spleni
10-TB
11-Thyroid 
12-Cancer
13-GU 
Bleeding
14-Diarrhoea
15-Others
Dietary 
History
1-Vegan
2-Non 
Vegan
Habits
0-No
1-Alcohol
2-Smoking
3-Tea/Cofee 
excess intake
Palor
1-Sclrea
2-Tongue
3- Both
31. 15364 patrakali 66 F
exertional 
dyspnoea
4,11
2 0 2
38. 38421 guruvammal 60 F
exertional 
dyspnoea
1,2
2 2 2
43. 3904 velayutham 65 M
chestpain 
giddiness
4,11
2 0 2
6.15779 kosalai 65 F fatigue
5, 8
2 3 1
35. 16214 navaneetham 71 F
exertional 
dyspnoea
2
1 0 3
29. 6858 gandhi 85 M hematemesis
. .
1 . . 3
4.4798 esther 62 F
abdominal 
pain 
dyspnoea
1,5
2 . . 1
44. 3422 shanmugathammal 65 F
exertional 
dyspnoea 
pedal edema
15
2 2 1
60 73 F
pedal eema 
chest pain 
fatigue
2, 5, 6
1 0 3
67 selvaraj 62 M
easy 
fatiguability 
loss of 
apetite
2, 15
. . 2,3 3
42. 14794 soundarajan 62 M
exertional 
dyspnoea 
palpitation
2, 3
2 . . 2
13. 43705 madasamy 70 M
pedal edema 
dyspnoea
15
1 0 3
18. 44867 mariappan 62 M
pedal edema 
facial 
puffiness
1, 10
2 2,3 1
47. 3490 jesumichel 65 M
pedal edema 
loss of 
weight
12
2 0 1
1.5654 saraswathy 77 F
dyspnoea, 
pedal edema 
decreased 
urine output
1
2 0 2
37. 4632 rajeshwari 63 F
easy 
fatiguability 
loss of 
apetite
1,2,, 6
2 0 1
64 61 F
fatigue chest 
pain 
giddiness
15
2 3 3
11. 60969 lakshmi 66 F fatigue diarrhoea
3
68 71 F fatigue vomiting
, ,
22. 40029 veeramariammal 70 F
fever 
abdominal 
pain
. .
10.2039 mariyal 63 F
giddiness 
exertional 
dyspnoea
12, 14
2 3 1
65 74 F
giddiness, 
chestpain 
palpitation
12
2 1 1
14. 45911 madathi 65 F
hemoptysis, 
fever
8, 12, 14
2 2 1
39. 19917 ramani 67 F loss of apetite
8
2 2 3
50. 22754 saroja 68 F
pedal edema 
facial 
puffiness
1
48. 76231 subbulakshmi 61 F vomiting fever
1,2,3
. 0 3
48. 76231 subbulakshmi 61 F vomiting fever
15
2 3 1
52 76 F
..
2 1, 3 2
61 gnanam 69 F
15
2 2 1
14. 45911 madathi 65 F
hemoptysis, 
fever
2
2 1, 2, 3 2
6.15779 kosalai 65 F fatigue
1
2 0 2
45. 3398 sudalaimadan 61 M
abdominal 
pain malena
1,2,, 6
2 0 1
15. 43507 gurusamy 70 M dyspnoea
2,5,
2 . . 1
17. 42094 subbiah 60 M
dyspnoea 
decreased 
urine output
15
. . 2 1
63 60 M
exertional 
dyspnoea
10, 15
2 3 3
24. 47881 paramasivan 62 M
exertional 
dyspnoea 
pedal edema 
2,3,6
2 .? 1
25. 48220 murugan 63 M fever
1
2 3 3
41. 31693 kannimalar 70 M giddiness
5
2 3 1
56 61 M giddiness
15
57 sudalaimuthu 73 M giddiness
1
28. 14794 sundar raj 69 M giddiness 
. .
46. 4954 krishnan 69 M
giddiness 
pedal edema
2
2 3 1
36. 42317 ganapathy 66 M
loss of 
apetite 
fatigue
..
8.4471 santhivinayagam 65 M ulcer leg
15
2 3 1
20. 46728 esakki 72 M weakness limbs
..
2 1, 3 2
8.4471 santhivinayagam 65 M ulcer leg
15
2 2 1
36. 42317 ganapathy 66 M
loss of 
apetite 
fatigue
1,2,3
. 0 3
46. 4954 krishnan 69 M
giddiness 
pedal edema
10, 15
2 3 3
54 66 F fatigue
2, 10
2 1 1
9.9578 bagavathy 66 F fatigue
2, 3, 10
1 3 2
16. 61113 shanmugasundaram 62 M
cough 
palpitation 
pedal edema
15
2 3 1
3.1364 seetha 65 F
dyspnoea on 
exertion
3,8,10,15
2 3 3
7. 12487 subramanian 65 M
dyspnoea 
chestpain
1
. . 0 3
49. 50267 ponnammal 66 F
exertional 
dyspnoea 
palpitation
5 , 10
2 0 1
55 60 F giddiness
10.2039 mariyal 63 F
giddiness 
exertional 
dyspnoea
5, 8
. . 3 2
58 velu 67 F
giddiness 
loss of 
apetite fever
14
2 3 1
62 81 F
loss of 
apetite 
vomiting 
fatigue
2,4
2 2,3 1
21. 50914 esakkkiammal 66 F mass abdomen
…
2 , 2
2.6784 saraswathy 65 F
mass P/V 
urinary 
disturbances
1,2,4,6
1 0 2
19. 49305 arumugam 76 M
facial 
puffiness 
pedal edema
33. 47768 muthukrishnan 72 M
giddiness 
pedal edema
, ,
23. 45982 srinivasan 74 M
giddiness 
swaying 
while 
walking
4
30. 9806 ramar 67 M paraparesis
5. 1400 pathmanaban 61 M
pedal edema 
abdominal 
pain
Lymphad
enopathy
0-No
1-Isolated
2-
Generalized
Spleen
0-No
1-Minimal
2-Moderate
3-Marked
Liver
0-No
1-Mild
2-Moderate
3-Marked
Pedal Edema
0-No
1-Yes PR BP
Resp
Rate
Systems
Describe 
Changes
Radiology
Describe
Changes
Endoscopy
Describe
1 1 0 0 71 140/70 19
mild 
splenomegal
y
fatty liver 
mild 
splenomegal
y congested GI mucosa
0 1 1 1 73 170/100 20
ESM, 
hepatospleno
megaly
mild 
cardiomegal
y congested GI mucosa
1 1 0 0 71 140/70 19 mild splenomegaly
fatty liver 
mild 
splenomegal
y congested GI mucosa
0 3 1 0 88 100/70 18
liver just 
palpable 
massivesplen
omegaly
cardiomegal
y 
splenomegal
y dilated 
portal vein
esophageal 
varices 
severe PHT/ 
gastropathy
0 0 0 1 96 140/90 26 NAD
mild 
splenomegal
y
gastric 
mucosal 
prolapse
0 0 0 0 70 11o /70 23
hemic 
murmur, 
thyromegaly
B/L MRD 
type I CKD normal
0 0 0 1 76 140/70 16 b/l crepts
cardiomegal
y  mild 
pleural 
effusion 
minimal 
ascitis normal
0 0 0 0 104 140/80 26 NAD NAD normal
1 1 0 1 76 110/80 16 mild splenomegaly
splenomegal
y 
cardiomegal
y normal
0 0 0 0 84 130/70 20 NAD cardiomegaly normal
1 0 1 1 78 160/100 23 tender hepatomegaly
B/L medical 
renal disease 
type III RPD 
changes normal
0 0 0 1 68 110/ 80 14 venous hum NAD normal
0 0 0 1 88 120/80 14 ESM normal normal
0 0 0 0 64 130/ 80 14 ca breast NAD normal
0 0 0 0 82 110/80 16
ca breast on 
treatment NAD not done
0 0 0 1 66 130/100 26 NAD fatty liver not done
0 0 0 1 78 140/80 23 b/l crepts
pneumonitic 
changes mild 
cardiomegal
y not done
not done
not done
not done
0 0 0 0 84 120/ 80 18 ca breast NAD not done
0 0 0 0 68 14/ 80 18 k/c/o ca alveolus NAD not done
1 0 0 0 62 140/60 19 k/c/o ca stomach NAD not done
0 0 0 0 78 150/60 21
hemic 
murmur, 
haemorrhoid
s NAD not done
not done
0 2 0 0 86 130/90 22
hemic 
murmur, 
splenomegal
y splenomegaly not done
0 2 0 1 76 110/60 14
hemic 
murmur, B/L 
crepts, 
splenomegal
y
old PT, 
Splenomegal
y, increased 
renal cortical 
echoes not done
0 2 0 1 92 150/80 14
moderate 
splenomegal
y
 splenomegalynot done
1 2 0 0 70 130/80 20
moderate 
splenomegal
y 
hepatospleno
megaly not done
0 0 0 1 80 150/80 18
spastic 
quadriparesis
non 
compressive 
myelopathy not done
0 0 0 0 82 110/80 16ca breast on treatment NAD not done
0 0 0 1 66 130/100 26 NAD fatty liver not done
0 0 0 0 68 130/90 24 hemic murmur
mild 
cardiomegal
y not done
0 0 0 1 88 120/70 22 NAD cardiomegaly not done
0 0 0 1 68 140/90 20 hemic murmur
old PT 
cardiomegal
y not done
1 0 0 1 93 140/70 22 NAD
mild 
splenomegal
y not done
0 0 0 0 78 120/70 18 NAD NAD not done
0 0 0 0 84 130/80 16 hemic murmur NAD not done
not done
not done
not done
0 0 1 1 96 130/80 15 hemic murmur
cardiomegal
y moderate 
splenomegal
y not done
not done
0 2 0 1 76 110/60 14
hemic 
murmur, B/L 
crepts, 
splenomegal
y
old PT, 
Splenomegal
y, increased 
renal cortical 
echoes not done
0 2 0 1 92 150/80 14
moderate 
splenomegal
y
 splenomegalynot done
1 2 0 0 70 130/80 20
moderate 
splenomegal
y 
hepatospleno
megaly not done
0 2 0 0 86 130/90 22
hemic 
murmur, 
splenomegal
y splenomegaly not done
0 0 0 1 68 140/90 20 hemic murmur
old PT 
cardiomegal
y not done
0 0 0 1 110 130/80 22
systolic 
murmur NAD pale UGI mucosa
1 0 0 0 63 120/80 16 NAD
old PT B/L 
small 
kidneys pale UGI mucosa
0 0 0 1 80 150/70 14 systolic murmur
cardiomegal
y B/L 
minimal PE pale UGI mucosa
0 0 0 1 85 120/ 70 18
systolic 
murmur B/L 
crepts
old PT B/L 
medical 
renal disease 
type I RPD 
changes pale upper GI mucosa
0 0 1 1 76 110/70 22
mild 
hepatomegal
y, B/L crepts NAD pale upperGImucosa
0 0 2 1 84 110/80 14
epigatric 
tenderness 
hepatomegal
y old PT
1 2 1 1 72 120/60 15
splenomegal
y, tender 
hepatomegal
y
splenomegal
y, renal 
calculi
1 0 2 1 90 120/80 16 hepatomegaly hepatomegaly
0 1 1 1 92 120/80 22
jaundice 
hepatomegal
y
hepatospleno
megaly
0 1 1 1 94 130/80 16
jaundice 
hepatomegal
y
splenomegal
y calculous 
cholecystitis 
TRBC
x106cells/cu
mm
TLC
x103cells/cu
mm
PLC
x105cells/cu
mm
HB
gms/dl HCT MCV   MCH   MCHC Retic C
1.19 11.4 1.73 8.1 24.9 116.9 32.7 31.3 0.5
2.19 4.3 1.35 6.3 20.3 92.7 28.8 31.1 1.2
1.19 11.4 1.73 8.1 24.9 116.9 32.7 31.3 < 0.5
2.22 4.2 0.41 6.3 18.4 93.6 18.4 22.3 1.2
3.47 5 2.98 5.3 22.3 64.3 15.3 23.8 1
2.1 3.9 2.12 5.6 24 76.4 21.6 28.8 1
1.01 5.8 2.92 6.8 16.6 65.3 15.8 24.2 0.5
3.2 5.8 90 10.4 33.7 97.4 32.9 33.8 1.5
1.78 4.7 3.96 7.4 23.5 77.2 19.3 27.4 0.5
3 4.5 4.22 7 24 66 18.7 22.6 1
2.68 4.5 2.31 8.2 24.7 99.6 30.6 30.8 0.5
1.96 7.8 2.3 5.9 18.8 78.2 20.5 25.7 0.5
2.89 3.7 1.93 9.1 31 107.3 31.5 20.4 1.2
2.91 5.4 3.15 11.1 26.8 97.5 24.3 31.7 0.5
3.11 4.8 2.45 7.6 22.3 84.7 24.5 30.2 0.5
2.39 4.3 2.69 6.6 22.1 94 23.8 27.4 1.4
1.87 9.2 1.48 5.7 19.4 76.9 21.5 27.3 0.6
5.6 2.29 8.2 69.6 0.5
2.9 1.13 5.7 62.9 1
3.8 1.06 11.2 77.6 1
2.2 6.5 2.98 10.3 32.3 88.7 25.6 32.1 0.5
2.88 6.5 3.32 10.2 33.1 66.6 26.2 29.7 0.5
2.26 5.2 2.13 6.2 24.8 68.7 23.2 25.7 0.5
2.99 6.3 4.32 8.9 30.1 78.9 21.2 32.2 <0.5
5.3 2.73 6.3 59.7 0.5
2.2 145 0.28 6.9 18.9 85.9 31.5 36.5 1
1.8 125 3.19 7.7 21.3 83.3 26.1 31.3 0.5
2.12 90,000 1.74 8.9 20.9 63.7 21.3 27.4 1
1.83 1.53 3.24 6.7 22.1 106 23.2 26.9 0.5
1.63 1200 1.27 7.7 25.6 104 31.3 30.1 0.6
3.11 4.8 2.45 7.6 22.3 84.7 24.5 30.2 1.5
2.39 4.3 2.69 6.6 22.1 94 23.8 27.4 1
3.3 12 3.3 9.1 36 89.4 23.6 30.1 1
2.63 5.9 2.94 9.1 29.6 100.4 22.6 28.3 0.3
1.56 3.2 0.9 6.8 19.6 128 18.7 26.6 0.5
1.92 2.9 71000 4.8 16 83.3 24.5 29.4 0.3
2.5 6.9 2.5 5.6 16 89.3 23.6 27.9 3
3 10.5 1.8 6.2 26 74 22 22 0.5
5.3 2.84 10.8 90.4 0.5
7.8 2.78 7.5 83.2 1
4.7 3.16 9.3 87.4 1
1.95 7.3 1.42 5.1 13.8 70.8 16.4 23.2 0.5
6.3 1.85 6.8 81.7 2
1.8 125 3.19 7.7 21.3 83.3 26.1 31.3 . .
2.12 90,000 1.74 8.9 20.9 63.7 21.3 27.4 . .
1.83 1.53 3.24 6.7 22.1 106 23.2 26.9 . .
2.2 145 0.28 6.9 18.9 85.9 31.5 36.5 . .
1.56 3.2 0.9 6.8 19.6 128 18.7 26.6 0.5
2.34 5.3 2.05 6.4 28.1 73.4 24.5 26.2 1.5
2.09 5.4 2.31 7.1 26.4 65.5 16.7 25.1 1.1
2.23 6.4 2.11 8.3 20.6 98.4 22.1 28.4 1.3
2.5 3.2 0.4 6.8 22.4 128 27 32 0.5
3.1 6.2 1.5 6.1 18 102.4 23.2 26.8 1
2.28 7.8 2.95 5.9 14.4 63.2 14.9 23.6 1.2
4.1 1.52 7.7 86.6 1
2.7 11 0.19 6.4 19.3 72.5 21.3 31.1 0.5
1.96 10.6 3.55 5.8 20.1 66.4 21.2 29.6 0.5
2.99 7.3 2.65 8.3 20.2 56.5 19.3 22.4 0.5
6.1 3.41 6.9 74.8 0.5
3.2 9.9 4.1 8.7 30.6 72.9 19.6 26.9 <0.5
1.88 6.5 3.26 8.3 36.8 86.5 22.6 28.7 0.5
7.2 1.79 10.4 88.3 1
7.4 2.53 8.7 82.6 2
8.6 2.64 6.6 72.3 1.3
9.1 1.02 7.9 86.6 0.5
ESR
1Hr BSR BUN SCR SBRT SGOT SGPT ALP SPROT
74
55 100 137 44 1 1.6 25 41 109 7
50, 105 96 129 2.2 1.2 36 26 206 5.3
32 60 98 63 1.2 2.7 105 123 197 5.8
110 150 106 29 0.8 0.9 32 21 96 6.2
20 130 157 150 5.4 1.1 46 39 114 4.8
15 30 60 44 1.2 0.8 17 24 89 5.4
42 60 48 1.3 0.7 28 33 89 5.6
50 76 28 0.6 0.9 18 21 87 5.4
60 97 20 0.9 0.7 19 22 94 6.1
50 100 110 28 0.8 . . . . .
100 130 114 44 1.2 2.4 19 22 85 5.3
28/50 128 30 1.1 2.1 21 28 90 4.6
100 150 125 22 1 0.6 31 31 85 7.9
. . 146 38 1.1 0.6 18 29 107 5.3
100 75 41 1.1 1.2 37 44 107 5.6
55 110 86 40 0.8 0.9 21 32 97 6.2
40 92 19 1 1.1 16 21 76 6.2
45, 85 65 41 1.2 3.8 48 24 65 6.7
10 40 90 21 0.8 0.8 24 21 108 6.2
40 85 89 32 0.9 0.8 34 28 116 6.1
50, 100 74 24 0.8 1 42 36 151 8.6
100  150 104 29 0.9 0.8 41 36 112 5.2
48 66 22 0.8 0.7 34 42 92 5.8
 30 50 106 22 1.1 0.6 36 29 99 5.3
26 80 76 16 0.6 1.2 34 22 107 6.1
55 64 21 0.6 0.9 18 26 100 4.9
50 105 117 76 1.4 0.6 26 26 145 5.9
80 120 78 36 0.9 1.1 . . . .
130 112 35 1.1 1.2 26 41 101 6.3
30 50 112 42 0.9 1.1 20 24 88 5.3
100 130 126 29 1.1 0.9 32 40 112 6
. . 68 20 0.8 . . . . .
98 130 70 30 1.1 0.7 20 22 102 4.6
60 73 38 1.2 0.5 62 66 110 4.9
. 92 65 3 . . . . .. . . . .
40 92 19 1 1.1 16 21 76 6.2
110 150 106 29 0.8 0.9 32 21 96 6.2
10 22 137 27 0.7 2.4 63 54 109 4.8
100 132 132 95 4.3 0.6 40 20 104 7.1
.. 113 43 0.6 .. . . . .
100 130 65 50 1 1 38 27 79 6.3
110 102 36 0.9 1 26 28 88 6.2
52 35 3 28 1.3 0.6 18 22 86 5.8
50 94 23 0.9 0.6 34 36 102 5.4
5, 20 75 16 1.3 0.5 18 21 88 5.9
12, 45 178 56 1.5 0.6 46 37 99 7.5
 55 120 148 24 0.8 1 40 36 104 5.7
30 60 146 21 0.8 1.1 41 44 118 4.8
10 22 115 34 1.5 0.4 34 42 98 6.1
55 100 146 20 0.8 0.9 40 36 106 5.2
ALB T3 T4 TSH
PSS-RBC
Describe 
RBC
PSS-RBC
Impression
PSS-RBC
1-
Normocytic
2-Microcytic
3-Macrocytic
4-Dimorphic
5-Others
PSS-WBC
Describe
PSS-WBC
Impression
normocytic 
anemia 1 RN
dimorphic 
anemia 4 RN
4 1.4 70 0.5
 number 
decreased 
microcytic 
and 
macrocytic 
RBCs 
MCHC 
anemia 2
normal in 
number n 
morphology normal
0.7
dimorphic 
anemia 4 normal
MCHC 
anemia mild 
anisocytosis 2 n RN
2.6 1.3 86 0.6
number 
decreased 
microcytic 
and 
macrocytic 
RBCs
dimorphic 
anemia 4
normal in 
number n 
morphology normal
3 1.5 61 0.5
number 
decreased 
microcytic n 
normocytic
dimorphic 
anemia 4
normal in 
number n 
morphology normal
3.2 68 4.5 2.1
number 
decreased 
normocytic n 
macrocytic 
RBCs
macrocytic 
anemia 3
increase in 
neutrophils
reactive 
neutrophilia
2.8 . . .
 number 
decreased 
microcytic 
and 
macrocycytic 
RBCs
dimorphic 
anemia 4
increase in 
neutrophils RN
2.3 . . .
number 
decreased 
normocytic 
normochrom
ic RBCs 
occassional 
macrocyte
normocytic 
anemia 1
increase in 
neutrophils 
shift to left
reactive 
neutrophilic 
leucocytosis
2.8 . . .
number 
decreased 
microcytic n  
macrocytic  
RBCs
MCHC 
anemia 2
increase in 
neutrophils
reactive 
neutrophilia
2.5 1.3 91 0.4
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
normal in 
number n 
morphology Normal
3.2 1.2 76 0.6
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
normal 
number n 
morphology normal
. 1.2 65 0.7
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
rphologynor
mal number 
n mo normal
normocytic 
anemia 1 Normal
MCHC 
anemia 2 RN
1.3
MCHC 
anemia 2 normal
0.4
normocytic 
anemia 1 normal
2.2 1.7 89 1
number 
decreased 
microcytic  
hypochromic 
RBCs
MCHC 
anemia 2
increase in 
neutrophils 
toxic 
vacuoles
reactive 
neutrophia
2.5 . . .
 number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
 number 
decreased leucopenia
4.4 . . 1
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
number 
decreased leucopenia
2.2 1.1 86 0.7
number 
decreased 
normocytic n 
macrocytic 
RBCs
macrocytic 
anemia 3
normal 
number n 
morphology Normal
3.2 . . .
number 
decreased 
microcytic n 
macrocytic 
RBCs
dimorphic 
anemia 4
normal 
number n 
morphology Normal
2.9 . . . . 3.5
number 
decreased 
microcytic n 
macrocytic 
RBCs
dimorphic 
anemia 4
number 
increased 
shift to left
reactive 
neutrophilia
3.1 . . 0.7
number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia 3
number 
decreased leucopenia
3.2 1.2 89 2.3
number 
decreased 
microcytic n 
macrocytic 
RBCs
dimorphic 
anemia 4
normal in 
number n 
morphology normal
0.4
MCHC 
anemia 2 RN
3.1 1.8 92 0.6
number 
decreased 
normoctic 
normochrom
ic RBCs
normocytic 
anemia 1
normal 
number n 
morphology normal
0.8
MCHC 
anemia 2 normal
2.9 . . .
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 
anisopoikilo
cytosis 2
normal 
number n 
morphology normal
4.6 . . .
number 
decreased 
normoctic 
normochrom
ic RBCs
normocytic 
anemia 1
normal 
number n 
morphology normal
2.9 0.5 74 0.8
number 
decreased 
microcytic  
hypochromic 
RBCs
MCHC 
anemia 2
increase in 
neutrophils 
toxic 
vacuoles n 
granules RNL
2.7 1.1 83 0.7
number 
decreased 
microcytic 
hypochromic 
RBCs 
MCHC 
anemia 2
normal 
number n 
morphology Normal
1.7
MCHC 
anemia 2 normal
1.9
normocytic 
anemia 1 normal normal
2.8 . . .
number 
decreased 
normocytic n 
microcytic 
RBCs 
anisopoikilo
cytosis
dimorphic 
anemia 4
increase in 
neutrophils RN
3 1.3 91 0.4
number 
decreased 
microcytic 
hypochromic  
RBCs 
dimorphic 
anemia 4
normal  
number n 
morphology normal
2.7 0.9 91 0.3
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
increase in 
number shift 
to left
reactive 
neutrophilia
2.5
 number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
normal  
number n 
morphology normal
. . . .
number 
decreased 
normocytic 
normochrom
ic RBCs 
normocytic 
anemia 1
increase in 
neutrophils
reactive 
neutrophilia
3.2 1.5 61 0.5
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
normal 
number n 
morphology normal
3.2
 number 
decreased  
microcyti 
hypochromic 
RBCs
MCHC 
anemia 2
normal in 
number n 
morphology Normal
2.9 1.2 69.1 0.6
number 
decreased 
microcytic n 
macrocytic 
RBCs
dimorphic 
anemia 4
number 
normal 
hypersegmen
ted 
neutrophils normal
. . 0 0 0
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 
NRBC 2
increase in 
mature 
neutrophil, 
band forms, 
myelocyt 
basophils
CML- 
accelerated 
phase
2.7 . . .
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
increased in 
neutrophils 
band forms 
occassional 
blasts
CML - 
chronic 
phase 
2.2 . . .
number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia 3
number 
increased 
mature 
neutrophils, 
band forms 
myelocytes 
occasssional 
blasts
CML - 
acc.phase
. . 0 0 0
 number 
decreased  
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
increased 
myelolasts
acute 
leukemia
3.1 . . 0.7
number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia 3
number 
decreased leucopenia
3.2 68 4.5 2.1
number 
decreased 
normocytic n 
macrocytic 
RBCs
macrocytic 
anemia 3
increase in 
neutrophils
reactive 
neutrophilia
3.1 0.5 78 0.9
number 
decreased 
schistocytes
hemolytic 
blood picture 
MCHC 2
normal 
number n 
morphology RN
3 . . 1.1
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
increase in 
neutrophils
reactive 
neutrophilia
. . . .
MCHC 
anemia 2 Normal
0.6
MCHC 
anemia 2 normal
0.7
dimorphic 
anemia 4 normal
3.2 2 92 3.3
number 
decreased 
microcytic n 
normocytic 
RBCs 
dimorphic 
anemia 4
number 
decreased leucopenia
1.3
MCHC 
anemia 2 RN
2.9 0.7 74 1.9
number 
decreased 
normocytic 
BBCs
normocytic 
anemia 
NRBC 1
normal 
number n 
morphology Normal
3.1 1.1 83 0.7
number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia 3
normal 
number n 
morphology Normal
3 1.2 66 0.4
number 
decreased 
microcytic n  
macrocytic  
RBCs
dimorphic 
anemia 4
normal 
number n 
morphology normal
2.7 1.3 78 0.3
 number 
decreased 
macrocytic 
RBCs
macrocytic 
anemia 3
normal in 
number n 
morphology Normal
3.5 0.6 60 0.5
number 
decreased 
microcytic n 
macrocytic 
RBCs
dimorphic 
anemia 4
normal in 
number n 
morphology normal
3.1 1.6 82 1.2
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 
anisopoikilo
cytosis 2
normal in 
number n 
morphology RN
2.6 1.8 88 0.6
number 
decreased  
microcytic  
hypochromic 
RBCs
MCHC 
anemia 2
normal  
number n 
morphology normal
3.1 1.2 83 0.5
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
normal 
number n 
morphology Normal
3.2 0.8 88 1.2
number 
decreased 
microcytic 
hypochromic 
RBCs
MCHC 
anemia 2
normal 
number n 
morphology normal
PSS-WBC
0-Normal
1-Reactive
2-Suspicious
3-
Malignancy
4-
Inconclusive
PSS-PL
Describe
PSS-PL
Impression
PSS-PL
0-Normal
1-High
2-Low
3-Giant Pl
Marrow
Cellularity
0-Normal
1-Hypo
2-Hyper
Marrow 
Erythroid
Describe
Marrow 
Myeloid 
Describe
Marrow 
Megk
Describe
Marrow 
Others
Describe
1 n normal 0 0
1 normal 0 2
0
 number 
increased 
normal  
morphology
reactive 
thrombocyto
sis 1 2
 number 
increased 
micro n 
macro 
normoblastic 
maturation
normal  
number n 
morphology
normal  
number n 
morphology
0 normal 0 2
1 normal 0 0
0
normal in 
number n 
morphology normal 0 2
number 
increased 
megaloblasti
c maturation
number 
increased 
dysmyelopoi
esis
normal in 
number n 
morphology
0
normal in 
number n 
morphology normal 0 1
micro 
normoblastic 
maturation 
dyserythropo
iesis
normal 
maturation
dysmorphic 
megks
plasmacytosi
s
1normal  
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
normal 
number  
normal 
maturation
normal  
number n 
morphology
1
normal  
number and 
morphology normal 0 2
 number 
increased 
megaloblasti
c maturation 
increase in 
metamyelocy
tes giant 
band forms
normal in 
number n 
morphology
1
normal  
number n 
morphology normal 0 2
number 
normal early 
megaloblasti
c maturation
 increase in 
band forms
normal in 
number n 
morphology
1
normal 
number n 
morphology normal 0 2
number 
increased 
micronormo
blastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
0
normal 
number n 
morphology normal 0 0
number 
increased 
normal 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
0
 number 
increased  
normal 
morphology
reactive 
thrombocyto
sis 1 0
number 
increased 
micro n 
macro 
normoblastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
0
normal 
number n 
morphology normal 0 0
number 
increased 
micronormo
blastic 
maturation
normal 
number  
normal 
maturation
normal 
number n 
morphology
0 normal 0 0
1 normal 0 0
0 reactive thrombocytosis1 0
0 normal 0 0
1
 number 
reduced 
normal 
morphology
thrombocyto
penia 2 2
dividing 
cells 
dyserythropo
iesis
dysmyelopoi
sis
normal 
morphology
2
 number 
reduced 
normal 
morphology
thrombocyto
penia 2 2
number 
decreased 
micro n 
macronormo
blastic 
maturation 
dividing 
cells 
dyserythropo
iesis 
number 
increased 
myeloblasts 
promyelocyt
es mature 
forms variable
2
number 
decreased
thrombocyto
penia 2 2
number 
decreased 
dyserythropo
iesis
number 
increased 
dysmyelopoi
esis
reduced 
number 
dysmorphic 
forms
0
normal 
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
normal 
number n 
maturation
normal 
number n 
morphology
0
normal 
number n 
morphology normal 0 2
number 
increased 
megaloblasti
c maturation
number 
increased 
megaloblasti
c maturation
normal 
number n 
morphology
1
normal  
number n 
morphology normal 0 2
 number 
increased 
megaloblasti
c maturation
increased 
giant 
metamyelocy
tes band 
forms
normal  
number n 
morphology
2
number 
decreased 
normal 
morphology
thrombocyto
penia 2 2
number 
increased 
megaloblasti
c maturation
number 
increased 
megaloblasti
c maturation
normal 
number n 
morphology
0
normal in 
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
megaloblasti
c maturation
normal 
number n 
morphology
1 decreased 2 1
0normal 
number n 
morphology normal 0 1
number 
increased 
megaloblasti
c maturation
dysmyelopoi
sis
normal 
number n 
morphology
0 normal 0 0
0
normal 
number n 
morphology normal 0 0
number 
increased 
normal 
maturation
number 
increased 
normal 
maturation
normal 
number n 
morphology
0
normal 
number n 
morphology normal 0 0
number 
normal 
normoblastic 
maturation
number 
increased 
normal 
maturation
normal 
number n 
morphology
1
number 
reduced 
normal 
morphology
thrombocyto
penia 2 2
number 
normal 
micronormo
blastic 
maturation
increase in 
metamyelocy
tes, band 
forms, 
mature 
neutrophils
normal  
number n 
morphology
0
normal 
number n 
morphology normal 0 0
number 
increased 
micro n 
macronormo
blastic 
maturation 
normal 
number n 
maturation
normal 
number n 
morphology
0 normal 0 0
0 normal 0 0
1
number 
increased 
normal in  
morphology
reactive 
thrombocyto
sis 1 0
 number 
increased  
micro n 
macro 
normoblastic  
maturation 
incresed in 
number 
normal 
maturation
normal in 
number n 
morphology
0
reduced in 
number
thrombocyto
penia 2 0
number 
increased 
micronormo
blastic 
maturation
normal in 
number n 
morphology
normal in 
number n 
morphology
1
normal 
number n 
morphology normal 0 0
number 
increased 
micronormo
blastic 
maturation
number 
increased 
normal 
maturation
normal 
number n 
morphology
0normal  
number n 
morphology normal 0 0
number 
increased 
micronormo
blastic 
maturation
normal in 
number n 
maturation
normal  
number n 
morphology
1
number 
decreased 
giant 
platelets
thrombocyto
penia 2 0
 number 
increased 
normal 
maturation
number 
increased 
normal 
maturation
normal  
number n 
morphology
0
 number 
increased  
giant 
platelets
reactive 
thrombocyto
sis 1 0
number 
increased 
micronormo
blastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
0
normal in 
number n 
morphology normal 0 2
 number 
increased 
micro 
normoblastic  
maturation 
normal in 
number n 
morphology
normal in 
number n 
morphology
0
normal in 
number n 
morphology normal 0 2
number 
increased 
micro n 
macronormo
blastic 
maturation 
dividing 
cells
number 
increased 
dysmyelopoi
esis
normal in 
number n 
morphology
3
 number 
increased 
normal 
morphology
thrombocyto
sis 1 2
 number 
decreased 
micronormo
blastic 
maturation
increase in 
myeloblasts 
promyelocyt
es 
metamyelocy
tes basophils
number 
increased 
normal 
morphology
3
 number 
increased 
normal 
morphology
thrombocyto
sis 1 2
number 
decreased 
micronormo
blastic 
maturation
increase in 
myeloblasts 
promyelocyt
es 
metamyelocy
tes 
normal  
number n 
morphology
3
number 
increased 
normal in  
morphology
reactive 
thrombocyto
sis 1 2
number 
decreased 
micro n 
macronormo
blastic 
maturation  
increase in 
myeloblasts 
promyelocyt
es 
myelocytes 
band forms 
mature 
neutrophils 
normal in 
number n 
morphology
3
 number 
reduced 
thrombocyto
penia 2 2
 number 
decreased 
micronormo
blastic 
maturation
increased in 
number 
myeloblasts 
>90% decreased
2
number 
decreased 
normal 
morphology
thrombocyto
penia 2 2
number 
increased 
megaloblasti
c maturation
number 
increased 
megaloblasti
c maturation
normal 
number n 
morphology
1
normal  
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
normal 
number  
normal 
maturation
normal  
number n 
morphology
1
number 
increased
reactive 
thrombocyto
sis 1 0
number 
increased 
micronormo
blastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
1
normal in 
number n 
morphology normal 0 0
number 
increased 
normal 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
0 n normal 0 0
0 normal 0 0
0 normal 0 2
2
number 
decreased 
normal 
morphology
thrombocyto
penia 2 1
number 
decreased 
dyserythropo
iesis
number 
decreased 
dysmyelopoi
esis
normal 
number 
dysmorphic 
megks
1 normal 0 1
0
normal 
number n 
morphology normal 0 0
number 
increased 
megaloblasti
c maturation
normal 
number n 
maturation
normal 
number n 
morphology
0 normal 
number n 
morphology normal 0 2
number 
increased 
megaloblasti
c maturation
number 
increased 
giant 
metamyelocy
tes
normal 
number n 
morphology
0
normal 
number n 
morphology normal 0 0
number 
normal 
megaloblasti
c maturation
number 
normal giant 
metamyelocy
tes band 
forms
normal 
number n 
morphology
0
normal in 
number n 
morphology normal 0 2
 number 
increased 
megaloblasti
c maturation
 number 
increased 
myelocyte 
metamyelocy
te giant band 
forms
normal in 
number n 
morphology
0
number 
increased 
giant 
platelets
reactive 
thrombocyto
sis 1 2
number 
increased 
micro n 
macro 
normoblastic 
maturation 
dividing 
cells
normal in 
number n 
morphology
normal 
number n 
morphology
1
normal in 
number n 
morphology normal 0 2
 number 
increased 
micro n 
macro 
normoblasti 
maturation 
normal in 
number n 
morphology
normal in 
number n 
morphology
0
normal  
number n 
morphology normal 0 2
 number 
increased, 
micro and 
macro 
normoblasti 
maturation 
normal  
number n 
morphology
normal  
number n 
morphology
plasmacytosi
s
0
normal 
number n 
morphology normal 0 2
number 
increased 
micronormo
blastic 
maturation
normal 
number n 
maturation
normal 
number n 
morphology
0
normal 
number n 
morphology normal 0 2
number 
increased 
normal 
maturation
number 
increased 
normal 
maturation
normal 
number n 
morphology
Marrow 
Impression
Describe diagnosis
combined 
deficiency combined
combined 
deficiency combined
micronormo
blastic 
maturation 
hyperplastic 
marrow with 
micronormo
blastic 
maturation
combined 
deficiency combined
megaloblasti
c marrow 
with 
dysmyelopoi
esis s/o MDS-
RA MDS
MDS with 
plasmacytosi
s MDS
erythroid 
hyperplasia 
withmegalob
lastic 
maturation 
consistent 
with 
megaloblasti
c anemia
megaloblasti
c anemia meg ane
normocellula
r marrow 
with 
micronormo
blastic 
maturation
reactive 
marrow s/o 
IDA
REH with 
micronormo
blastic 
maturation
REH with 
micronormo
blastic 
maturation
REHs/o IDA
combined 
deficiency combined
combined 
deficiency combined
hyperplastic 
marrow with 
micronormo
blastic 
maturation
hyperplastic 
marrow with 
micronormo
blastic 
maturation
MDS RCMD MDS
MDS RCMD MDS
MDS 
trilineage 
dysplasia -
RAEB MDS
megaloblasti
c anemia meg ane
megaloblasti
c anemia meg ane
megaloblasti
c anemia meg ane
megaloblasti
c anemia meg ane
megaloblasti
c anemia meg ane
megaloblasti
c 
dysmegakary
opoiesis meg.mega
megaloblasti
c 
ysmyelopoie
sis
p/o MDS 
meg 
dysmyelo
micronormo
blastic 
maturation 
micronormo
blastic 
maturation 
micronormo
blastic 
maturation 
micronormo
blastic 
maturation 
micronormo
blastic 
maturation 
micronormo
blastic 
maturation 
reactive 
hyperplasia 
micronormo
blastic 
maturation
reactive 
marrow with 
micro n 
macronormo
blastic 
maturation  
s/o combined 
deficiency combined
Reactive 
marrow with 
micro 
normoblastic 
maturation
reactive 
marrow with 
micro 
normoblastic 
maturation
reactive 
marrow with 
micro 
normoblastic 
maturation 
s/o IDA
reactive 
marrow with 
micro 
normoblastic 
maturation 
s/o IDA
Reactive 
marrow with 
micronormo 
blastic 
maturation
REH s/o 
IDA
REH with 
micro n 
macro 
normoblasti
maturation 
with features 
s/o 
myelodyspla
sia p/o MDS
CML - 
accelerated 
phase CML
CML 
chronic 
phase CML
CML - accc. 
phase CML
AML-M1 AML
megaloblasti
c anemia meg ane
erythroid 
hyperplasia 
withmegalob
lastic 
maturation 
consistent 
with 
megaloblasti
c anemia meg ane
florid 
erythroid 
hyperplasia 
with 
micronormo
blastic 
maturations/
o IDA 
micronormo
blastic 
maturation 
combined 
deficiency combined
micronormo
blastic 
maturation 
combined 
deficiency
MDS- 
RCMD MDS
meg. 
Yserythropoi
esis
meg. 
Yserythropoi
esis
megaloblasti
c anemia meg ane
megaloblasti
c anemia meg ane
megaloblasti
c anemia meg ane
megaloblasti
c anemia meg ane
reactive 
marrow with 
micro n 
macronormo
blastic 
maturationpo
ssibility of 
MDSmay be 
thought of
p/o MDS 
dyserythropo
iesis
REH with 
micro n 
macro 
normoblastic 
maturation  
s/o combinrd 
deficiency combined
REH with 
micro n 
macro 
normoblasti
maturation 
and 
plasmacytosi
s combined
REH with 
micro 
normoblastic 
maturation 
s/o IDA
REH with 
micronormo
blastic 
maturation
